Page last updated: 2024-12-05

tegafur

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID5386
CHEMBL ID20883
CHEBI ID32188
SCHEMBL ID4552
MeSH IDM0008871

Synonyms (153)

Synonym
AC-2112
MLS001076521
HMS3393B15
AB00572620-15
MLS000069497 ,
smr000059106
5-fluoro-1-(tetrahydrofuran-2-yl)pyrimidine-2,4(1h,3h)-dione
17902-23-7
2, 4(1h,3h)-pyrimidinedione, 5-fluoro-1-(tetrahydro-2-furanyl)-, (r)-
5-fluoro-1-tetrahydro-2-furanyl-2,4(1h,3h)-pyrimidinedione
5-fluoro-1-tetrahydrofuran-2-yl-pyrimidine-2,4-dione
UPCMLD-DP063:001
neberk
uracil, 5-fluoro-1-(tetrahydro-2-furyl)-
nsc-148958
futraful
ft 207
tegafur ,
fluorofur
citofur
ftorafur
sinoflurol
fental
5-fluoro-1-(tetrahydro-2-furyl)uracil
SR-01000639511-1
MLS000759414
UPCMLD-DP063
atillon (tn)
tegafur (jp17/usan/inn)
D01244
NCGC00159418-04
c8h9fn2o3
florafur
riol
2,4(1h,3h)-pyrimidinedione, 5-fluoro-1-(tetrahydro-2-furanyl)-
ccris 2762
n(sub 1)-(2'-furanidyl)-5-fluouracil [czech]
1-(tetrahydro-2-furanyl)-5-fluoro-2,4-pyrimidinedione
ts-1
uracil, 1-(tetrahydrofuran-2-yl)-5-fluoro-
franroze
ft-207
nitobanil
5-fluoro-1-(tetrahydrofuran-2-yl)uracil
lamar
furflucil
5-fluoro-1-(tetrahydro-2-furanyl)-2,4-pyrimidinedione
lifril
brn 0525766
n1-(2-tetrahydrofuryl)-5-fluorouracil
nsc 148958
sunfral
fulfeel
mjf-12264
2,4(1h,3h)pyrimidinedione, 5-fluoro-1-(tetrahydro-2-furanyl)-
tegafurum [inn-latin]
racemic ftorafur
ft207
1-(tetrahydrofuran-2-yl)-5-fluorouracil
coparogin
furofutran
furafluor
phthorafur [czech]
einecs 241-846-2
5-fluoro-1-(tetrahydro-3-furyl)uracil
n1-(2'-tetrahydrofuryl)-5-fluorouracil
tefsiel c
n(sub 1)-(2-tetrahydrofuryl)-5-fluorouracil
exonal
1-(2-tetrahydrofuryl)-5-fluorouracil
HMS2051B15
HMS2090K04
5-fluoro-1-(tetrahydro-2-furfuryl)uracil
atillon
chebi:32188 ,
sunfural
franrose
fulaid
CHEMBL20883
HMS1665I05
FT-0653732
FT-0654170
FT-0693965
5-fluoro-1-(oxolan-2-yl)pyrimidine-2,4-dione
AKOS000121279
5-fluoro-1-(oxolan-2-yl)-1,2,3,4-tetrahydropyrimidine-2,4-dione
5-fluoro-1-tetrahydro-furan-2-yl-1h-pyrimidine-2,4-dione
1548r74nsz ,
phthorafur
unii-1548r74nsz
5-24-06-00285 (beilstein handbook reference)
tegafurum
tegafur [usan:inn:ban:jan]
n(sub 1)-(2'-furanidyl)-5-fluouracil
STK528044
A812417
MLS001424119
82294-77-7
2,4(1h,3h)-pyrimidinedione, 5-fluoro-1-(tetrahydro-2-furanyl)-, didehydroderiv.
HMS2232E05
CCG-100959
CCG-50110
HY-17400
CS-1128
FT-0674829
1189456-27-6
HMS3371H21
NC00209
BBL027795
SCHEMBL4552
tegafur [who-dd]
tegafur [ema epar]
tegafur [usan]
tegafur [inn]
tegafur component of teysuno
tegafur [mart.]
5-fluoro-1-(tetrahydro-2-furyl)-uracil
tegafur [mi]
tegafur [jan]
teysuno component tegafur
1-(tetrahydro-2-furyl)-5-fluorouracil
5-fluoro-1-(2-tetrahydrofuranyl)uracil
5-fluoro-1-(2-tetrahydrofuryl)uracil
n1 -(2-tetrahydrofuryl)-5-fluorouracil
ts-1 (salt/mix)
n1-(2'-furanidyl)-5-fluorouracil
fluorafur
f-5-fu
n1-(2'-furanidyl)-5-fluouracil
5-fluoro-1-(tetrahydro-2-furanyl)-2,4(1h,3h)-pyrimidinedione
Q-201784
ft-207 (nsc 148958)
79107-97-4
1-(2-tetrahydroformyl)-5-fluorouracil
OPERA_ID_1726
mfcd00012351
DB09256
sr-01000639511
SR-01000639511-4
HMS3654P13
tegafur, >=98% (hplc), powder
HMS3715D14
gtpl10513
BCP22714
DTXSID001009966
Q413370
tegafur ,(s)
5-fluoro-1-(tetrahydrofuran-2-yl)
AS-13528
tegafur (ft-207; nsc 148958)
EN300-21668
Z104508106
BP-58663

Research Excerpts

Overview

Tegafur is a 5-fluorouracil (5-FU) prodrug widely used outside the United States to treat colorectal cancer as well as cancers of the head and neck. UFT (tegafur and uracil) is an oral anticancer drug that has been developed in Japan.

ExcerptReferenceRelevance
"Tegafur-uracil is an oral fluoropyrimidine that has a similar effect to 5-fluorouracil as an adjuvant treatment for colorectal cancer."( Reversible Splenial Lesion Syndrome (RESLES) After Chemotherapy of Oral Tegafur-uracil in a Female With Locally Rectal Adenocarcinoma.
Bi, QQ; Chen, YJ; Ge, YX; Lin, YY, 2020
)
1.51
"Tegafur is a well-known prodrug of 5-FU."( [A Case Report of Successful Chemotherapy with Tegafur/Gimeracil/Oteracil and Nab-Paclitaxel for Gastric Cancer with Chronic Renal Failure].
Kurashima, Y; Miyazaki, T; Ohata, K; Ohno, K; Okawa, M; Tanaka, S; Uenishi, T; Yamamoto, T, 2015
)
1.4
"Tegafur (FT) is a 5-fluorouracil (5-FU) prodrug that has been clinically used for various cancer chemotherapies. "( Formation pathways of gamma-butyrolactone from the furan ring of tegafur during its conversion to 5-fluorouracil.
Matsushima, E; Nagayama, S; Yamamiya, I; Yoshisue, K, 2010
)
2.04
"Tegafur is a 5-fluorouracil (5-FU) prodrug widely used outside the United States to treat colorectal cancer as well as cancers of the head and neck. "( Development and utilization of a combined LC-UV and LC-MS/MS method for the simultaneous analysis of tegafur and 5-fluorouracil in human plasma to support a phase I clinical study of oral UFT®/leucovorin.
Hurwitz, HI; McManus, TJ; Peer, CJ; Petros, WP, 2012
)
2.04
"Tegafur is an oral fluorouracil prodrug used in the treatment of colorectal cancer. "( A clinical pharmacokinetic analysis of tegafur-uracil (UFT) plus leucovorin given in a new twice-daily oral administration schedule.
Bennouna, J; Cardot, JM; Château, Y; Douillard, JY; Etienne-Grimaldi, MC; François, E; Gamelin, E; Milano, G; Renée, N, 2007
)
2.05
"UFT (tegafur and uracil) is an oral anticancer drug that has been developed in Japan. "( UFT (tegafur and uracil) as postoperative adjuvant chemotherapy for solid tumors (carcinoma of the lung, stomach, colon/rectum, and breast): clinical evidence, mechanism of action, and future direction.
Tanaka, F, 2007
)
1.37
"Tegafur is an antimetabolite slowly metabolized to 5-fluorouracil in vivo. "( Phase II trial of an all-oral regimen of tegafur and folinic acid in patients with previously treated metastatic breast cancer.
Albanell, J; Bellmunt, J; Carulla, J; Gallego, OS; Ribas, A; Solé, LA, 1995
)
2
"Tegafur is an effective oral fluoropyrimidine that shows the same activity as 5-fluorouracil for a similar spectrum of cancers. "( Clinical experience with tegafur and low dose oral leucovorin: a dose-finding study.
Nogué, M; Saigí, E; Seguí, MA,
)
1.88
"Tegafur acts as a deport form of 5-fluorouracil when administered orally for long periods of time since it is an active drug in metastatic breast cancer, with response rates of 29-44%. "( Phase II trial of oral tegafur and folinic acid with mitoxantrone as first-line regimen in patients with metastatic breast cancer.
Alonso, M; Alonso, V; Escudero, P; Florian, J; Isla, MD; Saenz, A; Santader, C; Tres, A,
)
1.88
"Tegafur acts as a prodrug of 5-fluorouracil (5-FU), being slowly metabolized by cytochrome P450 to 5-FU."( UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer.
Benner, SE; Canetta, R; Hoff, PM; Pazdur, R, 1998
)
1.02
"Tegafur/uracil (UFT) is an oral fluorinated pyrimidine composed of a combination of uracil and tegafur in a 4:1 molar ratio. "( The role of tegafur/uracil in pulmonary malignancy.
Langer, CJ, 1999
)
2.13
"Tegafur is a prodrug of 5-fluorouracil (5-FU) consisting of a new class of oral chemotherapeutic agents, tegafur/uracil and S-1, which are classified as dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines. "( Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro.
Chiba, K; Ikeda, K; Kawaguchi, Y; Kobayashi, K; Matsushima, E; Nagayama, S; Tyson, CA; Yoshisue, K, 2000
)
2.09
"Tegafur is a prodrug that is converted to 5-fluorouracil (5-FU) and has been reported to be less toxic and to have a higher therapeutic index."( Phase II study of oral tegafur-uracil and folinic acid as first-line therapy for metastatic colorectal cancer: Taiwan experience.
Chen, PM; Chiou, TJ; Fan, FS; Hsieh, RK; Hsu, TC; Jiang, JK; Lin, JK; Lin, TC; Liu, JH; Wang, HS; Wang, WS; Yang, SH; Yen, CC, 2000
)
1.34
"Tegafur is a prodrug of 5-FU and is a component of S-1, another oral fluoropyrimidine active in a variety of solid tumors."( Case report: hand-foot syndrome induced by the oral fluoropyrimidine S-1.
Elasmar, SA; Hoff, PM; Saad, ED, 2001
)
1.03
"Tegafur is a prodrug of the antineoplastic agent fluorouracil, and is administered in a 1:4 molar ratio with the fluorouracil modulator uracil. "( Oral tegafur/uracil.
Goa, KL; Wellington, K, 2001
)
2.27
"Tegafur (Ftorafur) is an analog of 5-fluorouracil, and its oral form is well absorbed."( Phase II trial of cisplatin and tegafur (Ftorafur) as initial therapy in squamous-cell carcinoma of the head and neck.
Garcia-Giron, C; Garrido, P; Gavilan, J; Gonzalez-Baron, M; Martin, G; Martorell, V; Tomas, M; Vicente, J; Zamora, P, 1990
)
1.28
"Tegafur (FT) is a masked compound of 5-fluorouracil (5-FU) and supposed to be activated in the liver. "( [Anti-tumor effect of fluoropyrimidines on human tumor cell lines transplanted in nude mice with CCl4-induced liver dysfunction].
Imai, S; Nio, Y; Ohgaki, K; Shiraishi, T; Tobe, T, 1989
)
1.72
"Tegafur is a typical masked compound transformed into 5-FU by the hepatic drug-metabolizing enzyme P-450."( [Effects of krestin (PSK) on drug-metabolizing enzymes with special reference to the activation of FT-207].
Fujita, H; Ikuzawa, M; Kawai, Y; Matsuki, M; Muto, S; Nakajima, S; Ogawa, K; Shimamura, M; Togawa, M; Yoshikumi, C, 1986
)
0.99

Effects

Tegafur-uracil has been reported to have only minor adverse effects and is associated with liver injury in 1.79% of Japanese patients. UFT (tegafur + uracil) has been effective as an adjuvant in postoperative chemotherapy for non-small cell lung cancer (NSCLC)

ExcerptReferenceRelevance
"Tegafur-uracil has been reported to have only minor adverse effects and is associated with liver injury in 1.79% of Japanese patients. "( Tegafur-uracil-induced rapid development of advanced hepatic fibrosis.
Fujiya, M; Hasebe, T; Honda, S; Nakajima, S; Okumura, T; Sawada, K, 2017
)
3.34
"UFT (tegafur + uracil) has been reported to be effective as an adjuvant in postoperative chemotherapy for non-small cell lung cancer (NSCLC) in a randomized prospective study. "( Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (tegafur+uracil) in patients with non-small cell lung cancer.
Fujino, H; Kenzaki, K; Kondo, K; Miyoshi, T; Sakiyama, S; Takehisa, M; Tangoku, A; Toba, H; Yoshida, M,
)
0.84
"Tegafur has been shown to be converted enzymatically to 5-FU to exert its antitumor effect, and this conversion is principally catalyzed by CYP2A6."( The CYP2A6*4 allele is determinant of S-1 pharmacokinetics in Japanese patients with non-small-cell lung cancer.
Chida, K; Inui, N; Kaida, Y; Nakamura, H; Suda, T; Watanabe, H, 2008
)
1.07
"UFT (tegafur-uracil) has similar efficacy to continuous infusion 5-FU with improved tolerability and is more convenient for patients."( The role of UFT in advanced gastric cancer.
Aykan, NF; Idelevich, E, 2008
)
0.8
"UFT (tegafur and uracil) has been studied extensively in Japan, with documented efficacy in hepatobiliary and pancreatic cancer. "( UFT plus leucovorin in advanced hepatobiliary tumors and pancreatic adenocarcinomas.
Mani, S, 1997
)
0.81
"Tegafur/uracil has been commercially available in Japan since 1983 and examined extensively in various tumours."( Tegafur/uracil + calcium folinate in colorectal cancer: double modulation of fluorouracil.
Hoff, PM; Lassere, Y; Pazdur, R, 1999
)
2.47
"Tegafur-uracil has become an important regimen in the treatment of metastatic colorectal cancer. "( Phase II study of oral tegafur-uracil and folinic acid as first-line therapy for metastatic colorectal cancer: Taiwan experience.
Chen, PM; Chiou, TJ; Fan, FS; Hsieh, RK; Hsu, TC; Jiang, JK; Lin, JK; Lin, TC; Liu, JH; Wang, HS; Wang, WS; Yang, SH; Yen, CC, 2000
)
2.06

Treatment

Tegafur-uracil treatment is a useful, effective, and well-tolerated anticancer treatment for advanced oral cancer. The treatment resulted in the disappearance of pulmonary metastases, and a stabilization of the bone metastases.

ExcerptReferenceRelevance
"Tegafur-uracil treatment is a useful, effective, and well-tolerated anticancer treatment for advanced oral cancer."( The Impact of Metronomic Adjuvant Chemotherapy in Patients with Advanced Oral Cancer.
Chang, DC; Chen, G; Chen, MK; Chien, SY; Hsieh, MY, 2018
)
1.2
"The tegafur-uracil treatment resulted in the disappearance of pulmonary metastases, and a stabilization of the bone metastases."( [A case of recurrent lung cancer with bone metastases treated with tegafur-uracil and zoledronic acid for long-term survival].
Abiko, M; Harada, M; Sato, T; Shiono, S; Takanashi, I, 2014
)
1.12
"Tegafur-based treatment should be evaluated by a prospective randomised trial conducted in ER-positive patients."( Uracil-tegafur and tamoxifen vs cyclophosphamide, methotrexate, fluorouracil, and tamoxifen in post-operative adjuvant therapy for stage I, II, or IIIA lymph node-positive breast cancer: a comparative study.
Asaga, T; Higaki, K; Inaji, H; Ito, T; Koh, J; Kohno, N; Komichi, H; Koyama, H; Kyono, S; Mitsuyama, S; Nishikawa, H; Ogita, M; Okamura, K; Osaki, A; Park, Y; Saito, T; Suzuki, T; Tanaka, F; Yamazaki, K, 2009
)
1.53
"Treatment with tegafur/uracil was also given postoperatively."( Oral tegafur/uracil.
Goa, KL; Wellington, K, 2001
)
1.16

Toxicity

ExcerptReferenceRelevance
" As a single treatment ftorafur was about half as toxic as 5-FU on an mg/kg basis."( Comparison of 5-fluorouracil and ftorafur. I. Quantitative and qualitative differences in toxicity to mice.
Garibjanian, BT; Gaston, MR; Goldin, A; Houchens, DP; Johnson, RK; Kline, I; Syrkin, AB, 1976
)
0.26
" 5'-DFUR was less toxic to immune organs and the functions than those by other fluorinated pyrimidines."( [Antitumor activity and toxicity to the immune system and intestine, of the fluorinated pyrimidines FUra, 5'-DFUR, tegafur and UFT].
Fujimoto, K; Ishitsuka, H; Matsuura, N; Miwa, M; Ninomiya, Y; Ryu, M, 1988
)
0.48
" In this study, the two types of toxic behaviors and symptoms were observed in UFT, FT-207 and 5-FU."( A nine-month chronic toxicity study of tegafur-uracil mixture (UFT) in dogs.
Ariyoshi, T; Maruden, A; Morita, K; Sutou, H; Takenouchi, T; Yamashita, K, 1988
)
0.54
" Uracil plus tegafur was shown to be less toxic than the drug alone in all the species, and uracil was found to decrease the toxicity of tegafur."( Effect of coadministration of uracil on the toxicity of tegafur.
Haruno, A; Kunimune, Y; Morita, K; Unemi, N; Yamamoto, J; Yamashita, K; Yoshimura, Y, 1984
)
0.88
" The above findings suggest that the neurotoxicity of FU and its masked compounds FT and HCFU in long-term treatment produces changes morphologically identical with one another in respect to the site of their manifestation and nature of lesion, that their common degraded product alpha-fluoro-beta-alanine (FBAL) plays a crucial role in their neurotoxic actions, and that vacuolar lesions, to which myelin was more vulnerable than neurons, can develop where the toxic substance readily deposits and accumulates."( Neuropathologic study on chronic neurotoxicity of 5-fluorouracil and its masked compounds in dogs.
Karakama, T; Kimura, S; Mitsushima, T; Okeda, R; Toizumi, S; Yokoyama, Y, 1984
)
0.27
" In the CDHP and Oxo treatment groups of rats, the only toxic signs were soft or diarrheal stools on the dosing day."( [Oral single-dose toxicity study of a new antineoplastic agent S-1, and its components, CDHP, and Oxo].
Hayashi, T; Hirota, T; Irimura, K; Ohmae, S; Tanaka, G, 1996
)
0.29
" No adverse effects of S-1 on the length of gestation, gestation index, delivery and nursing ability were found."( [Reproductive and developmental toxicity study of a new antineoplastic agent, S-1 (IV)--Perinatal and postnatal study in rats by oral administration].
Fujimura, T; Furuhashi, T; Kato, M; Koida, M, 1996
)
0.29
" The correlation between pharmacokinetic parameters and toxic effects of UFT was evaluated."( Oral uracil and Ftorafur plus leucovorin: pharmacokinetics and toxicity in patients with metastatic cancer.
Brown, N; Covington, W; Creaven, PJ; Hayakawa, T; Ho, DH; Huo, YY; Kuritani, J; Lassere, Y; Lin, SN; Meropol, NJ; Pazdur, R; Rustum, YM, 2000
)
0.31
" The major toxic effects observed were diarrhea and nausea and vomiting."( Oral uracil and Ftorafur plus leucovorin: pharmacokinetics and toxicity in patients with metastatic cancer.
Brown, N; Covington, W; Creaven, PJ; Hayakawa, T; Ho, DH; Huo, YY; Kuritani, J; Lassere, Y; Lin, SN; Meropol, NJ; Pazdur, R; Rustum, YM, 2000
)
0.31
" The preliminary findings suggest that determination of plasma levels of 5-FU after oral administration of UFT may help predict subsequent toxic effects."( Oral uracil and Ftorafur plus leucovorin: pharmacokinetics and toxicity in patients with metastatic cancer.
Brown, N; Covington, W; Creaven, PJ; Hayakawa, T; Ho, DH; Huo, YY; Kuritani, J; Lassere, Y; Lin, SN; Meropol, NJ; Pazdur, R; Rustum, YM, 2000
)
0.31
"S-1 appears to be safe and highly active, with favorable longterm survival in patients with metastatic gastric cancer, particularly in those with diffuse-type histology and peritoneal metastasis."( Efficacy and safety profile of S-1 in patients with metastatic gastric cancer in clinical practice: results from a post-marketing survey.
Boku, N; Doi, T; Hamamoto, Y; Kawai, H; Mera, K; Muto, M; Nagashima, F; Ohtsu, A; Sano, Y; Yano, T; Yoshida, S, 2003
)
0.32
" In terms of safety, adverse reactions appeared in forty-five patients (82%) and the incidence was higher in the ADJ group."( [Efficacy and safety of novel oral fluoropyrimidine anticancer drug, TS-1 for advanced and recurrent gastric cancer patients].
Arai, K; Honma, S; Iwasaki, Y; Kimura, Y; Takahashi, K; Takahashi, T; Yamaguchi, T, 2003
)
0.32
" S-1 has safe and potent antitumor effects in patients with gastric cancer via these respective functions."( Safety and efficacy of S-1, a novel oral fluorouracil antitumor drug, for a chronic renal failure patient maintained on hemodialysis.
Arakawa, T; Fujiwara, Y; Hamaguchi, M; Higuchi, K; Matsumoto, T; Okazaki, H; Oshitani, N; Sasaki, E; Shiba, M; Suto, R; Tanigawa, T; Tominaga, K; Watanabe, T, 2004
)
0.32
" Liver metastases almost totally regressed with no adverse events 4 weeks after S-1 treatment (50 mg/body/day three times a week)."( Safety and efficacy of S-1, a novel oral fluorouracil antitumor drug, for a chronic renal failure patient maintained on hemodialysis.
Arakawa, T; Fujiwara, Y; Hamaguchi, M; Higuchi, K; Matsumoto, T; Okazaki, H; Oshitani, N; Sasaki, E; Shiba, M; Suto, R; Tanigawa, T; Tominaga, K; Watanabe, T, 2004
)
0.32
" The plasma 5-FU level was measured, and adverse events appearing after administration were monitored."( [Pharmacokinetics and adverse event of TS-1 administered through gastrostomy].
Hasegawa, M; Hirano, K; Nakamura, K, 2005
)
0.33
"To report canalicular stenosis as a side effect of the new antineoplastic agent S-1."( Canalicular and nasolacrimal duct blockage: an ocular side effect associated with the antineoplastic drug S-1.
Ajani, J; Esmaeli, B; Golio, D; Lubecki, L, 2005
)
0.33
"Canalicular and nasolacrimal duct blockage is a previously unreported side effect of S-1 and should be recognized and treated at its earliest possible stage so that complete closure of the canaliculi can be avoided."( Canalicular and nasolacrimal duct blockage: an ocular side effect associated with the antineoplastic drug S-1.
Ajani, J; Esmaeli, B; Golio, D; Lubecki, L, 2005
)
0.33
" There were less severe adverse events concerning paclitaxel despite of the second line therapy of TS-1, and 80 percent of all therapeutic courses was at an outpatient clinic."( [Safety and efficacy of chemotherapy using TS-1 followed by paclitaxel for advanced or recurrent gastric cancer with peritoneal dissemination].
Banba, T; Hatakeyama, K; Kanda, T; Kosugi, S; Ohashi, M; Tanabe, T; Yajima, K, 2005
)
0.33
"As a measure to ensure safe use of TS-1 during the early marketing period, a drug use investigation was conducted on an all-case basis."( [Example of safety measures for antineoplastic agents immediately after market launch--a case of TS-1 capsule all example use result investigation that executes safety monitoring--].
Ito, K, 2006
)
0.33
" The adverse effects observed were grade 3 leukopenia in 2 patients (11."( [Clinical efficacy and safety of weekly paclitaxel therapy as second-line chemotherapy for patients with advanced and recurrent gastric cancer who were previously treated with TS-1 therapy].
Hatori, S; Imada, T; Kunisaki, C; Ohshima, T; Ono, H; Otsuka, Y; Rino, Y; Sato, T; Yamada, R, 2006
)
0.33
" At least 1 serious adverse event occurred in 44% of patients."( Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study.
Ajani, JA; Benson, AB; Haller, DG; Lee, FC; Lenz, HJ; Phan, AT; Singh, D; Strumberg, D; Yanagihara, R; Yao, JC, 2007
)
0.34
" This article identifies the risk factors for severe adverse events of S-1 from nationwide survey data."( Analysis of risk factors for severe adverse effects of oral 5-fluorouracil S-1 in patients with advanced gastric cancer.
Fukushima, M; Ishiwata, R; Matsumoto, S; Nagai, Y; Teramukai, S; Yamanaka, T, 2007
)
0.34
" Univariate and multivariate analyses were performed to explore the risk factors for severe adverse events."( Analysis of risk factors for severe adverse effects of oral 5-fluorouracil S-1 in patients with advanced gastric cancer.
Fukushima, M; Ishiwata, R; Matsumoto, S; Nagai, Y; Teramukai, S; Yamanaka, T, 2007
)
0.34
"These findings identified possible risk factors for severe adverse events of S-1 and the patient subgroups at potentially higher risk from its administration."( Analysis of risk factors for severe adverse effects of oral 5-fluorouracil S-1 in patients with advanced gastric cancer.
Fukushima, M; Ishiwata, R; Matsumoto, S; Nagai, Y; Teramukai, S; Yamanaka, T, 2007
)
0.34
" on days 1-28, every 6 weeks) and assessed for all adverse events."( Safety evaluation of oral fluoropyrimidine S-1 for short- and long-term delivery in advanced gastric cancer: analysis of 3,758 patients.
Fukushima, M; Ishiwata, R; Matsumoto, S; Nagai, Y; Teramukai, S; Yamanaka, T, 2008
)
0.35
"An increase of sIL-2R, CD4+CD25+ T-cells and the CD4/8 ratio in patients with symptomatic adverse reactions were found."( Changes of immunological parameters reflect quality of life-related toxicity during chemotherapy in patients with advanced colorectal cancer.
Aizawa, M; Fujimoto, T; Itagaki, H; Kobayashi, R; Kuhara, K; Ogawa, K; Osawa, G; Otani, T; Yokomizo, H; Yoshimatsu, K,
)
0.13
" Although the preoperative chemotherapeutic regimen of S-1 and CDDP is regarded as effective, safe and well tolerable according to previous clinical study, we experienced a 74-year-old woman who suffered from life-threatening adverse events including severe myelosuppression during the neoadjuvant chemotherapy."( [Case report of gastric cancer patient who suffered life-threatening adverse events including severe myelosuppression during neoadjuvant chemotherapy with S-1 and CDDP combination].
Hashida, H; Kanai, M; Tada, M; Takabayashi, A; Ueda, S; Yoshida, M, 2008
)
0.35
"The toxic effects of S-1 can lead to discontinuation of treatment."( Comparison of alternate-day versus consecutive-day treatment with S-1: assessment of tumor growth inhibition and toxicity reduction in gastric cancer cell lines in vitro and in vivo.
Arai, W; Haruta, H; Hirashima, Y; Hosoya, Y; Hyodo, M; Kurashina, K; Nagai, H; Saito, S; Sakuma, K; Shirasaka, T; Yasuda, Y; Yokoyama, T; Zuiki, T, 2008
)
0.35
"We report a successful case of chemotherapy accompanied with grade 4 adverse events for unresectable advanced gastric cancer."( [A case of unresectable advanced gastric cancer successfully treated with continuous S-1 + CPT-11 chemotherapy accompanied by dose reduction against grade 4 hematological adverse event].
Furukawa, H; Imamura, H; Kishimoto, T; Miyazaki, Y; Ota, K; Tatsuta, M, 2008
)
0.35
" It was suggested that adverse effects might be alleviated by suppressing acid secretion in the stomach in the post-gastrectomy group."( [Discussion of alleviating digestive medication toxicity in S-1 administered patients--retrospective and comparative study of the health records of continuously-administered patients and withdrawal patients].
Fujii, H; Nakao, K, 2009
)
0.35
" Our results confirmed that longterm postoperative therapy with UFT alone was feasible, provided that early adverse events are carefully monitored."( [Safety and compliance with UFT (tegafur and uracil) alone and in combination with hormone therapy in patients with breast cancer].
Noguchi, S; Taguchi, T, 2009
)
0.63
"EP-UFT with lower UFT doses and without leucovorin support is a safe and effective regimen as first -line treatment of MGC."( Efficacy and toxicity of lower dose UFT without leucovorin in metastatic gastric cancer patients.
Alacacioglu, A; Meydan, N; Oztop, I; Somali, I; Tarhan, MO; Yilmaz, U,
)
0.13
" In conclusion, we considered that this S-1 plus docetaxel combination therapy was effective and safe in advanced gastric cancer, and convenient for outpatients."( [Efficacy and safety of S-1 plus docetaxel combination therapy for patients with advanced gastric cancer].
Ban, T; Fujiwara, K; Hayashi, K; Hori, Y; Iwasaki, H; Kurimoto, T; Nemoto, A; Nishiwaki, H; Orito, E; Shiroko, J; Tachi, K; Umemura, S; Yamada, T; Yamakawa, Y, 2009
)
0.35
" Five patients showed grade 3 and 4 adverse reactions, all hematological."( Safety and efficacy of S-1 chemotherapy in recurrent/metastatic head and neck cancer.
Ishikawa, K; Suzuki, S, 2009
)
0.35
" During the S-1 treatment,serious adverse events such as neutropenia were not observed; however, decreases in hemoglobin level were observed (grade 3)."( Safety, efficacy and pharmacokinetics of S-1 in a hemodialysis patient with advanced gastric cancer.
Arimori, K; Hanada, N; Hidaka, H; Hidaka, M; Kawaguchi, H; Kawano, Y; Nakamura, C; Tomiyama, N, 2010
)
0.36
"In patients with adverse events of S-1, the dose is generally reduced or the treatment cycle is shortened."( Alternate-day treatment with S-1 in patients with gastric cancer: a retrospective study of strategies for reducing toxicity.
Arai, W; Haruta, H; Hirashima, Y; Hosoya, Y; Hyodo, M; Kurashina, K; Nagai, H; Saito, S; Sakuma, K; Shirasaka, T; Ui, T; Yasuda, Y; Yokoyama, T; Zuiki, T, 2010
)
0.36
"2% had grade 3 adverse events."( Alternate-day treatment with S-1 in patients with gastric cancer: a retrospective study of strategies for reducing toxicity.
Arai, W; Haruta, H; Hirashima, Y; Hosoya, Y; Hyodo, M; Kurashina, K; Nagai, H; Saito, S; Sakuma, K; Shirasaka, T; Ui, T; Yasuda, Y; Yokoyama, T; Zuiki, T, 2010
)
0.36
"Alternate-day treatment with S-1 may have milder adverse events without compromising therapeutic effectiveness."( Alternate-day treatment with S-1 in patients with gastric cancer: a retrospective study of strategies for reducing toxicity.
Arai, W; Haruta, H; Hirashima, Y; Hosoya, Y; Hyodo, M; Kurashina, K; Nagai, H; Saito, S; Sakuma, K; Shirasaka, T; Ui, T; Yasuda, Y; Yokoyama, T; Zuiki, T, 2010
)
0.36
" However, many patients are often forced to give up long-term S-1 treatment owing to high incidence rates of adverse effects."( [Provision for adverse effect of S-1 containing chemotherapy in patients with advanced digestive cancer--combination with superfine dispersed lentinan].
Hazama, S; Nakazawa, S; Suga, T; Watanabe, S; Yagi, M; Yoshino, S, 2010
)
0.36
" Adverse events which had an undeniable causal relationship to SDL were observed in 2 patients (2."( [Provision for adverse effect of S-1 containing chemotherapy in patients with advanced digestive cancer--combination with superfine dispersed lentinan].
Hazama, S; Nakazawa, S; Suga, T; Watanabe, S; Yagi, M; Yoshino, S, 2010
)
0.36
"From the results of the present study, SDL is considered completely free of anything harmful to advanced digestive cancer patients and is effective for the suppression of adverse effects of S-1 or S-1+alpha therapy."( [Provision for adverse effect of S-1 containing chemotherapy in patients with advanced digestive cancer--combination with superfine dispersed lentinan].
Hazama, S; Nakazawa, S; Suga, T; Watanabe, S; Yagi, M; Yoshino, S, 2010
)
0.36
"Patients taking more than 8 courses of S-1 were classified in the continuous group (n=30) and those in whom S-1 was discontinued or reduced due to adverse reactions in the discontinuation/reduction group (n=29)."( [Continuous administration and safety of S-1 in adjuvant chemotherapy for gastric cancer].
Ito, D; Iwai, M; Kimura, M; Morihata, K; Nakao, T; Okada, K; Usami, E; Yasuda, T; Yoshimura, T, 2010
)
0.36
" The main adverse events were hematological toxicity, mucositis and dermatitis."( Efficacy and toxicity of concurrent chemoradiotherapy with nedaplatin and S-1 for head and neck cancer.
Murai, M; Ohashi, T; Ohnishi, M; Tanahashi, S, 2011
)
0.37
" Adverse events were assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events."( Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study.
Asaka, M; Hatanaka, K; Hosokawa, A; Iwanaga, I; Kato, T; Komatsu, Y; Kusumi, T; Miyagishima, T; Nakamura, M; Sakata, Y; Sogabe, S; Yuki, S, 2011
)
0.37
" No severe adverse effects of more than grade 3 were encountered."( [Palliative anti-cancer chemotherapy is safely executable in a hemodialytic patient with unresectable advanced gastric cancer].
Hosojima, Y; Miura, T; Nakamura, J; Nakazawa, Y; Ozeki, Y; Takahashi, T; Yamada, S; Yamazaki, H; Yanagi, M, 2011
)
0.37
"These results suggest that S-1 adjuvant chemotherapy for gastric cancer is safe and feasible, regardless of the age of the patient; especially for elderly patients who could be candidates for clinical trials."( Safety and feasibility of S-1 adjuvant chemotherapy for gastric cancer in elderly patients.
Aoyama, T; Cho, H; Hayashi, T; Ogata, T; Tsuburaya, A; Watanabe, T; Yoshikawa, T, 2012
)
0.38
"At least one adverse drug reaction was encountered by 858 patients, with an overall incidence of 63."( Post-marketing safety evaluation of S-1 in patients with inoperable or recurrent breast cancer: especially in patients treated with S-1 + trastuzumab.
Okamura, T; Oshitanai, R; Saito, Y; Suzuki, Y; Terada, M; Terao, M; Tokuda, Y; Tsuda, B, 2011
)
0.37
" Major adverse effects were hematological toxicities, gastrointestinal disturbance, neurosensory toxicity."( [Efficacy and side effects of combination therapy of oxaliplatin and S-1 for colorectal cancer].
Jin, ZM; Zhu, QC, 2011
)
0.37
" Adverse effects ≥ grade 2 were observed in 32% of the patients and adverse effects ≥ grade 3 in 15%."( Safety and outcome of chemoradiotherapy in elderly patients with rectal cancer: results from two French tertiary centres.
Bensadoun, RJ; Hamidou, H; Michel, P; Paillot, B; Roullet, B; Silvain, C; Tougeron, D; Tourani, JM, 2012
)
0.38
"In selected elderly patients, chemoradiotherapy is well-tolerated, without any significant increase in adverse events, and the results are similar to those recorded in younger patients."( Safety and outcome of chemoradiotherapy in elderly patients with rectal cancer: results from two French tertiary centres.
Bensadoun, RJ; Hamidou, H; Michel, P; Paillot, B; Roullet, B; Silvain, C; Tougeron, D; Tourani, JM, 2012
)
0.38
" The overall incidence of adverse events (AEs) were 80% in S-1 and 74% in UFT/LV."( Safety of UFT/LV and S-1 as adjuvant therapy for stage III colon cancer in phase III trial: ACTS-CC trial.
Boku, N; Endo, T; Ikejiri, K; Kameoka, S; Kinugasa, Y; Kotake, K; Matsubara, Y; Mochizuki, H; Mochizuki, I; Nakamoto, Y; Shinozaki, H; Sugihara, K; Takagane, A; Takahashi, K; Takahashi, Y; Takii, Y; Takiuchi, H; Tomita, N; Watanabe, M; Watanabe, T, 2012
)
0.38
"SACURA trial is a multicenter randomized phase III study which aims to evaluate the superiority of 1-year adjuvant treatment with UFT to observation without any adjuvant treatment after surgery for stage II colon cancer in a large population, and to identify "high-risk factors of recurrence/death" in stage II colon cancer and predictors of efficacy and adverse events of the chemotherapy."( Study protocol of the SACURA trial: a randomized phase III trial of efficacy and safety of UFT as adjuvant chemotherapy for stage II colon cancer.
Ishiguro, M; Ishikawa, T; Kanemitsu, Y; Kotake, K; Matsui, S; Mochizuki, H; Shimada, Y; Sugihara, K; Takahashi, K; Teramukai, S; Tomita, N; Ueno, H; Uetake, H; Watanabe, M, 2012
)
0.38
" The most common reasons for discontinuing treatment prior to the planned eight cycles were adverse events (n = 47, 15."( Safety and feasibility of adjuvant chemotherapy with S-1 for Korean patients with curatively resected advanced gastric cancer.
Jeong, JH; Kang, YK; Kim, BS; Kim, KC; Lee, SH; Lee, SS; Oh, ST; Park, I; Ryoo, BY; Ryu, MH; Yook, JH, 2012
)
0.38
"Adjuvant chemotherapy with S-1 for 1 year is safe and feasible in Korean patients."( Safety and feasibility of adjuvant chemotherapy with S-1 for Korean patients with curatively resected advanced gastric cancer.
Jeong, JH; Kang, YK; Kim, BS; Kim, KC; Lee, SH; Lee, SS; Oh, ST; Park, I; Ryoo, BY; Ryu, MH; Yook, JH, 2012
)
0.38
" Major grade 3/4 adverse events included neutropenia (28."( Uridine diphosphate glucuronosyl transferase 1 family polypeptide A1 gene (UGT1A1) polymorphisms are associated with toxicity and efficacy in irinotecan monotherapy for refractory pancreatic cancer.
Hamada, T; Hirano, K; Ijichi, H; Isayama, H; Kawakubo, K; Kogure, H; Koike, K; Miyabayashi, K; Mizuno, S; Mohri, D; Nakai, Y; Sasahira, N; Sasaki, T; Satoh, Y; Tada, M; Takahara, N; Takai, D; Uchino, R; Yamamoto, N; Yatomi, Y, 2013
)
0.39
" In conclusion, although adjuvant S-1 therapy has a high compliance rate, meticulous monitoring of adverse events is required in the early period of treatment."( Safety, compliance, and predictive parameters for dosage modification in adjuvant S-1 chemotherapy for gastric cancer.
Kim, HH; Kim, JH; Kim, SJ; Kim, YJ; Lee, JS; Lee, KW; Park, DJ, 2013
)
0.39
" The types and incidence rate of adverse events related to chemotherapy and the results of follow up of the patients were analyzed."( [A safety analysis in patients treated with oxaliplatin plus S-1 as adjuvant therapy for gastric cancer].
Chi, Y; Huang, J; Lü, X; Qu, T; Wang, JW; Yang, L; Zhou, Y, 2012
)
0.38
" The most common adverse events were neutropenia (n = 49, 69."( [A safety analysis in patients treated with oxaliplatin plus S-1 as adjuvant therapy for gastric cancer].
Chi, Y; Huang, J; Lü, X; Qu, T; Wang, JW; Yang, L; Zhou, Y, 2012
)
0.38
" Neutropenia, thrombocytopenia, nausea/vomiting and anorexia are the major treatment-related adverse events."( [A safety analysis in patients treated with oxaliplatin plus S-1 as adjuvant therapy for gastric cancer].
Chi, Y; Huang, J; Lü, X; Qu, T; Wang, JW; Yang, L; Zhou, Y, 2012
)
0.38
" Most treatment-related adverse events occurred at similar rates in both treatment arms."( Safety analysis of weekly paclitaxel plus S-1 versus paclitaxel plus 5-fluorouracil/calcium folinate as first-line therapy in advanced gastric cancer: a multicenter open random phase II trial.
Ba, Y; Deng, T; Guo, ZQ; Hu, CH; Huang, DZ; Meng, JC; Wan, HP; Wang, ML; Xiong, JP; Xu, N; Yan, Z; Yao, Y; Yu, Z; Yu, ZH; Zhang, Y; Zheng, RS; Zhuang, ZX, 2013
)
0.39
"4%) and renal adverse events (all grades: CS, 18."( Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study.
Ajani, JA; Bodoky, G; Buyse, M; Carrato, A; Cascinu, S; Douillard, JY; Ferry, D; Gorbunova, V; Heinemann, V; Lichinitser, M; Moiseyenko, V; Zaucha, R, 2013
)
0.39
" However, he experienced adverse effects, and subsequently, he was effectively treated with cisplatin (CDDP) and irinotecan (CPT-11)."( [An effective treatment by chemotherapy with CDDP+CPT-11 for recurrent gastric cancer which S-1 cannot be used owing to adverse effects].
Aoyagi, H; Hasegawa, K; Isogai, J; Kaneko, J; Maejima, S; Matsui, T; Yoshida, T, 2013
)
0.39
"8% and grade 3 or higher adverse events occurred in 12."( A combination of oral uracil-tegafur plus leucovorin (UFT + LV) is a safe regimen for adjuvant chemotherapy after hepatectomy in patients with colorectal cancer: safety report of the UFT/LV study.
Hasegawa, K; Ijichi, M; Kawasaki, S; Kokudo, N; Koyama, H; Makuuchi, M; Miyagawa, S; Oba, M; Saiura, A; Takayama, T; Teruya, M; Yamamoto, J; Yoshimi, F, 2014
)
0.69
" The overall incidence of adverse events (AEs) was 75."( Safety analysis of two different regimens of uracil-tegafur plus leucovorin as adjuvant chemotherapy for high-risk stage II and III colon cancer in a phase III trial comparing 6 with 18 months of treatment: JFMC33-0502 trial.
Baba, H; Hamada, C; Kakeji, Y; Katsumata, K; Koda, K; Kodaira, S; Kondo, K; Matsuoka, J; Morita, T; Nishimura, G; Sadahiro, S; Saji, S; Sasaki, K; Sato, S; Tsuchiya, T; Usuki, H; Yamaguchi, Y, 2014
)
0.65
"Oral UFT plus leucovorin given by either dosage schedule is a very safe regimen for adjuvant chemotherapy."( Safety analysis of two different regimens of uracil-tegafur plus leucovorin as adjuvant chemotherapy for high-risk stage II and III colon cancer in a phase III trial comparing 6 with 18 months of treatment: JFMC33-0502 trial.
Baba, H; Hamada, C; Kakeji, Y; Katsumata, K; Koda, K; Kodaira, S; Kondo, K; Matsuoka, J; Morita, T; Nishimura, G; Sadahiro, S; Saji, S; Sasaki, K; Sato, S; Tsuchiya, T; Usuki, H; Yamaguchi, Y, 2014
)
0.65
" The common adverse drug reactions were a decrease in hemoglobin levels, hypoalbuminemia, and anorexia, which were mild in severity (grades 1-2)."( Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma.
Arioka, H; Asaoka, Y; Ikeda, M; Koike, K; Kojima, Y; Kondo, S; Mitsunaga, S; Morizane, C; Nakachi, K; Okusaka, T; Sakamoto, Y; Shiina, S; Shimizu, S; Tateishi, R; Ueno, H, 2014
)
0.4
" The incidence of adverse events was 70."( Efficacy and safety of irinotecan plus S-1 (IRIS) therapy to treat advanced/recurrent colorectal cancer.
Abe, S; Egawa, Y; Futami, K; Higashi, D; Hirano, K; Hirano, Y; Inoue, R; Maekawa, T; Mikami, K; Miyake, T; Miyazaki, M; Takahashi, H; Uwatoko, S; Yamamoto, S, 2014
)
0.4
" IRIS therapy had a low incidence of serious adverse events and allowed patients to continue therapy on an out-patient basis."( Efficacy and safety of irinotecan plus S-1 (IRIS) therapy to treat advanced/recurrent colorectal cancer.
Abe, S; Egawa, Y; Futami, K; Higashi, D; Hirano, K; Hirano, Y; Inoue, R; Maekawa, T; Mikami, K; Miyake, T; Miyazaki, M; Takahashi, H; Uwatoko, S; Yamamoto, S, 2014
)
0.4
" Most adverse events were mild."( Safety and efficacy of S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-based chemotherapy: multi-institutional retrospective analysis.
Chen, ZB; Cheng, H; Lin, Z; Liu, YM; Ou, XQ; Peng, PJ; Tang, YN; Wang, SY; Wu, X; Zeng, LJ; Zhang, HY, 2014
)
0.4
"S-1 monotherapy is considered a safe and effective treatment option for recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-based chemotherapy."( Safety and efficacy of S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-based chemotherapy: multi-institutional retrospective analysis.
Chen, ZB; Cheng, H; Lin, Z; Liu, YM; Ou, XQ; Peng, PJ; Tang, YN; Wang, SY; Wu, X; Zeng, LJ; Zhang, HY, 2014
)
0.4
" The baseline characteristics, progressive-free survival, overall survival time and adverse events were retrospectively analyzed."( [Efficacy and safety of low-dose high intensity focused ultrasound combined with S-1 and oxaliplatin in metastatic colorectal patients with pelvic masses].
Guo, Z; Hong, L; Li, B; Liu, C; Si, T; Yu, H, 2014
)
0.4
" Major toxic effects included grade 3/4 neutropenia (15%), anemia (10%), thrombocytopenia (10%), diarrhea (15%) and hand-foot syndrome (10%) in the HIFU+SOX group."( [Efficacy and safety of low-dose high intensity focused ultrasound combined with S-1 and oxaliplatin in metastatic colorectal patients with pelvic masses].
Guo, Z; Hong, L; Li, B; Liu, C; Si, T; Yu, H, 2014
)
0.4
" Adverse events were observed in 27 patients(77%), and adverse events of Grade >3 were observed in 7 patients(20%)."( [Efficacy and safety of TS-1 monotherapy for advanced/metastatic breast cancer - an observational study by the Kumamoto Breast Cancer Cooperative Group(KBCCG)].
Hayashi, K; Iwase, H; Kawano, I; Kuramoto, M; Nishimura, R; Tanigawa, T; Yamamoto, Y; Yamamoto-Ibusuki, M, 2014
)
0.4
"We conducted a meta-analysis to compare oral S-1 and infusional 5-fluorouracil (5-FU) to determine which agent was more efficacious and less toxic in combination with PTX."( The efficacy and toxicity of paclitaxel plus S-1 compared with paclitaxel plus 5-FU for advanced gastric cancer: a PRISMA systematic review and meta-analysis of randomized controlled trials.
Chen, X; Gao, P; Liu, H; Lu, X; Song, Y; Sun, J; Wang, Z; Xu, H; Zhang, N, 2014
)
0.4
" There were only 4 patients in whom the treatment was discontinued due to adverse event, and TS-1 was generally well tolerated."( Effectiveness and safety of tegafur-gimeracil-oteracil potassium (TS-1) for metastatic breast cancer: a single-center retrospective study.
Ishizuna, K; Kawashima, M; Kojima, M; Ninomiya, J; Nozaki, M; Ogawa, T; Tsuji, E; Ueda, Y; Yamagishi, H, 2014
)
0.7
" With regard to adverse events, the rates of nausea (p<0."( [A three-week regimen of S-1 monotherapy reduced gastrointestinal toxicity and maintained efficacy in patients with gemcitabine-refractory advanced pancreatic cancer].
Funazaki, H; Ikeda, M; Katayama, S; Kobayashi, M; Kondo, S; Kuwahara, A; Mitsunaga, S; Morizane, C; Ochiai, A; Ohno, I; Okusaka, T; Okuyama, H; Sakamoto, Y; Shimizu, S; Takahashi, H; Tanaka, H; Ueno, H, 2015
)
0.42
"These results suggest that S-1 adjuvant chemotherapy for pancreatic cancer is safe and feasible, regardless of the age of the patient, especially for elderly patients who may be candidates for clinical trials."( Safety and feasibility of S-1 adjuvant chemotherapy for pancreatic cancer in elderly patients.
Aoyama, T; Atsumi, Y; Higuchi, A; Kanazawa, A; Katayama, Y; Kobayashi, S; Masuda, M; Morimoto, M; Morinaga, S; Murakawa, M; Oshima, T; Rino, Y; Shiozawa, M; Ueno, M; Yamamoto, N; Yamaoku, K; Yoshikawa, T, 2015
)
0.42
" S-1 was shown to be effective and safe in Japanese metastatic breast cancer patients treated with previous chemotherapy, including anthracyclines."( Safety and feasibility of adjuvant chemotherapy with S-1 in Japanese breast cancer patients after primary systemic chemotherapy: a feasibility study.
Hirokawa, E; Kanbayashi, C; Nakamiya, N; Osaki, A; Saeki, T; Sano, H; Sato, N; Sekine, H; Shigekawa, T; Shimada, H; Sugitani, I; Sugiyama, M; Takahashi, T; Takeuchi, H; Ueda, S, 2015
)
0.42
"3%) patients, and adverse events in 5/43 (11."( Safety and feasibility of adjuvant chemotherapy with S-1 in Japanese breast cancer patients after primary systemic chemotherapy: a feasibility study.
Hirokawa, E; Kanbayashi, C; Nakamiya, N; Osaki, A; Saeki, T; Sano, H; Sato, N; Sekine, H; Shigekawa, T; Shimada, H; Sugitani, I; Sugiyama, M; Takahashi, T; Takeuchi, H; Ueda, S, 2015
)
0.42
"The percentage of Japanese breast cancer patients completing the 18-course treatment and the cumulative percentage of administration for 365 days using S-1 after standard primary systemic chemotherapy were similar with the results of another study of adjuvant chemotherapy for the Japanese gastric cancer patients with no severe adverse effects."( Safety and feasibility of adjuvant chemotherapy with S-1 in Japanese breast cancer patients after primary systemic chemotherapy: a feasibility study.
Hirokawa, E; Kanbayashi, C; Nakamiya, N; Osaki, A; Saeki, T; Sano, H; Sato, N; Sekine, H; Shigekawa, T; Shimada, H; Sugitani, I; Sugiyama, M; Takahashi, T; Takeuchi, H; Ueda, S, 2015
)
0.42
" Severe adverse events were observed in 22 patients (91."( Feasibility and toxicity of adjuvant chemotherapy using S-1 granules for local advanced squamous cell carcinoma of the head and neck.
Honda, K; Ishikawa, K; Sato, T; Suzuki, S; Yamazaki, K, 2015
)
0.42
" The efficacy and adverse reactions in patients of the study and control groups were observed and compared."( [Safety and efficacy of gemcitabine combined with S-1 in the treatment of advanced pancreatic cancer].
He, P; Jiang, Y; Yang, K; Zheng, L; Zhong, H, 2015
)
0.42
" The major adverse reactions were myelosuppression and digestive tract reactions, and the adverse reactions in the study group were lower than those in the control group."( [Safety and efficacy of gemcitabine combined with S-1 in the treatment of advanced pancreatic cancer].
He, P; Jiang, Y; Yang, K; Zheng, L; Zhong, H, 2015
)
0.42
"Gemcitabine combined with S-1 is effective and safe in the treatment of advanced pancreatic cancer, with less side effects, and can be tolerated by the patients."( [Safety and efficacy of gemcitabine combined with S-1 in the treatment of advanced pancreatic cancer].
He, P; Jiang, Y; Yang, K; Zheng, L; Zhong, H, 2015
)
0.42
" Grade 3 or worse adverse events were less frequent in the elderly group receiving SOX than in the elderly group receiving CS except for the low incidence of sensory neuropathy (5."( Efficacy and safety of S-1 and oxaliplatin combination therapy in elderly patients with advanced gastric cancer.
Amagai, K; Bando, H; Chin, K; Fujii, H; Gotoh, M; Hamada, C; Hironaka, S; Hyodo, I; Imamura, H; Miwa, H; Nishikawa, K; Nishina, T; Niwa, Y; Shimada, K; Sugimoto, N; Tanabe, S; Tsuda, M; Tsuji, A; Yamada, Y; Yamaguchi, K; Yasui, H, 2016
)
0.43
" Data were extracted for overall survival (OS), progression-free-survival (PFS), objective response rate (ORR) and grade 1-2 and grade 3-4 adverse events."( The efficacy and safety of S-1-based regimens in the first-line treatment of advanced gastric cancer: a systematic review and meta-analysis.
Lodder, P; Mohammad, NH; Ngai, LL; Samaan, M; Ter Veer, E; van Laarhoven, HW; van Oijen, MG, 2016
)
0.43
" In respect of adverse events, both the rates of hematological and non-hematological toxicities were low and similar between the two groups (P>0."( [Comparison of the efficacy and safety of capecitabine or tegafur, gimeracil and oteracil potassium capsules combined with oxaliplatin chemotherapy regimens in the treatment of advanced gastric cancer].
Hui, H; Sun, S; Wan, Y; Wang, X; Wu, J, 2016
)
0.68
" The purpose of the current study was to identify which of the adverse events (AEs) contributed to the deterioration of QOL."( Identification of adverse events that have a negative impact on quality of life in a clinical trial comparing docetaxel versus S-1 with cisplatin in lung cancer.
Aotani, E; Gemma, A; Hamano, T; Kobayashi, K; Takebayashi, T; Takeuchi, M, 2016
)
0.43
" Adverse reactions included grade I/II radiation esophagitis and pneumonitis, with good tolerance."( Efficacy and safety of S-1 (tegafur, gimeracil, and oteracil potassium) concurrent with 3-dimensional conformal radiotherapy for newly diagnosed squamous cell carcinoma of the lung in elderly patients.
Li, QL; Qiu, MQ; Wang, T; Zhang, SF, 2016
)
0.73
" For them, we performed a pilot study to evaluate the feasibility of chemotherapy with carboplatin and S-1, which are known as cytotoxic drug with rare development of ILD as adverse event."( Safety and efficacy of S-1 in combination with carboplatin in non-small cell lung cancer patients with interstitial lung disease: a pilot study.
Baba, T; Hagiwara, E; Ikeda, S; Iwasawa, T; Kato, T; Komatsu, S; Ogura, T; Okuda, R; Satoh, H; Sekine, A; Shinohara, T, 2016
)
0.43
"It was unclear whether the transhiatal approach and D2 total gastrectomy after neoadjuvant chemotherapy (NAC) for adenocarcinoma of the esophago-gastric (AEG) junction are as feasible and safe as D2 gastrectomy following NAC."( Feasibility and Safety of Transhiatal Approach and D2 Total Gastrectomy after Neoadjuvant Chemotherapy for Adenocarcinoma of the Esophago-Gastric Junction: A Subset Analysis of the COMPASS Trial.
Aoyama, T; Cho, H; Hayashi, T; Ito, Y; Miyashita, Y; Nishikawa, K; Sakamoto, J; Tanabe, K; Tsuburaya, A; Yoshikawa, T, 2016
)
0.43
"The transhiatal approach and D2 total gastrectomy after NAC seem to be as safe and feasible as D2 gastrectomy for non-AEG cancer."( Feasibility and Safety of Transhiatal Approach and D2 Total Gastrectomy after Neoadjuvant Chemotherapy for Adenocarcinoma of the Esophago-Gastric Junction: A Subset Analysis of the COMPASS Trial.
Aoyama, T; Cho, H; Hayashi, T; Ito, Y; Miyashita, Y; Nishikawa, K; Sakamoto, J; Tanabe, K; Tsuburaya, A; Yoshikawa, T, 2016
)
0.43
"Nutritional therapy is used to reduce the adverse events (AEs) of anticancer drugs."( Oral administration of the amino acids cystine and theanine attenuates the adverse events of S-1 adjuvant chemotherapy in gastrointestinal cancer patients.
Hashimoto, T; Honda, H; Kakita, T; Kayahara, T; Kurihara, S; Oikawa, M; Oishi, H; Oyama, A; Shibakusa, T; Tochikubo, K; Tsuchiya, T, 2016
)
0.43
" The combined hazard ratio (HR) or risk ratio; the corresponding 95% confidence intervals of progression-free survival, overall survival, and overall response rate; and grade 3-4 adverse events were examined."( Therapeutic efficacy and safety of S-1-based combination therapy compare with S-1 monotherapy following gemcitabine failure in pancreatic cancer: a meta-analysis.
Hu, Z; Ju, B; Lu, S; Wang, W; Xie, H; Yang, Q; Zhang, Y; Zhao, X; Zheng, S; Zhou, D; Zhou, L; Zhou, X, 2016
)
0.43
" Previous studies have suggested that apatinib is safe and effective in some solid tumors."( Significant efficacy and well safety of apatinib in an advanced liver cancer patient: a case report and literature review.
Kong, L; Kou, P; Shao, W; Wang, H; Yu, J; Zhang, J; Zhang, Y; Zhu, H, 2017
)
0.46
" Evidence for safe administration of S-1 following 5-FU cardiotoxicity is limited to a case report in an Asian patient."( Safe administration of S-1 after 5-fluorouracil-induced cardiotoxicity in a patient with colorectal cancer.
Franck, C; Malfertheiner, P; Venerito, M, 2017
)
0.46
" Common grade 3 or higher adverse events included neutropenia (1 in XP, 3 in SP, and 2 in SOX), decreased appetite (1 in SP), and hypertension (2 in XP)."( Safety, pharmacokinetic, and clinical activity profiles of ramucirumab in combination with three platinum/fluoropyrimidine doublets in Japanese patients with chemotherapy-naïve metastatic gastric/gastroesophageal junction cancer.
Gritli, I; Inoue, K; Kadowaki, S; Muro, K; Nishina, T; Ozeki, A; Piao, Y; Sakai, D; Shitara, K; Yoshikawa, R, 2018
)
0.48
" The incidences of any grade ≥3 adverse events in the second-line group and the third-line group were 60."( Efficacy and safety of taxane monotherapy in advanced gastric cancer refractory to triplet chemotherapy with docetaxel, cisplatin, and S-1: a multicenter retrospective study.
Boku, N; Iizumi, S; Kawai, S; Matsushima, T; Muro, K; Nagashima, K; Narita, Y; Tajika, M; Takahari, D; Takashima, A; Yasui, H, 2017
)
0.46
"00%) had grade 3 adverse events."( Safety and Efficacy of the S-1/Temozolomide Regimen in Patients with Metastatic Neuroendocrine Tumors.
Chi, Y; Zhao, H; Zhao, J, 2018
)
0.48
"The aim of this study was to investigate the impact of adverse events (AEs) on health utility and health-related quality of life (HRQOL) in patients with metastatic breast cancer undergoing first-line chemotherapy."( Impact of Adverse Events on Health Utility and Health-Related Quality of Life in Patients Receiving First-Line Chemotherapy for Metastatic Breast Cancer: Results from the SELECT BC Study.
Fukuda, T; Hagiwara, Y; Kawahara, T; Mukai, H; Ohashi, Y; Shimozuma, K; Shiroiwa, T; Taira, N; Uemura, Y; Watanabe, T, 2018
)
0.48
" The overall incidence of any Grade adverse events (AEs) were 91."( Planned Safety Analysis of the ACTS-CC 02 Trial: A Randomized Phase III Trial of S-1 With Oxaliplatin Versus Tegafur and Uracil With Leucovorin as Adjuvant Chemotherapy for High-Risk Stage III Colon Cancer.
Aiba, K; Baba, H; Boku, N; Ishiguro, M; Itabashi, M; Kotake, K; Kunieda, K; Kusumoto, T; Maeda, A; Mochizuki, I; Morita, S; Okabe, M; Ota, M; Sakamoto, Y; Sugihara, K; Sunami, E; Takahashi, K; Tomita, N; Yamauchi, J; Yoshida, K, 2018
)
0.69
" Hematological adverse events were commonly seen in both group (12."( Efficacy and safety comparison of nabpaclitaxel plus S-1 and gemcitabine plus S-1 as first-line chemotherapy for metastatic pancreatic cancer.
Fan, Y; Feng, Y; Guo, X; Liu, T; Lou, W; Wang, D; Wang, Y; Wu, L; Wu, W; Xu, B; Xu, Y; Zhou, Y, 2018
)
0.48
" S-1 monotherapy was relatively effective and safe in the treatment of advanced breast cancer in elderly patients."( Clinical efficacy and safety of S-1 monotherapy in the treatment of advanced breast cancer in elderly patients.
Cui, S; Sun, Y; Ye, M; You, D; Zhao, Q, 2018
)
0.48
" Most frequent (>10%) grade 3/4 treatment-related adverse events were neutropenia (14."( Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (A
Azuma, M; Boku, N; Chen, LT; Cho, H; Chung, HC; Fumita, S; Hara, H; Kang, WK; Kang, YK; Kato, K; Komatsu, Y; Lee, KW; Minashi, K; Ryu, MH; Tsuda, M; Yamaguchi, K, 2019
)
0.51
" Major grade 3/4 adverse events during NAC were neutropenia (29."( Randomized phase III trial of gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer, the short-term safety and surgical results: Japan Clinical Oncology Group Study (JCOG0501).
Boku, N; Hirao, M; Ito, Y; Iwasaki, Y; Kaji, M; Katai, H; Katayama, H; Kimura, Y; Kurita, A; Mizusawa, J; Nakamura, K; Sano, T; Sasako, M; Takagi, M; Terashima, M; Yamada, M; Yoshikawa, T, 2019
)
0.51
" We analyzed the clinical response, survival rate, acute adverse events, and late swallowing toxicity."( Long-term efficacy and toxicity of concurrent chemoradiotherapy with nedaplatin and S-1 for head and neck squamous cell carcinoma.
Ohashi, T; Ohnishi, M; Okuda, H; Takada, N; Takagi, C; Takahashi, H, 2019
)
0.51
" The main acute adverse events were leukopenia, neutropenia, mucositis, and dermatitis."( Long-term efficacy and toxicity of concurrent chemoradiotherapy with nedaplatin and S-1 for head and neck squamous cell carcinoma.
Ohashi, T; Ohnishi, M; Okuda, H; Takada, N; Takagi, C; Takahashi, H, 2019
)
0.51
"Previous studies have shown sex-related differences in the incidence of adverse events following treatment with fluoropyrimidines, however the mechanism of this difference is unknown."( Sex differences in the safety of S-1 plus oxaliplatin and S-1 plus cisplatin for patients with metastatic gastric cancer.
Amagai, K; Chin, K; Fujii, H; Fuse, N; Gotoh, M; Hironaka, S; Hyodo, I; Imamura, H; Koizumi, W; Nishikawa, K; Nishina, T; Niwa, Y; Shimada, K; Sugimoto, N; Tsuda, M; Tsuji, A; Yamada, Y; Yamaguchi, K; Yasui, H, 2019
)
0.51
" Odds ratio and hazard ratio of available outcomes including objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and adverse events (AEs) were pooled for analysis."( Comparison of efficacy and safety of S-1 and capecitabine in patients with metastatic colorectal carcinoma: A systematic review and meta-analysis.
Chen, J; Wang, J; Xu, T, 2019
)
0.51
" Adverse events (AEs) were recorded to evaluate the safety."( Clinical efficacy and safety of apatinib combined with S-1 in advanced esophageal squamous cell carcinoma.
Lei, J; Song, X; Wang, Y; Yu, J; Zhang, C; Zhang, N; Zhang, S; Zhao, J, 2020
)
0.56
"S-1 plus oxaliplatin in advanced gastric cancer patients with impaired renal function appears safe and has demonstrated efficacy given appropriate dose modification."( Clinical impact of renal impairment on the safety and efficacy of S-1 plus oxaliplatin in patients with advanced gastric cancer: a single institutional study.
Bando, H; Demachi, K; Kawasaki, T; Nomura, H; Shitara, K; Yamaguchi, M; Yoshino, T, 2020
)
0.56
" Grade ≥3 treatment-related adverse events (TRAEs) were reported by 57."( Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study.
Amagai, K; Azuma, M; Baba, H; Esaki, T; Han, SR; Hara, H; Hosaka, H; Kawakami, H; Kawazoe, A; Komatsu, Y; Machida, N; Negoro, Y; Nishina, T; Omuro, Y; Oshima, T; Shiratori, S; Shitara, K; Tsuda, M; Yamaguchi, K; Yasui, H; Yoshida, K, 2020
)
0.56
"The SHSP regimen could be administered in outpatient settings and was considered safe as it did not cause renal toxicity."( [Analysis of Renal Toxicity of S-1 plus CDDP Regimen with Short Hydration for Outpatients with Gastric Cancer].
Hasegawa, T; Hirakawa, K; Kinoshita, H; Mori, T; Nakamoto, K; Noda, E; Ohira, M; Teraoka, H, 2019
)
0.51
" Outcomes included objective response rate (ORR); 6-, 12-, and 18-month progression-free survival (PFS); 1-, 2-, and 3-year overall survival (OS); and adverse events."( The efficacy and safety of capecitabine-based versus S-1-based chemotherapy for metastatic or recurrent gastric cancer: a systematic review and meta-analysis of clinical randomized trials.
Feng, J; Feng, Z; He, X; Hou, X; Yan, P; Yang, K, 2020
)
0.56
" The baseline characteristics of the patients, response to S-1 monotherapy, and adverse events (AEs) were investigated, retrospectively."( Efficacy and safety of S-1 monotherapy in previously treated elderly patients (aged ≥75 years) with non-small cell lung cancer: A retrospective analysis.
Imai, H; Ishihara, S; Kaburagi, T; Kaira, K; Kanazawa, K; Kasahara, N; Kasai, T; Kishikawa, T; Minato, K; Minemura, H; Mori, K; Naruse, I; Shibata, Y; Suzuki, K; Uchino, J; Umeda, Y; Wasamoto, S; Yamada, Y; Yamaguchi, O, 2020
)
0.56
" (20%) terminated S-1 due to adverse events."( Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tract cancer.
Andoh, A; Fukutomi, A; Fushiki, K; Hamauchi, S; Inoue, H; Kawakami, T; Machida, N; Onozawa, Y; Shirasu, H; Todaka, A; Tsushima, T; Yamazaki, K; Yasui, H; Yokota, T, 2021
)
0.62
" The incidence of adverse events (AEs) was 100%."( Short-term survival and safety of apatinib combined with oxaliplatin and S-1 in the conversion therapy of unresectable gastric cancer.
Chen, L; Chen, S; Lin, Z; Wang, Y; Wang, Z; Wei, S; Ye, Z; Zeng, Y, 2021
)
0.62
"Nab-paclitaxel plus S1 was more efficient in terms of ORR and DCR than S1 monotherapy in elderly pancreatic ductal adenocarcinoma patients while the side effect was controllable with a higher probability of leukopenia."( Safety and efficacy of S1 monotherapy or combined with nab-paclitaxel in advanced elderly pancreatic cancer patients: A meta-analysis.
Chen, D; Chen, X; Chen, Y; Cui, S; Du, J; Gu, J; Lin, Z; Luo, H; Ma, C; Wang, C; Yang, L; Yin, M, 2021
)
0.62
" Thirty-two patients developed 54 events of CRT-related adverse events, including only one patient with a grade 3 event (stomatitis)."( Tolerability and safety of adjuvant chemoradiotherapy with S-1 after limited surgery for T1 or T2 lower rectal cancer.
Doki, Y; Eguchi, H; Kitakaze, M; Miyoshi, N; Mizushima, T; Murata, K; Noura, S; Ohue, M; Takahashi, H; Tei, M; Uemura, M, 2021
)
0.62
" Treatment was terminated in case of life-threatening adverse events or tumor progression, or patients' demand for termination."( Efficacy and Safety of Additional S-1 Chemotherapy to S-1 Plus Oxaliplatin Regimen Chemotherapy for Stage III Gastric Carcinoma after Radical Resection.
Chen, C; Huang, SX; Shen, CL; Tang, CW, 2022
)
0.72
" The main adverse events (AEs) of anlotinib combined with S-1 were fatigue (58."( Effect and safety of anlotinib combined with S-1 for recurrent or metastatic esophageal cancer patients who refused or were intolerant to intravenous chemotherapy.
Cai, J; Liu, A; Luo, Y; Zhou, S, 2021
)
0.62
" The use of camrelizumab did not increase postoperative complications or the adverse effects of neoadjuvant therapy."( Safety and Efficacy of Camrelizumab in Combination With Nab-Paclitaxel Plus S-1 for the Treatment of Gastric Cancer With Serosal Invasion.
Chen, QY; Huang, CM; Li, P; Lin, JL; Lin, JP; Lin, JX; Lu, J; Wang, JB; Xie, JW; Zheng, CH, 2021
)
0.62
" We compared the antibody titers of SARS-CoV-2 vaccines and the adverse events between patients who received adjuvant UFT and patients who did not."( Comparable efficacy and safety of COVID-19 vaccines for patients receiving tegafur-uracil as postoperative adjuvant chemotherapy.
Doi, T; Funakoshi, Y; Hojo, W; Hokka, D; Maniwa, Y; Minami, H; Mitsui, S; Nishikubo, M; Ohji, G; Sakai, H; Tanaka, Y; Yakushijin, K, 2023
)
1.14
" The prevalence of adverse events did not differ significantly between the groups, and no severe adverse events occurred."( Comparable efficacy and safety of COVID-19 vaccines for patients receiving tegafur-uracil as postoperative adjuvant chemotherapy.
Doi, T; Funakoshi, Y; Hojo, W; Hokka, D; Maniwa, Y; Minami, H; Mitsui, S; Nishikubo, M; Ohji, G; Sakai, H; Tanaka, Y; Yakushijin, K, 2023
)
1.14

Pharmacokinetics

Study was to investigate the effect of gimeracil (CDHP), a reversible dihydropyrimidine dehydrogenase (DPD) inhibitor, on the pharmacokinetics of 5-fluorouracil.

ExcerptReferenceRelevance
"Methods for pharmacokinetic modulation of the plasma 5-fluorouracil (5-FU) level to increase antitumor activity during continuous venous infusion (CVI) of low doses of 5-FU were examined in Yoshida sarcoma-bearing rats."( Pharmacokinetic modulation of plasma 5-fluorouracil concentrations to potentiate the antitumor activity of continuous venous infusion of 5-fluorouracil.
Fujii, S; Fukushima, M; Shimamoto, Y; Shirasaka, T, 1989
)
0.28
" Pharmacokinetic study after single oral administration of 300 to 1200 mg of UFT-E was carried out in cancer patients measuring tagafur, uracil and 5-FU levels in serum, normal tissue and tumor tissue using HPLC and GC-mass."( [Pharmacokinetics and a phase I study of tegafur-uracil enterogranules in cancer patients].
Fujii, S; Hoshino, A; Kamiya, O; Kimura, K; Kojima, T; Nagata, K; Ohara, K; Sugihara, T; Suzuki, M; Yamada, M, 1983
)
0.53
" By considering these pharmacokinetic behaviors, a suitable method of administration should be established."( [Chemical modification of anticancer agents from viewpoints of their pharmacokinetics].
Fujita, H, 1984
)
0.27
" The following pharmacokinetic results were obtained in comparison with single administration."( [Pharmacokinetics of FT-207 rectum suppository in squamous cell carcinoma of the uterine cervix. (II) Pharmacokinetics in continuous administration at a daily dose of 1 gram].
Chin, N; Endoh, S; Fukui, H; Hasegawa, T; Hayashi, Y; Ishii, Y; Kohno, I; Nakagiri, Y; Okazaki, H; Rin, K, 1984
)
0.27
"To evaluate the effect of the oral fluoropyrimidines, tegafur and uracil (UFT) and 5-fluorouracil (5-FU), a pharmacodynamic analysis was conducted using a nude mouse system and patients."( A pharmacodynamic and pharmacokinetic study of fluoropyrimidines in a nude mouse system and in postoperative patients with gastric cancer.
Hishinuma, S; Ikeda, T; Inada, T; Kotake, K; Koyama, Y; Kubota, T; Ogata, Y; Ozawa, I; Shimizu, H, 1993
)
0.53
" Pharmacokinetic parameters [ftorafur, uracil, 5-fluorouracil (5-FU), 5-methyltetrahydrofolate] showed wide interpatient variations."( A phase I and pharmacokinetic study of oral uracil, ftorafur, and leucovorin in patients with advanced cancer.
Creaven, PJ; Frank, C; Ho, DH; Kurowski, M; Meropol, NJ; Petrelli, NJ; Rodriguez-Bigas, M; Rustum, YM, 1996
)
0.29
" Pharmacokinetic examination after intravenous injection of low-dose MMC (0."( A case of advanced gastric cancer complicated by severe toxicity induced by a combination of tegafur, uracil and mitomycin C, and associated with abnormal pharmacokinetics.
Boku, N; Ishii, H; Kaneko, K; Kusada, O; Muro, K; Muto, M; Ohkuwa, M; Ohtsu, A; Sasaki, Y; Tajiri, H; Yoshida, S, 1996
)
0.51
" Pharmacokinetic evaluation showed that single-dose UFT results in maximum plasma levels and an area under the concentration-time curve that increased with escalating UFT doses."( Phase I and pharmacokinetic evaluations of UFT plus oral leucovorin.
Pazdur, R, 1997
)
0.3
" We administered pharmacokinetic modulating chemotherapy, based on the concept that the benefit of a continuous venous 5-fluorouracil (5FU) infusion can be potentiated by low-dose oral UFT, a combination of 1-(2-tetrahydrofuryl)-5-fluorouracil (tegafur) and uracil at a molar ratio of 1:4."( Effects of pharmacokinetic modulating chemotherapy using oral UFT and continuous venous 5FU infusion on the prognosis of irradiated rectal carcinomas with p53 overexpression.
Kotera, H; Kusunoki, M; Noda, M; Yamamura, T; Yanagi, H, 1998
)
0.48
"This study was performed to improve the prognosis of unresectable (primary non-curative and recurrent) colorectal carcinoma by using pharmacokinetic modulating chemotherapy (PMC), a combination of oral UFT and continuous venous 5FU infusion."( The usefulness of pharmacokinetic modulating chemotherapy (UFT plus 5FU) in the treatment of unresectable colorectal carcinomas.
Kusunoki, M; Noda, M; Yamamura, T; Yanagi, H,
)
0.13
" Pharmacokinetic parameters of plasma 5-FU were as follows: Cmax, 128."( Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug.
Aiba, K; Denno, R; Hirata, K; Horikoshi, N; Ishizuka, H; Nakano, Y; Okazaki, M; Sasaki, K; Shirasaka, T; Taguchi, T; Uno, S; Yamada, Y, 1999
)
0.3
"We performed pharmacokinetic modulating chemotherapy (PMC) postoperatively in patients with advanced gastric cancer and examined its antitumor and the side effects."( [PMC (pharmacokinetic modulating chemotherapy) for advanced gastric cancer].
Fujiwara, Y; Itoh, R; Kusunoki, M; Nakagawa, K; Nakao, K; Yamamura, T, 1999
)
0.3
" Plasma pharmacokinetics of 5-FU were linear; at the highest S-1 dose level, 5-FU plasma peak concentrations reached 1 to 2 micromol/L, and the half-life of 5-FU was 3 to 4 hours."( Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors.
de Vries, MJ; Gall, H; Giaccone, G; Hanauske, AR; Noordhuis, P; Peters, GJ; Pinedo, HM; Schornagel, JH; Swart, MS; Turner, SL; van Groeningen, CJ, 2000
)
0.31
" The ratio of FBAL to 5-FU in Cmax and AUC after dosing of UFT was the lowest among these four test compounds."( [Comparison of pharmacokinetics of 5-FU and alpha-fluoro-beta-alanine, a metabolite of 5-FU, in plasma after administration of UFT, tegafur, 5-FU or doxifluridine to rats].
Hirakawa, Y; Kawaguchi, Y; Kuwata, K; Matsushima, E; Nagayama, S, 2000
)
0.51
"We encountered a case of unresectable colon cancer that disappeared following pharmacokinetic modulating chemotherapy (PMC)."( [A case report of unresectable colon cancer that disappeared following pharmacokinetic modulation chemotherapy (PMC)].
Asahara, T; Nakahara, H; Nakahara, M; Okajima, M; Yano, M, 2000
)
0.31
" Intermittent hepatic arterial infusion of high-dose 5-FU was started on a weekly schedule and oral UFT was added as pharmacokinetic modulating chemotherapy 4 weeks after the initial chemotherapy."( [A successful case of preoperative intermittent hepatic arterial infusion of high-dose 5-FU and pharmacokinetic modulating chemotherapy against unresectable liver metastasis of colon cancer].
Hamazaki, K; Inagaki, M; Kawashima, T; Morichika, T; Sadamori, H; Shima, Y; Tanaka, N; Uetsuka, H; Yagi, T, 2000
)
0.31
" The correlation between pharmacokinetic parameters and toxic effects of UFT was evaluated."( Oral uracil and Ftorafur plus leucovorin: pharmacokinetics and toxicity in patients with metastatic cancer.
Brown, N; Covington, W; Creaven, PJ; Hayakawa, T; Ho, DH; Huo, YY; Kuritani, J; Lassere, Y; Lin, SN; Meropol, NJ; Pazdur, R; Rustum, YM, 2000
)
0.31
" Furthermore, he was administered tegafur/uracil (400 mg/day) 5 days weekly as a pharmacokinetic modulating chemotherapy (PMC)."( [A case of nonresectable scirrhous type gastric cancer treated by hypertensive subselective chemotherapy with pharmacokinetic modulating chemotherapy].
Ishikawa, T; Kobayashi, M; Matsuki, H; Mita, Y; Tashiro, K; Tashiro, S, 2001
)
0.59
" He was treated postoperatively with arterial infusion pharmacokinetic modulating chemotherapy (PMC) and venous infusion CPT-11 (modified PMC)."( [A case of rectal cancer with multiple liver metastases that responded dramatically to pharmacokinetic modulating chemotherapy/CPT-11 therapy].
Dan, T; Kitayama, Y; Kosaka, H; Maeda, S; Matsusaka, S; Okada, T; Tanabe, H; Yamasaki, H, 2002
)
0.31
" These findings demonstrate that administration of S-1 to patients with impaired renal function may need individualized dosing and pharmacokinetic monitoring."( Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function.
Furukawa, H; Ikeda, M; Imamura, H; Ishida, H; Kawasaki, T; Masutani, S; Satomi, T; Shimizu, J; Tatsuta, M, 2002
)
0.31
" Pharmacokinetic data are consistent with potent modulation of 5-fluorouracil (5-FU) by CDHP, with prolonged half-life and 5-FU AUC at least 10-fold higher than reported in previous studies of equitoxic doses of tegafur modulated by uracil."( Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancer.
Beard, M; Cohen, SJ; Damle, B; DeCillis, AP; Leichman, CG; Letrent, SP; Meropol, NJ; Proefrock, A; Roedig, B; Yeslow, G, 2002
)
0.5
" The pharmacokinetic data presented provide evidence of 5-FU modulation by CDHP."( Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancer.
Beard, M; Cohen, SJ; Damle, B; DeCillis, AP; Leichman, CG; Letrent, SP; Meropol, NJ; Proefrock, A; Roedig, B; Yeslow, G, 2002
)
0.31
"We treated a patient with unresectable rectal cancer with multiple liver, pulmonary and lymph node metastases that responded remarkably to pharmacokinetic modulating chemotherapy (PMC)."( [A case of unresectable rectal cancer with liver and pulmonary metastases that responded remarkably to pharmacokinetic modulating chemotherapy].
Chiba, M; Hayashi, K; Inaba, Y; Kamio, Y; Koyama, M; Ohe, S; Watabe, S, 2002
)
0.31
" Administration of modified pharmacokinetic modulating chemotherapy (PMC) using Leucovorin (intravenous infusion of 5-FU, 600 mg/m2/24 hours; oral administration of UFT, Taiho Pharmaceutical Co."( [A case of multiple liver metastases from colon cancer successfully treated with modified pharmacokinetic modulating chemotherapy using Leucovorin].
Hatada, T; Inoue, Y; Kobayashi, M; Kusunoki, M; Miki, C; Ojima, E, 2002
)
0.31
"Advanced unresectable hepatocellular carcinoma (HCC) was treated with modified pharmacokinetic modulation chemotherapy (PMC)."( [Modified pharmacokinetic modulation chemotherapy (PMC) with medication of UFT and intraarterial infusion of 5-FU for advanced unresectable HCC].
Ito, T; Kamachi, H; Kamiyama, T; Kondo, M; Kurauchi, N; Matsushita, M; Nakagawa, T; Nishikawa, M; Ogata, T; Todo, S, 2002
)
0.31
"The pharmacokinetics of ftorafur, 5-fluorouracil (5FU) and uracil were investigated in order to built a population pharmacokinetic model for the anticancer drug UFT, administered with leucovorin and vinorelbine."( Modelling of ftorafur and 5-fluorouracil pharmacokinetics following oral UFT administration. A population study in 30 patients with advanced breast cancer.
Bonneterre, J; Campone, M; Deporte-Fety, R; Fargeot, P; Fumoleau, P; Kerbrat, P; Urien, S, 2003
)
0.32
"Of the 31 patients treated, 30 were available for the pharmacokinetic analysis."( Modelling of ftorafur and 5-fluorouracil pharmacokinetics following oral UFT administration. A population study in 30 patients with advanced breast cancer.
Bonneterre, J; Campone, M; Deporte-Fety, R; Fargeot, P; Fumoleau, P; Kerbrat, P; Urien, S, 2003
)
0.32
"A pharmacokinetic model for ftorafur and 5FU was developed and should be useful to further study drug interactions and establish dosing guidelines."( Modelling of ftorafur and 5-fluorouracil pharmacokinetics following oral UFT administration. A population study in 30 patients with advanced breast cancer.
Bonneterre, J; Campone, M; Deporte-Fety, R; Fargeot, P; Fumoleau, P; Kerbrat, P; Urien, S, 2003
)
0.32
" Furthermore, he was administered tegafur/uracil (400 mg/day) 5 days weekly as pharmacokinetic modulating chemotherapy (PMC)."( [A case of advanced gastric cancer with liver and intra-abdominal lymph node metastasis treated by hypertensive selective chemotherapy with pharmacokinetic modulating chemotherapy].
Baba, Y; Hayashi, S; Ishikawa, T; Kamimura, T; Nomura, K; Oota, H; Yoshida, T, 2003
)
0.6
" Pharmacokinetic modulating chemotherapy (PMC) was performed after the operation."( [A case of multiple liver metastases from colon cancer successfully treated with pharmacokinetic modulating chemotherapy].
Futamura, N; Matsutomo, M; Sakamoto, K; Tateyama, K; Yasumura, M, 2003
)
0.32
"S-1 is an oral anticancer agent combining tegafur (FT), a prodrug of 5-fluorouracil (5-FU), with potassium oxonate (oteracil) and gimeracil (CDHP) respectively to mitigate gastrointestinal toxicity and increase the half-life of 5-FU."( Comparison of the pharmacokinetics of S-1, an oral anticancer agent, in Western and Japanese patients.
Comets, E; Fumoleau, P; Hoff, P; Ikeda, K; Tanigawara, Y; Wanders, J, 2003
)
0.58
" Pharmacokinetic modulating chemotherapy (PMC), a combination of infused 5-fluorouracil and oral uracil-tegafur, has been proven to be highly effective for the treatment of colorectal carcinoma."( Modified pharmacokinetic modulating chemotherapy using 5-fluorouracil, UFT, and taxotere (docetaxel) for advanced gastric cancer.
Kobayashi, M; Konishi, N; Kusunoki, M; Mohri, Y; Ohmori, Y; Tanaka, K; Tonouchi, H, 2003
)
0.53
" He was treated with pharmacokinetic modulating chemotherapy (PMC) and low-dose CPT-11."( [A case of highly advanced ascending colon cancer with multiple bone and liver metastases and pleuritis carcinomatosa treated with pharmacokinetic modulating chemotherapy and low-dose CPT-11].
Aihara, T; Fukuhara, A; Kouno, T; Murayama, M; Nakagawa, K; Nakamura, E; Niida, M; Nishimoto, Y; Nozaki, H; Syouda, S; Watanabe, Y; Yagyu, T; Yasuoka, H, 2004
)
0.32
" Pharmacokinetic studies after administration of S-1 revealed high and prolonged plasma 5-FU levels."( S-1-induced, prolonged complete regression of lung metastasis from gastric cancer refractory to 5'-DFUR: a case report with pharmacokinetic study.
Ajani, JA; Itoh, N; Itoi, H; Shirasaka, T; Ueda, Y; Yamagishi, H; Yamashita, T, 2004
)
0.32
" Blood samples for the pharmacokinetic study were obtained after the initial dose on day 1 of the first course."( Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV.
Abbruzzese, JL; Boku, N; Hoff, PM; Hyodo, I; Loehrer, PJ; Muro, K; Nagashima, F; O'Dwyer, PJ; Ohtsu, A; Shirao, K; Wadleigh, RG; Wadler, S; Yamada, Y, 2004
)
0.56
"The efficacy and pharmacokinetic parameters of UFT and LV are comparable in Japanese and American patients; however, a difference in toxicity profile, specifically diarrhea, was noted."( Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV.
Abbruzzese, JL; Boku, N; Hoff, PM; Hyodo, I; Loehrer, PJ; Muro, K; Nagashima, F; O'Dwyer, PJ; Ohtsu, A; Shirao, K; Wadleigh, RG; Wadler, S; Yamada, Y, 2004
)
0.56
"The main purpose of the present review article was to shed light on the different 5-fluorouracil (5-FU) prodrugs by underlining their respective pharmacological features in terms of metabolic activation, dihydropyrimidine dehydrogenase inhibition, pharmacokinetic profile and biomodulation ability."( Comparative pharmacology of oral fluoropyrimidines: a focus on pharmacokinetics, pharmacodynamics and pharmacomodulation.
Ferrero, JM; François, E; Milano, G, 2004
)
0.32
" The pharmacokinetic profiles of the tegafur, CDHP, and oxonic acid constituents were characterized."( Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
Chu, QS; Damle, B; DeCillis, AP; Denis, L; Hammond, LA; Letrent, SP; Molpus, K; Ochoa, L; Rha, SY; Roedig, B; Rowinsky, EK; Schwartz, G, 2004
)
0.6
" The pharmacokinetic data suggested potent inhibition of 5-FU clearance by CHDP, with resultant 5-FU exposure at least 10-fold higher than that reported from equitoxic doses of tegafur modulated by uracil in the oral fluoropyrimidine UFT."( Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
Chu, QS; Damle, B; DeCillis, AP; Denis, L; Hammond, LA; Letrent, SP; Molpus, K; Ochoa, L; Rha, SY; Roedig, B; Rowinsky, EK; Schwartz, G, 2004
)
0.52
" The pharmacokinetic data indicate substantial modulation of 5-FU clearance by CDHP."( Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
Chu, QS; Damle, B; DeCillis, AP; Denis, L; Hammond, LA; Letrent, SP; Molpus, K; Ochoa, L; Rha, SY; Roedig, B; Rowinsky, EK; Schwartz, G, 2004
)
0.32
" We conducted an analysis to evaluate the efficacy and feasibility of modified pharmacokinetic modulating chemotherapy, for gastric cancer patients with peritoneal dissemination."( [Modified pharmacokinetic modulating chemotherapy for progressive gastric cancer accompanied by peritoneal dissemination].
Ishikawa, T; Kamimura, T; Mizuno, K; Ohta, H; Seki, K; Togashi, T; Watanabe, K; Yoshida, T, 2005
)
0.33
" Furthermore, she was administered tegafur/uracil (400 mg/day) 5 days weekly for pharmacokinetic modulating chemotherapy (PMC)."( [A case of advanced gastric cancer with bone metastasis and severe DIC responding to hypertensive subselective chemotherapy with pharmacokinetic modulating chemotherapy].
Ishikawa, T; Kamimura, T; Mizuno, K; Ohta, H; Seki, K; Togashi, T; Watanabe, K; Yoshida, T, 2005
)
0.61
" Therefore, we initiated a phase I pharmacokinetic study of this combination in our gastric cancer patients."( Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma.
Ajani, JA; Anbe, H; Carr, KL; Faust, J; Houghton, M; Ikeda, K; Urrea, P; Yao, JC, 2005
)
0.33
" In conclusion, individual dose adjustment using pharmacokinetic study of 5-FU might be beneficial to patients with impaired renal function."( [A trial of TS-1 administration on the basis of the pharmacokinetic study for an advanced gastric cancer patient with impaired renal function].
Fukunaga, M; Furukawa, H; Imamura, H; Kamigaki, S; Kawasaki, T; Kishimoto, T; Kondo, M; Masutani, S; Nakayama, T; Oshiro, R; Takemoto, H; Tanaka, J; Tatsuta, M; Yamamoto, K, 2005
)
0.33
" A pharmacokinetic study was conducted in an additional 5 patients on days 7 and 8 during the first course given at the RD."( Phase I and pharmacokinetic study of S-1 combined with weekly paclitaxel in patients with advanced gastric cancer.
Fujitani, K; Furukawa, H; Gotoh, M; Hirao, M; Narahara, H; Satomi, E; Taguchi, T; Takiuchi, H; Tsujinaka, T, 2005
)
0.33
" There were no significant pharmacokinetic interactions between S-1 and paclitaxel."( Phase I and pharmacokinetic study of S-1 combined with weekly paclitaxel in patients with advanced gastric cancer.
Fujitani, K; Furukawa, H; Gotoh, M; Hirao, M; Narahara, H; Satomi, E; Taguchi, T; Takiuchi, H; Tsujinaka, T, 2005
)
0.33
" In the total gastrectomy cases the post-operative tmax of both 5-FU and CDHP was shorter than the pre-operative tmax, and no significant differences were observed between the pre- and post-operative AUC0-8 h values."( Effect of gastrectomy on the pharmacokinetics of 5-fluorouracil and gimeracil after oral administration of S-1.
Kamano, T; Kawai, K; Kitajima, M; Ochiai, T; Sakamoto, K; Shirasaka, T; Tsuruoka, Y; Watabe, S, 2006
)
0.33
" Pharmacokinetic parameters of 5-FU in the serum were as follows: Cmax, 159 ."( [Pharmacokinetics of 5-FU after S-1 oral administration for adjuvant chemotherapy in gastric cancer patients].
Fuchimoto, M; Fujikura, H; Hato, S; Higashida, M; Hirabayashi, Y; Hirai, T; Kawabe, Y; Matsumoto, H; Murakami, H; Tsunoda, T; Urakami, A; Yamashita, K, 2007
)
0.34
" We aimed to develop a pharmacokinetic model to describe the kinetics of tegafur and 5-FU after the administration of TS-1 and UFT."( Development of a pharmacokinetic model to optimize the dosage regimen of TS-1, a combination preparation of tegafur, gimeracil and oteracil potassium.
Hori, S; Inoue, S; Ohtani, H; Sawada, Y; Tsujimoto, M, 2007
)
0.78
"From 2002 to 2007, a total of 10 consecutive patients with Stage IVA HCC accompanied by PVTT were studied prospectively to examine the efficacy of treatment by intra-arterial infusion of a chemotherapeutic agents consisting of etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil."( Improved survival for hepatocellular carcinoma with portal vein tumor thrombosis treated by intra-arterial chemotherapy combining etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil: a p
Imai, M; Ishikawa, T; Kamimura, H; Kamimura, T; Ohta, H; Seki, K; Togashi, T; Tsuchiya, A; Watanabe, K; Yoshida, T, 2007
)
0.69
" The pharmacokinetic parameters were analysed after logarithmic transformation according to a general linear model."( A clinical pharmacokinetic analysis of tegafur-uracil (UFT) plus leucovorin given in a new twice-daily oral administration schedule.
Bennouna, J; Cardot, JM; Château, Y; Douillard, JY; Etienne-Grimaldi, MC; François, E; Gamelin, E; Milano, G; Renée, N, 2007
)
0.61
"To test the efficacy and safety of pharmacokinetic modulating chemotherapy combined with cisplatin (PMC-cisplatin) as induction chemotherapy (ICT) before definitive treatment in patients with respectable locally advanced head and neck squamous cell carcinoma (HNSCC)."( Effectiveness of pharmacokinetic modulating chemotherapy combined with cisplatin as induction chemotherapy in resectable locally advanced head and neck cancer: phase II study.
Chang, PM; Chang, SY; Chen, PM; Chu, PY; Huang, JL; Tai, SK; Tsai, TL; Wang, LW; Wang, YF; Yang, MH, 2008
)
0.35
" Thus, we prospectively analyzed the effects of the CYP2A6 genotype, plasma level of CDHP, and patient characteristics on the pharmacokinetic (PK) variability of FT and 5-FU."( CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1.
Akiyama, Y; Ando, Y; Araki, K; Endo, H; Endo, S; Fujita, K; Ichikawa, W; Kamataki, T; Kawara, K; Kodama, K; Miwa, K; Miya, T; Nagashima, F; Narabayashi, M; Sasaki, Y; Sunakawa, Y; Tanaka, R; Yamamoto, W, 2008
)
0.55
" A physiologically based pharmacokinetic (PBPK) model was developed and fitted to experimental data from literature."( A combined pharmacokinetic-pharmacodynamic (PK-PD) model for tumor growth in the rat with UFT administration.
Dhiman, A; Shuler, ML; Sung, JH, 2009
)
0.35
"9% and obviously prolonged half-life than the free drug."( [Preparation of tegafur magnetic long-circulating thermosensitive liposomes and its pharmacokinetics in rats].
Wang, XL; Zeng, ZW; Zhang, YD; Zhou, WH, 2008
)
0.69
" Because the replacement of 2-day-infusional 5-fluorouracil (5-FU) of FOLFIRI with oral tegafur-uracil/leucovorin (UFT/LV) would be highly beneficial for clinical management, we performed a phase I trial using oral UFT/LV and a pharmacokinetic evaluation."( Phase I and pharmacokinetic study of tegafur-uracil/leucovorin combined with 5-fluorouracil/leucovorin and irinotecan in patients with advanced colorectal cancer.
Azuma, T; Chayahara, N; Hirai, M; Inoue, Y; Kadowaki, Y; Kasuga, M; Maeda, T; Miki, I; Nishisaki, H; Okumura, K; Okuno, T; Sakaeda, T; Tamura, T; Tsuda, M; Yamamori, M, 2009
)
0.85
" Pharmacokinetic evaluation suggested continuous exposure to 5-FU by means of oral UFT/LV administration in this combination."( Phase I and pharmacokinetic study of tegafur-uracil/leucovorin combined with 5-fluorouracil/leucovorin and irinotecan in patients with advanced colorectal cancer.
Azuma, T; Chayahara, N; Hirai, M; Inoue, Y; Kadowaki, Y; Kasuga, M; Maeda, T; Miki, I; Nishisaki, H; Okumura, K; Okuno, T; Sakaeda, T; Tamura, T; Tsuda, M; Yamamori, M, 2009
)
0.63
" A pharmacokinetic study of PTX was also performed."( Phase I pharmacokinetic study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer.
Hidemura, A; Ishigami, H; Kaisaki, S; Kamei, T; Kitayama, J; Miyato, H; Nagawa, H; Otani, K; Soma, D; Yamashita, H, 2009
)
0.35
" Coadministration of S-1 changed the pharmacokinetic behavior of CPT-11 and its metabolites."( Effects of oral administration of S-1 on the pharmacokinetics of SN-38, irinotecan active metabolite, in patients with advanced colorectal cancer.
Hamada, A; Saito, H; Sasaki, Y; Tazoe, K; Yokoo, K, 2009
)
0.35
" Pharmacokinetic analyses were performed following a single dose of S-1 on D-5 and D1 of the first cycle."( Phase I/II and pharmacokinetic study of S-1 and oxaliplatin in previously untreated advanced gastric cancer.
Bae, KS; Chang, HM; Jang, G; Kang, YK; Kim, TW; Lee, JL; Lee, SS; Park, I; Ryu, MH; Sym, SJ; Yoo, C, 2010
)
0.36
"In this study, we compared the pharmacokinetic profiles of 5-fluorouracil (5-FU), tegafur, 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate (Oxo) after administration of S-1 at 35 or 40 mg/m(2) bid for 28 consecutive days, in Cycles 1 and 3, in patients with advanced gastric cancer."( Two dosages of oral fluoropyrimidine S-1 of 35 and 40 mg/m2 bid: comparison of the pharmacokinetic profiles in Korean patients with advanced gastric cancer.
Ahn, JB; Chung, HC; Jeung, HC; Noh, SH; Rha, SY; Roh, JK; Shin, SJ, 2010
)
0.59
" Pharmacokinetic profiles on day 28 were similar to previous Japanese report."( Two dosages of oral fluoropyrimidine S-1 of 35 and 40 mg/m2 bid: comparison of the pharmacokinetic profiles in Korean patients with advanced gastric cancer.
Ahn, JB; Chung, HC; Jeung, HC; Noh, SH; Rha, SY; Roh, JK; Shin, SJ, 2010
)
0.36
"We suggest that these pharmacokinetic profiles of Asian population could provide a basis for schedule optimization and for additional studies on interaction with other antitumor drugs."( Two dosages of oral fluoropyrimidine S-1 of 35 and 40 mg/m2 bid: comparison of the pharmacokinetic profiles in Korean patients with advanced gastric cancer.
Ahn, JB; Chung, HC; Jeung, HC; Noh, SH; Rha, SY; Roh, JK; Shin, SJ, 2010
)
0.36
" Following intravenous administration of S-1, the blood concentration-time profiles of CDHP were similar between control rats and rats with hepatic dysfunction, but the half-life of tegafur was significantly prolonged."( Effect of dimethylnitrosamine-induced liver dysfunction on the pharmacokinetics of 5-fluorouracil after administration of S-1, an antitumour drug, to rats.
Chikamoto, J; Kanie, S; Nagayama, S; Nishimura, T; Yoshisue, K, 2009
)
0.54
"The pharmacokinetic profiles of tegafur, 5-FU and CDHP were altered by changes in the elimination rate of tegafur induced by a decrease in the conversion of tegafur to 5-FU."( Effect of dimethylnitrosamine-induced liver dysfunction on the pharmacokinetics of 5-fluorouracil after administration of S-1, an antitumour drug, to rats.
Chikamoto, J; Kanie, S; Nagayama, S; Nishimura, T; Yoshisue, K, 2009
)
0.64
"Intrahepatic cholangiocellular carcinoma after curative surgery was treated with pharmacokinetic modulation chemotherapy (PMC) as adjuvant chemotherapy."( [Effects of pharmacokinetic modulation chemotherapy (PMC) using oral UFT and venous 5-FU infusion as adjuvant chemotherapy for intrahepatic cholangiocellular carcinoma].
Fukumori, D; Kamachi, H; Kamiyama, T; Matsushita, M; Nakagawa, T; Nakanishi, K; Tahara, M; Todo, S; Yokoo, H, 2009
)
0.35
"The maximum concentration (Cmax), the area under the curve from the drug administration to the infinite time (AUCinf), and the elimination half-life (T1/2) of GEM were not significantly different between GEM administration with and without S-1."( Plasma pharmacokinetics after combined therapy of gemcitabine and oral S-1 for unresectable pancreatic cancer.
Amano, R; Hirakawa, K; Hirakawa, T; Nakao, S; Nakata, B; Okita, Y; Shinto, O; Tamura, T; Yamada, N, 2010
)
0.36
"We developed a population pharmacokinetic (PPK) model of S-1 including the cytochrome P450 (CYP) 2A6 genotype and then used this PPK model to assess the influence of the CYP2A6 genotype on PK parameters of S-1 and the relationship between toxicity and the individual maximum concentrations (Cmax) or the area under the concentration-time curve (AUC) of 5-fluorouracil (5-FU) in Japanese patients with advanced cancer."( Pharmacokinetics of S-1 and CYP2A6 genotype in Japanese patients with advanced cancer.
Adachi, M; Fujita, K; Hirose, T; Ishida, H; Miwa, K; Mizuno, K; Nagashima, F; Nishimura, K; Sasaki, Y; Sunakawa, Y; Tanigawara, Y; Yamashita, K, 2010
)
0.36
"To evaluate the efficacy, safety and pharmacokinetic profiles of S-1, which composed of tegafur (FT, a prodrug of 5-FU), 5-chloro-2,4-dihydroxypyridine and potassium oxonate (Oxo), in Taiwanese advanced gastric cancer (AGC) patients."( A phase II and pharmacokinetic study of first line S-1 for advanced gastric cancer in Taiwan.
Chao, TY; Chao, Y; Chen, JS; Chen, LT; Chen, PM; Cheng, AL; Chiou, TJ; Hsieh, RK; Whang-Peng, J; Yeh, KH, 2011
)
0.59
" Single-dose pharmacokinetic study showed trend toward lower AUC(5-FU), and higher AUC(FT) and AUC(Oxo) comparing to most Western reports."( A phase II and pharmacokinetic study of first line S-1 for advanced gastric cancer in Taiwan.
Chao, TY; Chao, Y; Chen, JS; Chen, LT; Chen, PM; Cheng, AL; Chiou, TJ; Hsieh, RK; Whang-Peng, J; Yeh, KH, 2011
)
0.37
"The efficacy, toxicity and pharmacokinetic profiles of S-1 in current study are compatible with those from other Asian populations."( A phase II and pharmacokinetic study of first line S-1 for advanced gastric cancer in Taiwan.
Chao, TY; Chao, Y; Chen, JS; Chen, LT; Chen, PM; Cheng, AL; Chiou, TJ; Hsieh, RK; Whang-Peng, J; Yeh, KH, 2011
)
0.37
"The purpose of this study was to investigate the effect of gimeracil (CDHP), a reversible dihydropyrimidine dehydrogenase (DPD) inhibitor, on the pharmacokinetics of 5-fluorouracil (5-FU) and other related metabolites by comparing the pharmacokinetic (PK) profile of S-1 (tegafur [FT] + CDHP + oteracil potassium [Oxo]) to that of FT alone."( A phase I study evaluating the effect of CDHP as a component of S-1 on the pharmacokinetics of 5-fluorouracil.
Mendelson, DS; Ravage-Mass, L; Rosen, LS; Saif, MW; Saito, K; Zergebel, C, 2011
)
0.55
" We conducted a phase I study to evaluate the safety and pharmacokinetic of TSU-68 when used with S-1 and oxaliplatin (SOX) in metastatic colorectal cancer (mCRC) patients."( A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy.
Ahn, JB; Chung, HC; Jeung, HC; Jung, M; Kim, HR; Rha, SY; Roh, JK; Shin, SJ, 2012
)
0.38
" Potential predictive pharmacokinetic parameters and pharmacodynamic biomarkers have been found."( Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers.
Allegrini, G; Arrighi, G; Barletta, MT; Bocci, G; Brandi, G; Canu, B; Chericoni, S; Ciarlo, A; Danesi, R; Di Desidero, T; Di Paolo, A; Falcone, A; Fioravanti, A; Fontana, A; Giusiani, M; Kerbel, RS; Loupakis, F; Lucchesi, S; Masi, G; Orlandi, P, 2012
)
0.38
"This pharmacokinetic study of S-1 was conducted in patients in whom glomerular filtration rate (GFR) was directly measured to explore the possibility of adjusting the S-1 dose on the basis of GFR in patients with normal or nearly normal renal function."( Pharmacokinetic study of S-1 in patients in whom inulin clearance was measured.
Ando, Y; Fujimoto, Y; Fujita, K; Hiramatsu, M; Inada, M; Kawada, K; Mitsuma, A; Morita, S; Yasuda, Y, 2012
)
0.38
" Blood samples for pharmacokinetic analysis were collected on the seventh day of treatment."( An immunoassay method for the pharmacokinetics of 5-fluorouracil in patients with gastric cancer administered adjuvant chemotherapy.
Higashida, M; Hirai, T; Kubota, H; Matsumoto, H; Murakami, H; Nakamura, M; Nakashima, H; Oka, Y; Okumura, H; Tsutsumi, K, 2012
)
0.38
" The pharmacokinetic parameters of tegafur, 5-fluorouracil, gimeracil, potassium oxonate and uracil after single oral administration were as follows: (2,207 +/- 545), (220."( [Pharmacokinetics of S-1 capsule in patients with advanced gastric cancer].
Chu, Y; Ding, L; Liu, HY; Yu, Y; Zhu, H, 2012
)
0.66
" No pharmacokinetic interaction between S-1 and gefitinib was detected."( Phase I and pharmacokinetic study of gefitinib and S-1 combination therapy for advanced adenocarcinoma of the lung.
Azuma, K; Daga, H; Hayashi, H; Kiyota, H; Miyazaki, M; Murakami, H; Naito, T; Nakagawa, K; Okada, H; Okamoto, I; Takeda, K; Takeda, M; Tanaka, K; Terashima, M; Yamamoto, N, 2013
)
0.39
" Pharmacokinetic parameters, including Cmax, Tmax, t1/2, AUC0-t, and AUC0-∞ were determined using non-compartmental models with DAS2."( Pharmacokinetic evaluation of novel oral fluorouracil antitumor drug S-1 in Chinese cancer patients.
Bian, HH; Chen, L; Pu, WY; Wang, H; Wang, J; Zhang, H; Zhu, H; Zhu, MG; Zhuang, ZX, 2013
)
0.39
" However, there is a paucity of data from sufficiently powered pharmacokinetic and pharmacodynamic studies to support dosage recommendations in such patients."( Optimization of cancer chemotherapy on the basis of pharmacokinetics and pharmacodynamics: from patients enrolled in clinical trials to those in the 'real world'.
Fujita, K; Sasaki, Y, 2014
)
0.4
"We performed a pharmacokinetic phase I trial of the combination of S-1 granules and nedaplatin for head and neck squamous cell carcinoma (HNSCC)."( Phase I pharmacokinetic study of S-1 granules and nedaplatin for advanced head and neck cancer.
Doi, K; Fujisaka, Y; Hayashi, H; Kawakami, H; Nakagawa, K; Nishimura, Y; Nishina, S; Okamoto, I; Okamoto, K; Satoh, T; Takeda, M; Tanaka, K; Terao, K; Ueda, S, 2013
)
0.39
" Pharmacokinetic parameters of S-1 granule did not differ from the capsula formulation."( Phase I pharmacokinetic study of S-1 granules and nedaplatin for advanced head and neck cancer.
Doi, K; Fujisaka, Y; Hayashi, H; Kawakami, H; Nakagawa, K; Nishimura, Y; Nishina, S; Okamoto, I; Okamoto, K; Satoh, T; Takeda, M; Tanaka, K; Terao, K; Ueda, S, 2013
)
0.39
" This study explored the pharmacokinetics of S-1 and pharmacokinetic changes after gastric surgery in patients with resectable gastric cancer who received pre- and postoperative S-1 plus docetaxel."( Postgastrectomy pharmacokinetic changes of S-1 in patients with localized advanced gastric cancer.
Hwang, A; Ju Choi, I; Kim, MJ; Kim, YW; Lee, JH; Lim, HS; Park, SR; Park, YI; Ryu, KW, 2015
)
0.42
"We conducted a prospective pharmacokinetic study to develop an S-1 dosage formula based on renal function."( Development of an S-1 dosage formula based on renal function by a prospective pharmacokinetic study.
Boku, N; Booka, E; Gomi, D; Hamamoto, Y; Ichiyama, T; Imamura, CK; Kawakubo, H; Kitagawa, Y; Mizukami, T; Soejima, K; Takahashi, T; Takeuchi, H; Tanigawara, Y; Tateishi, K, 2016
)
0.43
" The purpose of this study was to evaluate the pharmacokinetic (PK), bioequivalence, and safety of a newly developed generic formulation of S-1 compared with the branded reference formulation, in Korean gastric cancer patients."( Pharmacokinetic and bioequivalence study between two formulations of S-1 in Korean gastric cancer patients.
Cho, K; Cho, S; Gwon, MR; Kang, WY; Kim, BK; Kim, JG; Lee, HW; Ohk, B; Seong, SJ; Sung, YK; Yoon, YR, 2019
)
0.51

Compound-Compound Interactions

Both amrubicin (Am) and S-1 are effective against non-small-cell lung cancer (NSCLC) Preclinical studies have demonstrated that the effect of tegafur/uracil in combination with Am significantly inhibits tumor growth.

ExcerptReferenceRelevance
" The administration of 3'-MeDAB in combination with 1-(2-tetrahydrofuryl)-5-fluorouracil and uracil (UFT) delayed the appearance of oval cells and the formation of hyperplastic nodules, which were observed in the liver from 3 and 5 weeks, respectively, after the onset of 3'-MeDAB feeding, and also delayed the transient increase of serum alpha-fetoprotein level, which transiently peaked at 5 weeks, and completely suppressed the transient increase of tissue thymidylate synthetase activity, but not thymidine kinase, which were induced by 3'-MeDAB at 5 weeks, and finally reduced markedly the incidence of hepatocarcinomas."( Inhibition by 1-(2-tetrahydrofuryl)-5-fluorouracil in combination with uracil of hepatocarcinogenesis induced by 3'-methyl-4-dimethylaminoazobenzene in rats.
Endo, Y; Hirai, H; Kasahara, N; Kato, T; Kudo, H; Kuwa, K; Sakamoto, S; Sunaga, T; Taga, H; Uchikoshi, T,
)
0.13
"We investigated the antitumor activities of 5-fluorouracil (5-FU), 5'-deoxy-5-fluorouridine (5'-DFUR), 1-hexylcarbamoyl-5-fluorouracil (HCFU) and 1-(tetrahydro-2-furanyl)-5-fluorouracil (FT-207) in combination with hyperthermia in vitro."( Comparative antitumor activity of 5-fluorouracil and its prodrugs in combination with hyperthermia in vitro.
Akazai, Y; Fuchimoto, S; Iwagaki, H; Matsubara, N; Orita, K; Shiiki, S; Watanabe, T, 1991
)
0.28
"A case of local recurrence of rectal cancer was successfully treated by UFT combined with two-route CDDP chemotherapy under the AT-II induced hypertension."( [A case of local recurrence of rectal cancer successfully treated by UFT combined with two-route CDDP chemotherapy under the AT-II induced hypertension].
Ishizawa, T; Iwashige, H; Maenohara, S; Mure, H; Shimazu, H; Takao, S; Yamada, K, 1991
)
0.28
"To study the effect of tegafur administration combined with hormonal therapy on the survival rate of newly diagnosed patients with stage D prostatic cancer, 66 patients, 70."( [Effect of tegafur administration combined with hormonal therapy in patients with newly diagnosed stage D prostatic cancer].
Horiuchi, S; Kobayashi, N; Kojima, S; Negishi, T; Saitoh, H; Satake, I; Takahashi, T; Tari, K; Tsujii, T; Yoshida, K, 1990
)
0.98
" the same therapy in combination with UFT as a maintenance therapy (group B; 8 patients)."( [Clinical evaluation of MMC-mc-chemoembolization therapy and its combination with UFT in hepatocellular carcinoma].
Matsuo, SK; Ohmura, K; Ohtsuka, Y; Suzuki, M, 1987
)
0.27
" The total concentration of FT in the plasma and the tumor when it was given in combination with L-cystine was significantly increased when compared with FT alone 1 h after oral administration."( Potentiation of the chemotherapeutic action of tegafur against solid adenocarcinoma 755 by combination with L-cystine.
Hoshi, A; Iigo, M; Kitagawa, H, 1986
)
0.53
"Ten patients with carcinomatous peritonitis of gastrointestinal cancer have been treated with administrations of CDDP-Ip (50-150 mg/body), in combination with systemic chemotherapy simultaneously combined with sodium thiosulfate (STS) iv in 4 patients."( [Intraperitoneal (Ip) administration of cisplatin in combination with systemic chemotherapy in patients with malignant ascites of gastrointestinal cancer: clinical evaluation and pharmacokinetics].
Fukushi, A; Hirayama, M; Koda, K; Kure, T; Morita, K; Nakazawa, O; Takahashi, H; Terada, S; Terui, T; Yoshizaki, N, 1988
)
0.27
"Thermotherapy combined with tegafur (FT-207) and Picibanil was performed in 13 patients with cancer of the urinary bladder."( [Thermotherapy for cancer of the urinary bladder in combination with tegafur suppository and picibanil--concentrations of tegafur in the serum and tissues in bladder carcinoma].
Arai, T; Honda, M; Kanbe, K; Kaneko, K; Maeda, S; Mukae, K; Murahashi, I; Sakuma, H; Tabata, Y; Takasaki, E, 1985
)
0.8
"A short-term intensive chemotherapy (STIC) consisting of large dose of mitomycin C (MMC), tegafur (FT-207), streptococcus preparation picibanil (OK-432) and Krestin (PSK), combined with IVH was performed in 72 patients with advanced gastric cancer."( [Short-term intensive chemotherapy (STIC) combined with intravenous hyperalimentation in advanced stomach cancer].
Hamazoe, R; Kanayama, H; Karino, T; Koga, S; Maeta, M; Oda, M; Osaki, Y; Shimizu, N; Yamane, T, 1983
)
0.49
"Thermotherapy combined with Tegafur and Picibanil was performed in 32 patients with cancer of the urinary bladder."( [Thermotherapy for cancer of the urinary bladder in combination with tegafur and picibanil--with special reference to the serum bladder and bladder cancer tissue concentrations of tegafur in a perfusion fluid].
Honda, M; Kanbe, K; Kaneko, K; Maeda, S; Murahashi, I; Takahashi, E, 1984
)
0.8
"5 degrees C, 3 X 60 min) alone and in combination with polychemotherapy (BCNU) and Ftorafur) was used for the treatment of AMMN-(N-nitrosoacetoxymethyl-methylamine) induced autochthonous colonic carcinomas in Sprague-Dawley rats."( [Effect of local moderate hyperthermia in combination with N-nitroso-1,3-bis-(2-chloroethyl)urea (BCNU) and 5-fluoro-(tetrahydro-2-furyl)uracil (ftorafur) on induced autochthonous colonic cancers in the rat. 3: Polychemotherapy in combination with hyperth
Biwer, E; Habs, M; Lorenz, M; Schmähl, D, 1984
)
0.27
"In combination with chemotherapy [ftorafur (FT)], allogeneic lymphoid cells were transferred to inhibit the growth of a 3-methylcholanthrene-induced transplantable KMT-17 fibrosarcoma in Wistar-King-Aptekman/Hok rats."( Effect of normal allogeneic lymphoid cell transfer in combination with chemotherapy on a transplantable tumor in rats.
Akiyama, J; Gotohda, E; Hosokawa, M; Kawamura, T; Kobayashi, H; Kodama, T; Yamada, Y, 1980
)
0.26
"A total of 58 cases with inoperable advanced gastric carcinomas were treated by radiotherapy combined with tegafur, and the result was analyzed mainly from the aspects of life expectancies and some prognostic factors."( [Radiotherapy combined with tegafur for inoperable advanced gastric cancer].
Asakawa, H; Matsumoto, K; Otawa, H; Yamada, S, 1982
)
0.77
" Conclusion ACNU has a strong antitumor activity and may be more effective if combined with antimetabolite agent, such as 5FU."( [Physiological effects and antitumor efficiency of ACNU in postoperative patients with stomach cancer--an evaluation of the treatment combined with FT-207 or 5-FU dry syrup].
Inuo, T; Kaneko, H; Ohashi, A; Sekizawa, Y; Tsuchiya, S, 1982
)
0.26
"The effectiveness of 5-fluorouracil (5-FU), FT-207 and FT-207 + uracil in combination with two repetitions of 43 degrees C hyperthermia in the treatment of the Meth-A-Fibrosarcoma and Sarcoma-180 was examined in vivo in BALB/c mice."( The antitumor effect of hyperthermia combined with fluorouracil and its analogues.
Harada, S; Matsuo, M; Miyata, M; Obara, T; Oikawa, H; Ping, L; Takahashi, T; Yanagisawa, T, 1995
)
0.29
"We evaluated the usefulness of hormonal therapy combined with UFT as initial treatment in comparison with hormonal therapy alone in 92 patients with Stage D2 prostatic cancer treated at the Department of Urology, Dokkyo University School of Medicine between 1974 and 1993."( [Clinical evaluation of chemohormonal therapy as an initial treatment for stage D2 prostatic cancer--effect of UFT administration combined with hormonal therapy].
Chen, JA; Honda, M; Hosoya, Y; Imai, T; Maeda, S; Suzuki, T; Takasaki, E, 1995
)
0.29
"To prevent postoperative recurrence a randomized prospective trial was performed on 45 patients with bladder cancers by dividing them into 2 groups given either UFT therapy alone or UFT therapy in combination with Bestatin."( Adjuvant therapy with 5-fluoro-1-(2-tetrahydrofuryl)-2,4 (1H,3H)-pyrimidinedione (UFT) and Bestatin in patients with transitional cell carcinoma of the bladder--comparison between UFT therapy alone and UFT therapy in combination with Bestatin.
Koshida, K; Kunimi, K; Uchibayashi, T; Yamamoto, H, 1995
)
0.29
" The object of this study is to evaluate the efficacy of preoperative chemotherapy combined with radiation therapy for bladder cancer."( [The long-term effect and outcome of preoperative chemotherapy combined with radiation therapy for bladder cancer].
Hayashida, S; Kamata, S; Mitsui, H; Nakane, H; Nasu, T, 1996
)
0.29
"The effects of 1-(2-tetrahydrofuryl)-5-fluorouracil in combination with uracil (UFT) on mammary carcinogenesis and growth of tumors induced with 7,12-dimethylbenz[a]anthracene (DMBA) were investigated in rats."( 1-(2-Tetrahydrofuryl)-5-fluorouracil in combination with uracil suppresses mammary carcinogenesis and growth of tumors induced with 7,12-dimethylbenz[a]anthracene in rats.
Kudo, H; Maemura, M; Mitamura, T; Nakayama, T; Sakamoto, S; Sassa, S; Suzuki, S; Yoshimura, S, 1996
)
0.29
"A comparative, randomized trial was conducted to determine the efficacy of oral UFT (Tegafur and Uracil) versus 5-fluorouracil (5-FU) in combination with cyclophosphamide and doxorubicin in patients with metastatic breast cancer."( A comparative, randomized trial of UFT and 5-fluorouracil in combination with cyclophosphamide and doxorubicin in the treatment of advanced breast cancer patients at The Philippines General Hospital.
De Guzman, LM; Fernando, GY; Guancia, AA; Romana, IB; Samson, MC; Villalon, AH, 1997
)
0.52
" Oral administration of 1-(2-tetrahydrofuryl)-5-fluorouracil in combination with uracil (UFT) markedly reduced the number and accumulated area of colonic carcinomas, and TS activity in the poorly differentiated adenocarcinomas."( Preventive effect of 1-(2-tetrahydrofuryl)-5-fluorouracil in combination with uracil on colonic carcinogenesis induced by 1,2-dimethylhydrazine in rats.
Iwama, T; Kawachi, Y; Kudo, H; Murakami, S; Okayasu, I; Sagara, T; Sakamoto, S; Tsukada, K, 1997
)
0.3
" Based on those results, we conducted a pilot study to confirm the feasibility and antitumor effect of UFT in combination with cisplatin in patients with advanced non-small cell lung cancer (NSCLC)."( Pilot study of UFT combined with 5 consecutive days cisplatin in non-small cell lung cancer.
Koinumaru, S; Matsuda, T; Nakai, Y; Saitoh, J, 1997
)
0.3
"To evaluate the efficacy of chemoendocrine therapy for the initial treatment of stage D2 prostate cancer, we conducted a prospective randomized study which compared combined androgen blockade alone to that combined with UFT."( [Primary treatment for stage D2 prostate cancer: a randomized study of combined androgen blockade alone versus combined with UFT].
Akazawa, S; Aki, M; Hashine, K; Kuwahara, M; Sumiyoshi, Y; Takenaka, A; Yamamoto, A, 1999
)
0.3
"Pharmacokinetic modulating chemotherapy (PMC) is a new therapeutic concept in combination with continuous 5-fluorouracil (5-FU) infusion and UFT."( Results of pharmacokinetic modulating chemotherapy in combination with hepatic arterial 5-fluorouracil infusion and oral UFT after resection of hepatic colorectal metastases.
Kusunoki, M; Noda, M; Yamamura, T; Yanagi, H; Yoshikawa, R, 2000
)
0.31
" We describe the design of a phase II study to investigate the safety and efficacy of UFT/leucovorin combined with mitomycin-C in a larger group of previously untreated patients with metastatic colorectal cancer."( UFT/leucovorin combined with mitomycin-C in metastatic colorectal Ca.
Jakobsen, A, 2000
)
0.31
" Protracted infusional 5-FU has been associated with decreased tumor recurrence and improved survival when combined with postoperative adjuvant pelvic radiotherapy."( Postoperative radiation therapy for rectal cancer combined with UFT/leucovorin.
Haller, DG; Minsky, BD; Rosenthal, DI; Saltz, L; Semple, D, 2000
)
0.31
"We randomized patients with locally advanced cervical cancer to receive radiotherapy combined with transcatheter arterial infusion (TAI) of cisplatin or oral fluoropyrimidine anticancer agents, and compared the prognosis by a prospective follow-up study."( Radiotherapy combined with transcatheter arterial infusion of cisplatin versus oral fluoropyrimidine anticancer agent for locally advanced carcinoma of the uterine cervix: a prospective follow-up study.
Hirokawa, Y; Murakami, J; Nagai, N; Ohama, K; Oshita, T; Shigemasa, K,
)
0.13
"This prospective and randomized clinical study was initiated to compare the efficacy and safety of combined androgen blockade with combination with UFT in patients with untreated prostate cancer."( Prospective and randomized comparison of combined androgen blockade versus combination with oral UFT as an initial treatment for prostate cancer.
Kuriyama, M; Ohshima, S; Ono, Y; Sahashi, M; Shimizu, H; Takahashi, Y; Tanaka, T, 2001
)
0.31
") UFT (250 mg/m(2)/day) for 21 days of a 28-day cycle combined with increasing intravenous (i."( Phase I trial of weekly irinotecan combined with UFT as second-line treatment for advanced colorectal cancer.
Alonso, V; Antón, A; Escudero, P; Herrero, A; Isla, MD; Martinez-Trufero, J; Mayordomo, JI; Sáenz, A; Tres, A; Zorrilla, M, 2001
)
0.31
"To evaluate the antitumor efficacy against metastatic breast cancer of fluoropyrimidines alone and combined with other chemotherapeutic agents, we developed a murine model of breast cancer metastatic to the lung by orthotopically implanting MDA-MB-435S breast tumors into mice."( [Antimetastatic and antitumor effects of fluoropyrimidines alone and combined with taxanes in a murine model of breast cancer metastatic to the lung].
Fujioka, A; Fukushima, M; Nakagawa, F; Nukatsuka, M; Ohshimo, H, 2002
)
0.31
" We report three cases of advanced gastric cancer treated using TS-1 in combination with a low-dose of cisplatinum (CDDP) that well responded."( [Three cases of advanced gastric cancer treated by TS-1 in combination with low-dose cisplatinum].
Gomi, T; Kanaya, S; Katayama, T; Momoi, H; Ohtoshi, M; Tamaki, N; Wada, Y, 2002
)
0.31
" cis-Diaminedichloroplatinum (cisplatin) has been reported to immunomodulate, especially when used in low dose in combination with 5-Fluorouracil (5-FU)."( Immunomodulatory effects of low dose cis-Diaminedichloroplatinum (cisplatin) combined with UFT and PSK in patients with advanced colorectal cancer.
Ando, K; Fukuzawa, M; Kanou, H; Kimura, T; Nagata, Y; Nezu, T; Shibata, M; Takekawa, M, 2002
)
0.31
" Its combination with uracil in a molar ratio of 1:4 (UFT) increases the 5-FU concentration in tumor cells compared with ftorafur alone."( A phase I study of oral uracil-ftorafur plus folinic acid in combination with weekly paclitaxel in patients with solid tumors.
Beck, J; Boehlke, I; Bokemeyer, C; Hartmann, JT; Kanz, L; Mayer, F; Schroeder, M; von Pawel, J, 2002
)
0.31
" The objectives of this study were to determine the clinical toxicities, antitumor effect, survival duration, and a recommended dosage schedule in combination with TS-1 and CDDP."( [A pilot study of TS-1 combined with cisplatin in patients with advanced gastric cancer].
Ina, K; Indo, T; Iwase, H; Iyo, T; Kaida, S; Kusugami, K; Mizuno, T; Nakamura, M; Nakarai, K; Okeya, M; Shimada, M, 2002
)
0.31
"The aim of this study was to evaluate the efficacy of preoperative radiation therapy for resectable rectal adenocarcinoma (T3-T4) when delivered in combination with chemotherapy (oral tegafur-uracil modulated with leucovorin)."( Efficacy of preoperative radiation therapy for resectable rectal adenocarcinoma when combined with oral tegafur-uracil modulated with leucovorin: results from a phase II study.
Batlle, JF; Carpeño, Jde C; García, AG; Grande, AG; Juberías, AM; Olivar, LM; Piñeiro, EH; Sánchez Santos, ME; Uzcudun, AE; Velasco, JC, 2002
)
0.72
"Our neoadjuvant radiation therapy protocol is efficient for the preoperative treatment of resectable rectal adenocarcinoma when combined with chemotherapy (oral tegafur-uracil modulated with leucovorin)."( Efficacy of preoperative radiation therapy for resectable rectal adenocarcinoma when combined with oral tegafur-uracil modulated with leucovorin: results from a phase II study.
Batlle, JF; Carpeño, Jde C; García, AG; Grande, AG; Juberías, AM; Olivar, LM; Piñeiro, EH; Sánchez Santos, ME; Uzcudun, AE; Velasco, JC, 2002
)
0.73
" In conclusion, the placement of a self-expandable metallic stent in combination with cholangioscopic microwave coagulation therapy and TS-1 was very effective in managing the obstructive jaundice due to the local recurrence of gastric cancer."( A self-expandable metallic stent in combination with cholangioscopic microwave coagulation therapy and chemotherapy with oral TS-1 against obstructive jaundice due to recurrent gastric cancer: a case report of successful treatment.
Hashimoto, K; Higami, T; Itakura, M; Koike, M; Nio, Y; Omori, H; Yano, S,
)
0.13
" Since clinical studies have demonstrated that bisphosphonates (BPs), specific inhibitors of osteoclastic bone resorption, are beneficial for breast cancer patients with bone metastases, we next examined the effects of UFT combined with the BP zoledronic acid (ZOL) on established bone metastases."( Effects of oral UFT combined with or without zoledronic acid on bone metastasis in the 4T1/luc mouse breast cancer.
Hata, K; Hiraga, T; Ikeda, F; Tamura, D; Ueda, A; Williams, PJ; Yoneda, T, 2003
)
0.32
" A biological response modifier, lentinan (LNT) prolonged the survival period of patients with UARG when combined with tegafur (FT)."( [Pilot study of TS-1 combined with lentinan in patients with unresectable or recurrent advanced gastric cancer].
Atomi, Y; Kusano, M; Mitsumori, N; Nakajima, M; Nimura, H; Suzuki, S; Tokunaga, A; Tsukagoshi, S; Yoshiyuki, T, 2003
)
0.53
") cisplatin combined with a fixed dose of a new oral dihydropyrimidine dehydrogenase-inhibitory fluoropyrimidine, S-1, on an outpatient basis."( A phase I study of S-1 combined with weekly cisplatin for metastatic gastric cancer in an outpatient setting.
Endo, H; Endo, S; Hirao, K; Hirasaki, S; Hyodo, I; Kurita, A; Masumoto, T; Moriwaki, T; Nasu, J; Nishina, T; Tajiri, H; Terao, T, 2003
)
0.32
"A dose-escalation study of cisplatin (CDDP) combined with S-1, a new oral dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, was performed to determine the maximum-tolerated dose (MTD), recommended dose (RD), dose-limiting toxicities (DLTs), and objective response rate (RR) in advanced gastric cancer (AGC)."( Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer.
Boku, N; Gotoh, M; Koizumi, W; Matsumura, Y; Nagashima, F; Ohtsu, A; Saigenji, K; Shirao, K; Tanabe, S, 2003
)
0.32
" Therefore, we conducted a phase II study of gemcitabine combined with UFT in metastatic pancreatic cancer patients and assessed the efficacy and the toxicity of the regimen."( Phase II study of gemcitabine combined with uracil-tegafur in metastatic pancreatic cancer.
Choi, SH; Heo, JS; Im, YH; Jung, CW; Kang, WK; Kim, K; Kim, WS; Lee, J; Lee, JK; Lee, KT; Lee, MH; Lee, SI; Lim, DH; Park, JO; Park, K; Song, SY, 2004
)
0.58
" Therapy was therefore designed with an oral drug daily given in combination with RT in order to determine the efficacy and toxicity."( [Radiotherapy in combination with low-dose chemotherapy in locally advanced head and neck cancer].
Molnár, J; Nagy, B; Paczona, R; Rovó, L; Thurzó, L, 2004
)
0.32
" These findings suggest that the local DC therapy in combination with TS-1 and OK-432 may be a useful strategy for the treatment of solid tumors, and that TLR4 signaling is involved in the success of this therapy."( Anti-tumor effect of an intratumoral administration of dendritic cells in combination with TS-1, an oral fluoropyrimidine anti-cancer drug, and OK-432, a streptococcal immunopotentiator: involvement of toll-like receptor 4.
Ahmed, SU; Hiroshima, T; Kan, S; Moriya, Y; Ohue, H; Okamoto, M; Oshikawa, T; Ryoma, Y; Saito, M; Sasai, A; Sato, M; Tano, T,
)
0.13
"To evaluate the antitumor and antimetastatic efficacy of oral fluoropyrimidines, alone and combined with taxane on human breast cancer xenografts model, we developed a breast cancer model that spontaneously metastasizes to the lung by orthotopic implantation of MDA-MB-435S-HM tumors into the mammary fat pad (mfp) of SCID mice."( Antimetastatic and anticancer activity of S-1, a new oral dihydropyrimidine-dehydrogenase-inhibiting fluoropyrimidine, alone and in combination with paclitaxel in an orthotopically implanted human breast cancer model.
Fujioka, A; Fukushima, M; Kitazato, K; Nagayama, S; Nakagawa, F; Nukatsuka, M; Oshimo, H; Sugimoto, Y; Uchida, J, 2004
)
0.32
" These findings suggest that local DC therapy in combination with TS-1 and OK-432 may well be a useful strategy for the treatment of solid tumors, and that TLR4 signaling is involved in the success of this therapy."( [Anti-tumor effect of intratumoral administration of dendritic cells in combination with TS-1 and OK-432].
Ahmed, SU; Okamoto, M; Oshikawa, T; Sato, M; Tano, T, 2004
)
0.32
"Our aim was to determine the dose-limiting toxicities (DLTs), maximum tolerated dose (MTD) and recommended dose of oxaliplatin combined with oral tegafur-uracil and leucovorin."( Phase I dose escalation study of oxaliplatin combined with oral tegafur-uracil and leucovorin in patients with advanced gastric cancer.
Chen, JS; Huang, JS; Liau, CT; Lin, YC; Rau, KM; Wang, HM; Yang, TS, 2005
)
0.77
"The aim of this multicentric trial was to determine the clinical toxicities and antitumor effects of a chemotherapy regimen of S-1 combined with cisplatin in patients with inoperable locally or metastatic advanced gastric cancer."( A phase II multicentric trial of S-1 combined with 24 h-infusion of cisplatin in patients with advanced gastric cancer.
Goto, S; Haruta, J; Horiuchi, Y; Ina, K; Iwase, H; Kumada, S; Kusugami, K; Shimada, M; Sugihara, M; Tsuzuki, T; Yamaguchi, T,
)
0.13
"The objective of this study was to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of S-1, an oral fluorouracil derivative, combined with gemcitabine, the current standard treatment for advanced pancreatic cancer (APC)."( Phase I trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer.
Ishihara, T; Kato, H; Kobayashi, A; Nakamura, K; Saisho, H; Sudo, K; Tadenuma, H; Yamaguchi, T, 2005
)
0.33
") gemcitabine (GEM) at low dose plus oral chemotherapy with uracil-tegafur (UFT) and cyclophosphamide (CPA) in combination with radiotherapy (RT) against recurrent and advanced pancreatic cancers."( Phase II study on low dose gemcitabine plus oral chemotherapy with uracil-tegafur and cyclophosphamide in combination with radiotherapy against recurrent and advanced pancreatic cancer.
Endo, S; Hashimoto, K; Higami, T; Itakura, M; Koike, M; Maruyama, R; Nio, Y; Tsuji, M; Yamaguchi, K; Yano, S, 2005
)
0.8
" The purpose of this study was to examine whether Skp2 expression can be a useful prognostic factor in oral SCC patients treated by UFT in combination with radiation."( High expression of S-phase kinase-associated protein 2 (Skp2) is a strong prognostic marker in oral squamous cell carcinoma patients treated by UFT in combination with radiation.
Harada, K; Itashiki, Y; Kawaguchi, S; Kawashima, Y; Sato, M; Yoshida, H,
)
0.13
"We designed an outpatient regimen consisting of fractional cisplatin in combination with S-1, a novel oral fluoropyrimidine derivative for the treatment of recurrent or advanced gastric cancer and conducted a phase I study to determine the dose limiting toxicities (DLTs) and recommended dose (RD)."( Performance of outpatient regimen of S-1 in combination with fractional cisplatin for advanced or recurrent gastric cancers: a phase I study.
Hiki, N; Imamura, K; Kaminishi, M; Mafune, K; Shimoyama, S; Yamaguchi, H, 2005
)
0.33
" S-1 in combination with fractional cisplatin is a promising regimen that allows repeated drug administration, in an outpatient setting, for advanced or recurrent gastric cancers."( Performance of outpatient regimen of S-1 in combination with fractional cisplatin for advanced or recurrent gastric cancers: a phase I study.
Hiki, N; Imamura, K; Kaminishi, M; Mafune, K; Shimoyama, S; Yamaguchi, H, 2005
)
0.33
"A dose-escalation study of irinotecan (CPT-11) combined with S-1, a novel oral fluoropyrimidine, was performed to determine the maximum-tolerated dose (MTD), recommended dose (RD) and dose-limiting toxicities (DLTs) in advanced gastric cancer."( Phase I study of S-1 combined with irinotecan (CPT-11) in patients with advanced gastric cancer (OGSG 0002).
Fujitani, K; Furukawa, H; Gotoh, M; Iishi, H; Katsu, K; Kawabe, S; Narahara, H; Taguchi, T; Takiuchi, H; Tatsuta, M; Tsujinaka, T, 2005
)
0.33
"To investigate the effect and feasibility of concurrent radiation and chemotherapy combined with endorectal brachytherapy in T3 rectal cancer with complete pathologic remission as end point."( Preoperative chemoradiation of locally advanced T3 rectal cancer combined with an endorectal boost.
Bisgaard, C; Hansen, JW; Jakobsen, A; Lindebjerg, J; Mortensen, JP; Rafaelsen, SR, 2006
)
0.33
" The patient was treated with TS-1 combined with CPT-11."( [A case of an increase in resectability with preoperative chemotherapy TS-1 combined with CPT-11 for unresectable rectal cancer in downstaging].
Doi, M; Egawa, T; Hayashi, S; Kitano, M; Nagashima, A; Yoshii, H, 2005
)
0.33
"A dose-escalation study of weekly paclitaxel combined with S-1, a novel oral fluoropyrimidine, was performed to determine the maximum tolerated dose (MTD), the recommended dose (RD) and the dose-limiting toxicities (DLTs) in advanced gastric cancer."( Phase I and pharmacokinetic study of S-1 combined with weekly paclitaxel in patients with advanced gastric cancer.
Fujitani, K; Furukawa, H; Gotoh, M; Hirao, M; Narahara, H; Satomi, E; Taguchi, T; Takiuchi, H; Tsujinaka, T, 2005
)
0.33
"Weekly paclitaxel combined with S-1 was demonstrated to exhibit a tolerable toxicity profile with therapeutic plasma concentration at the dose of 50 mg/m(2)."( Phase I and pharmacokinetic study of S-1 combined with weekly paclitaxel in patients with advanced gastric cancer.
Fujitani, K; Furukawa, H; Gotoh, M; Hirao, M; Narahara, H; Satomi, E; Taguchi, T; Takiuchi, H; Tsujinaka, T, 2005
)
0.33
" Between February 2002 and October 2002, 64 patients received UFT 300 mg m(-2) day(-1) and LV 90 mg day(-1) from day 1 to day 14 combined with oxaliplatin 130 mg m(-2) on day 1, every 3 weeks."( 'A phase II study of oral uracil/ftorafur (UFT) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer'.
Bennouna, J; Bordenave, S; Cvitkovic, F; Dorval, E; Douillard, JY; Hebbar, M; Jacob, JH; Malek, K; Paillot, B; Perrier, H; Priou, F; Seitz, JF; Tonelli, D, 2006
)
0.33
"A total of 208 cycles of chemotherapy were given with a median of 4 per patient."( Fixed dose-rate infusion of gemcitabine in combination with cisplatin and UFT in advanced carcinoma of the pancreas.
Barón, MG; Casado, E; Castañón, C; Castro, J; Cruz, M; Feliu, J; Fonseca, E; Jara, C; Jaráiz, AR; León, A; Lomas, M; Sáenz, JG, 2006
)
0.33
" After 33 months, a high dose of CDDP was administered twice in combination with TS-1, because elevation of serum CEA levels and paraortic lymphnode swelling were observed for the first time."( [A case of gastric cancer with peritoneal dissemination who achieved five-year survival by successive treatments with TS-1 alone and in combination with other drugs].
Aiko, S; Ishizuka, T; Kumano, I; Maehara, T; Sakano, T; Sugiura, Y; Yoshizumi, Y, 2006
)
0.33
" In total, 79 courses were administered with a median of 3 (range 1-6)."( UFT in combination with oxaliplatin: clinical phase I study in patients with advanced or metastatic solid tumors.
Abad, A; Aranda, E; Carrato, A; Díaz-Rubio, E; Gallego, J; Gómez, A; López, E; Manzano, JL; Sastre, J, 2006
)
0.33
"A dose-escalation study of irinotecan (CPT-11) combined with S-1, an oral dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, was performed to determine the maximum-tolerated dose (MTD), recommended dose (RD), dose-limiting toxicities (DLTs), and objective response rate (RR) in advanced gastric cancer (AGC)."( Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer.
Ichikawa, W; Inokuchi, M; Kawano, T; Kojima, K; Nihei, Z; Sugihara, K; Yamada, H; Yamashita, T, 2006
)
0.33
" The purpose of this study was to examine whether Jab1 expression can be a useful prognostic factor in OSCC patients treated by 1 M Tegafur and 4 M uracil (UFT) in combination with radiation."( High expression of Jun activation domain-binding protein 1 (Jab1) is a strong prognostic marker in oral squamous cell carcinoma patients treated by UFT in combination with radiation.
Harada, K; Kawashima, Y; Sato, M; Yoshida, H,
)
0.34
"We conducted a phase II trial of gemcitabine with S-1, oral fluorouracil (5-FU) prodrug tegafur combined with two modulators, 5-chloro-2, 4-dihydroxypyridine and potassium oxonate, to evaluate the activity and toxicity of such a combination in metastatic pancreatic cancer (MPC) patients."( Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer.
Ishihara, T; Kato, H; Nakamura, K; Saisho, H; Sudo, K; Yamaguchi, T, 2006
)
0.56
" Because it was the yearend, we selected neoadjuvant TS-1 combined with CDDP therapy."( [Advanced gastric cancer responding to pathological CR after neoadjuvant TS-1 combined with CDDP therapy--report of a case].
Nakagawa, S; Nashimoto, A; Ohta, T; Takii, Y; Tanaka, O; Tsuchiya, Y; Yabusaki, H, 2006
)
0.33
"We developed a combination chemotherapy, comprising weekly dosing of iv cisplatin (days 1 and 8) combined with a fixed dose (70 mg/m2/day) of S-1 (days 1-14) for patients with metastatic gastric cancer."( [S-1 combined with weekly dosing of cisplatin for metastatic gastric cancer].
Hyodo, I, 2006
)
0.33
"S-1 Combined with Weekly Paclitaxel in Patients with Advanced Gastric Cancer: Masahiro Gotoh, Shin-ichiro Kawabe and Hiroya Takiuchi (Dept."( [S-1 combined with weekly paclitaxel in patients with advanced gastric cancer].
Gotoh, M; Kawabe, S; Takiuchi, H, 2006
)
0.33
"Lentinan (LNT) is a beta-glucan known to have a life-prolonging effect in combination with chemotherapy for patients with unresectable or recurrent gastric cancer."( [S-1 combined with lentinan in patients with unresectable or recurrent gastric cancer].
Kashimura, H; Kashiwagi, H; Mitsumori, N; Nimura, H; Takahashi, N; Takayama, S; Yanaga, K, 2006
)
0.33
"Chemoradiotherapy combined with 5-fluorouracil and cisplatin have been effective for the treatment of advanced esophageal cancer, but superior treatments are needed."( [Radiotherapy combined with S-1 and cisplatin for locally advanced and metastatic esophageal cancer].
Iwase, H, 2006
)
0.33
"Chemoradiotherapy combined with S-1 and cisplatin may be a promising treatment option for advanced esophageal cancer."( [Radiotherapy combined with S-1 and cisplatin for locally advanced and metastatic esophageal cancer].
Iwase, H, 2006
)
0.33
" This phase I/II study was designed to determine the maximum tolerated dose (MTD), recommended dose (RD), dose-limiting toxicity (DLT), and objective response rate of paclitaxel in combination with S-1."( Phase I/II study of S-1 combined with paclitaxel in patients with unresectable and/or recurrent advanced gastric cancer.
Aihara, R; Asao, T; Haga, N; Kamiyama, Y; Kuwano, H; Mochiki, E; Nakabayashi, T; Nakamura, J; Ohno, T; Ohsawa, H; Ojima, H; Takeuchi, K, 2006
)
0.33
"This randomised phase II study evaluates the safety and efficacy profile of uracil/tegafur/leucovorin combined with irinotecan (TEGAFIRI) or with oxaliplatin (TEGAFOX)."( Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study.
Aitini, E; Bajetta, E; Barone, C; Buzzoni, R; Di Bartolomeo, M; Ferrario, E; Iop, A; Isa, L; Jacobelli, S; Lo Vullo, S; Mariani, L; Pinotti, G; Recaldin, E; Zilembo, N, 2007
)
0.56
"To evaluate the enhancing effects of ginsenoside Rg3 combined with mitomycin C and tegafur (MF) on postoperative chemotherapy in advanced gastric cancer."( [Effect of adjuvant chemotherapy of ginsenoside Rg3 combined with mitomycin C and tegafur in advanced gastric cancer].
Chen, ZJ; Cheng, J; Han, SL; Huang, YP; Liu, NX; Yao, JG; Zhu, GB, 2007
)
0.79
"In this study, the response of human OSCC cells to TRAIL alone and in combination with S-1 was examined using nude mouse xenograft models."( Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
Ferdous, T; Harada, K; Itashiki, Y; Yoshida, H,
)
0.13
"To determine the safety profile and activity of IP docetaxel combined with S-1 for patients with peritoneal dissemination of gastric cancer, a multi-centric phase I/II study has started."( [A multi-centric phase I/II study of intraperitoneal docetaxel combined with S-1 for patients with peritoneal dissemination of gastric cancer].
Fujimura, T; Fukushima, N; Fushida, S; Goda, F; Hirono, Y; Imano, M; Kaji, M; Kurita, A; Kurita, N; Nashimoto, A; Ohta, T; Tanemura, H; Tsujitani, S; Watanabe, Y; Yamaguchi, K, 2007
)
0.34
" The patient was treated with S-1 combined with CPT-11."( [An elderly patient with recurrent rectal cancer successfully responded to S-1 combined with CPT-11].
Doi, M; Egawa, T; Hayashi, S; Ito, Y; Kitano, M; Nagashima, A; Sekine, K; Shimizu, M; Yoshii, H, 2007
)
0.34
"To evaluate the efficacy and safety of irinotecan combined with UFT for untreated and pretreated metastatic colorectal cancer."( Phase I/II study of 24-hour infusion of irinotecan combined with oral UFT for metastatic colorectal cancer.
Ishikawa, K; Maeda, Y; Makuuchi, H; Murayama, C; Sadahiro, S; Suzuki, T; Yasuda, S, 2008
)
0.35
"A 24-hour infusion of irinotecan combined with UFT is feasible and active for metastatic colorectal cancer."( Phase I/II study of 24-hour infusion of irinotecan combined with oral UFT for metastatic colorectal cancer.
Ishikawa, K; Maeda, Y; Makuuchi, H; Murayama, C; Sadahiro, S; Suzuki, T; Yasuda, S, 2008
)
0.35
"To test the efficacy and safety of pharmacokinetic modulating chemotherapy combined with cisplatin (PMC-cisplatin) as induction chemotherapy (ICT) before definitive treatment in patients with respectable locally advanced head and neck squamous cell carcinoma (HNSCC)."( Effectiveness of pharmacokinetic modulating chemotherapy combined with cisplatin as induction chemotherapy in resectable locally advanced head and neck cancer: phase II study.
Chang, PM; Chang, SY; Chen, PM; Chu, PY; Huang, JL; Tai, SK; Tsai, TL; Wang, LW; Wang, YF; Yang, MH, 2008
)
0.35
"We designed a phase I/II trial of S-1 combined with weekly docetaxel to determine the maximum tolerated dose (MTD) and recommended dose (RD) and to evaluate the efficacy and toxicity in metastatic gastric carcinoma (MGC)."( Phase I/II study of S-1 combined with weekly docetaxel in patients with metastatic gastric carcinoma.
Bae, JM; Choi, IJ; Kim, CG; Kim, HK; Kim, NK; Kim, YW; Lee, JH; Lee, JS; Park, SR; Ryu, KW, 2008
)
0.35
"We herein describe the case of a patient with advanced gastric carcinoma combined with extra-adrenal pheochromocytoma who received a radical operation after undergoing neoadjuvant chemotherapy."( Advanced gastric carcinoma combined with extra-adrenal pheochromocytoma resected after three courses of S-1 and cisplatin as neoadjuvant chemotherapy: report of a case.
Inamine, S; Miyata, M; Sunagawa, H; Takeshima, M; Zaha, H, 2008
)
0.35
"The purpose of this study was to determine the optimal dose of oxaliplatin, when combined with a fixed dose of S-1 (40 mg/m twice daily on days 1-14) on a 3-week schedule, for patients with advanced and/or metastatic colorectal cancer."( Phase I dose-escalating study of S-1 in combination with oxaliplatin for patients with advanced and/or metastatic colorectal cancer.
Cao, J; Li, J; Liu, Y; Lu, F; Yin, J; Zhu, X; Zuo, Y, 2008
)
0.35
"A phase 2 trial of S-1 combined with cisplatin was conducted for unresectable pancreatic cancer."( Phase 2 trial of oral S-1 combined with low-dose cisplatin for unresectable advanced pancreatic cancer.
Fujita, Y; Hirono, S; Ina, S; Kawai, M; Miyazawa, M; Nishioka, R; Tani, M; Yamaue, H,
)
0.13
" We treated the patient with S-1 combined with CPT-11."( [Three cases with liver metastasis from gastric or colon cancer successfully treated with S-1 combined with CPT- 11].
Ishii, Y; Mado, K; Manmoto, J; Masuda, H; Mazaki, T; Okame, H; Suzuki, K; Takayama, T, 2008
)
0.35
"To determine the clinical toxicities and antitumor effects of a chemotherapy regimen of FTQ, a compound preparation of tegafur, the drug prototype of 5-furacil (5-FU), gimeracil (CDHP), a decomposition inhibitor of 5-FU, oteracil potassium, phosphorylation inhibitor of 5-FU, and combined with cisplatin in patients with inoperable locally or metastatic advanced gastric cancer."( [Curative effects of FTQ combined with cisplatin in treatment of advanced gastric cancer: a multicenter study].
Dai, GH; Jiao, SC; Li, F; Li, Y; Liu, W; Lu, HS; Niu, RG; Song, SP; Wang, J; Xie, XD; Xu, JM; Yang, JL; Zhang, FC; Zhang, Y; Zhao, H, 2008
)
0.55
"The regimen of FTQ combined with cisplatin is generally well-tolerated and has substantial antitumor activity."( [Curative effects of FTQ combined with cisplatin in treatment of advanced gastric cancer: a multicenter study].
Dai, GH; Jiao, SC; Li, F; Li, Y; Liu, W; Lu, HS; Niu, RG; Song, SP; Wang, J; Xie, XD; Xu, JM; Yang, JL; Zhang, FC; Zhang, Y; Zhao, H, 2008
)
0.35
" This study was to evaluate the efficacy of three-dimensional conformal gamma-knife radiotherapy combined with thermochemotherapy on locally advanced pancreatic cancer."( [Efficacy of whole body gamma-knife radiotherapy combined with thermochemotherapy on locally advanced pancreatic cancer].
Cai, CL; Kang, JB; Li, JG; Nie, Q; Qi, WJ; Wang, B; Zhang, LP, 2008
)
0.35
"3-D conformal gamma-knife radiotherapy combined with thermochemotherapy is well tolerated and is relatively effective for most patients with locally advanced pancreatic cancer."( [Efficacy of whole body gamma-knife radiotherapy combined with thermochemotherapy on locally advanced pancreatic cancer].
Cai, CL; Kang, JB; Li, JG; Nie, Q; Qi, WJ; Wang, B; Zhang, LP, 2008
)
0.35
"To investigate the efficacy and toxicity of nedaplatin combined with tegafur in the treatment for patients with advanced esophageal cancer."( [Nedaplatin combined with tegafur in the treatment for advanced esophageal cancer].
Chen, XB; Fan, QX; Geng, L; Han, JW; Jiao, ZM; Lu, P; Lu, SP; Lu, TY; Luo, SX; Ma, ZY; Song, M; Wang, GJ; Wang, JS; Wang, R; Wang, RL; Wu, XA; Zhang, MZ; Zhao, YF, 2008
)
0.88
"The regimen of nedaplatin combined with tegafur is effective and tolerable for the treatment of advanced esophageal cancer."( [Nedaplatin combined with tegafur in the treatment for advanced esophageal cancer].
Chen, XB; Fan, QX; Geng, L; Han, JW; Jiao, ZM; Lu, P; Lu, SP; Lu, TY; Luo, SX; Ma, ZY; Song, M; Wang, GJ; Wang, JS; Wang, R; Wang, RL; Wu, XA; Zhang, MZ; Zhao, YF, 2008
)
0.91
" To determine the feasibility of S-1 combined with weekly irinotecan for patients with advanced NSCLC, we performed a phase I study to determine the maximum tolerated dose (MTD) and the recommended dose (RD) of irinotecan."( Phase I study of daily S-1 combined with weekly irinotecan in patients with advanced non-small cell lung cancer.
Honda, Y; Ishida, T; Ishimoto, O; Munakata, M; Sugawara, S, 2009
)
0.35
" In the present study, we conducted a phase I study to examine local control of S-1 in the combination with DOC using super-selective intra-arterial infusion with oral cancer."( [Clinical phase I trial of S-1 in the combination with DOC using super-selective intra-arterial infusion with oral cancer].
Harada, K; Horinaga, D; Mano, T; Mihara, M; Okafuji, M; Uchida, K; Ueyama, Y; Wada, N, 2009
)
0.35
"A dose-escalation study of weekly intraperitoneal paclitaxel (PTX) combined with S-1 and intravenous PTX was performed to determine the maximum-tolerated dose (MTD) and recommended dose (RD) in gastric cancer patients."( Phase I pharmacokinetic study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer.
Hidemura, A; Ishigami, H; Kaisaki, S; Kamei, T; Kitayama, J; Miyato, H; Nagawa, H; Otani, K; Soma, D; Yamashita, H, 2009
)
0.35
" This phase I/II trial was performed to evaluate the efficacy and safety of continuous infusion of irinotecan combined with UFT plus leucovorin (LV) for metastatic colorectal cancer."( Phase I/II study of twenty-four-hour infusion of irinotecan in combination with oral UFT plus leucovorin for metastatic colorectal cancer.
Ishikawa, K; Maeda, Y; Makuuchi, H; Murayama, C; Sadahiro, S; Suzuki, T; Tanaka, A, 2009
)
0.35
"A 24-hour infusion of irinotecan combined with UFT/LV is feasible and active for metastatic colorectal cancer."( Phase I/II study of twenty-four-hour infusion of irinotecan in combination with oral UFT plus leucovorin for metastatic colorectal cancer.
Ishikawa, K; Maeda, Y; Makuuchi, H; Murayama, C; Sadahiro, S; Suzuki, T; Tanaka, A, 2009
)
0.35
"To investigate the safety and immunological responses of personalized peptide vaccination in combination with oral administration of UFT and UZEL for metastatic colorectal carcinoma (mCRC), fourteen patients were enrolled in the present study."( Immunological evaluation of personalized peptide vaccination in combination with UFT and UZEL for metastatic colorectal carcinoma patients.
Hattori, T; Itoh, K; Komatsu, N; Mine, T; Okuno, K; Shiozaki, H; Yamada, A, 2009
)
0.35
"In this study, the response of human OSCC cells to cepharanthine alone and in combination with S-1 was examined using nude mouse xenograft models."( Effects of cepharanthine alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
Ferdous, T; Harada, K; Itashiki, Y; Mano, T; Mori, Y; Takii, M; Ueyama, Y, 2009
)
0.35
" paclitaxel (PTX) combined with S-1 was carried out in gastric cancer patients with peritoneal metastasis."( Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis.
Hidemura, A; Ishigami, H; Kaisaki, S; Kamei, T; Kato, M; Kitayama, J; Miyato, H; Nagawa, H; Otani, K; Soma, D; Yamashita, H, 2010
)
0.36
"As there is no standard treatment for advanced gastric cancer refractory to first-line chemotherapy, the feasibility of S-1 plus weekly docetaxel combined with concurrent radiotherapy was evaluated."( Feasibility study of S-1 plus weekly docetaxel combined with concurrent radiotherapy in advanced gastric cancer refractory to first-line chemotherapy.
Fujitani, K; Hirao, M; Kurokawa, Y; Tsujinaka, T; Yamasaki, H; Yoshida, K, 2009
)
0.35
"S-1 plus weekly docetaxel combined with concurrent RT exhibited a tolerable toxicity profile with sufficient symptom palliation and prolonged survival in patients with advanced gastric cancer refractory to first-line chemotherapy."( Feasibility study of S-1 plus weekly docetaxel combined with concurrent radiotherapy in advanced gastric cancer refractory to first-line chemotherapy.
Fujitani, K; Hirao, M; Kurokawa, Y; Tsujinaka, T; Yamasaki, H; Yoshida, K, 2009
)
0.35
" Tegafur and Uracil (UFT) have been widely used for the postoperative chemotherapy of breast cancer, and often combined with hormonal agents."( [Safety and compliance with UFT (tegafur and uracil) alone and in combination with hormone therapy in patients with breast cancer].
Noguchi, S; Taguchi, T, 2009
)
1.54
" Weekly intravenous and intraperitoneal PTX combined with S-1 was highly effective in gastric cancer with malignant ascites."( Weekly intravenous and intraperitoneal paclitaxel combined with S-1 for malignant ascites due to advanced gastric cancer.
Hidemura, A; Ishigami, H; Kaisaki, S; Kamei, T; Kato, M; Kitayama, J; Miyato, H; Nagawa, H; Otani, K; Soma, D; Yamashita, H, 2010
)
0.36
"Recently, in drug therapy for patients with advanced digestive cancer, S-1 (tegafur x gimeracil x oteracil potassium) alone or S-1 combined with other chemotherapeutic agents (S-1+alpha) is prescribed."( [Provision for adverse effect of S-1 containing chemotherapy in patients with advanced digestive cancer--combination with superfine dispersed lentinan].
Hazama, S; Nakazawa, S; Suga, T; Watanabe, S; Yagi, M; Yoshino, S, 2010
)
0.59
" In this study, the response of human OSCC cells to Lentinan alone and in combination with S-1 was examined using nude mouse xenograft models."( Effects of lentinan alone and in combination with fluoropyrimidine anticancer agent on growth of human oral squamous cell carcinoma in vitro and in vivo.
Harada, K; Itashiki, Y; Takenawa, T; Ueyama, Y, 2010
)
0.36
" His diagnosis was rectal perforation combined with intraperitoneal abscess."( [A case of rectal cancer combined with intraperitoneal abscess responding completely to uracil/tegafur (UFT) plus oral leucovorin (LV) therapy].
Hamaya, M; Hojyo, K; Honda, A; Kaneko, H; Kawashima, H; Narabashi, K; Noda, S; Okamoto, N; Onoda, K; Yamada, K; Yokote, K, 2010
)
0.58
"Although there are many randomized clinical trials of late course accelerated hyperfractionated radiotherapy (LCAHFR) combined with FP chemotherapy for esophageal cancer, the efficacy and toxicity are controversial."( Meta-analysis of late course accelerated hyperfractionated radiotherapy combined with FP chemotherapy for esophageal carcinoma.
Gao, XS; Li, XY; Liu, CX, 2010
)
0.36
"Reports of randomized clinical trials on LCAHFR combined with FP chemotherapy for esophageal cancer published between January 1999 and January 2009 were researched through Wanfang, CNKI, and PubMed databases."( Meta-analysis of late course accelerated hyperfractionated radiotherapy combined with FP chemotherapy for esophageal carcinoma.
Gao, XS; Li, XY; Liu, CX, 2010
)
0.36
" Of the 2030 patients, 1006 underwent LCAHFR (LCAHFR group), and 1024 underwent LCAHFR combined with FP chemotherapy (combination group)."( Meta-analysis of late course accelerated hyperfractionated radiotherapy combined with FP chemotherapy for esophageal carcinoma.
Gao, XS; Li, XY; Liu, CX, 2010
)
0.36
"LCAHFR combined with FP chemotherapy can improve the survival rate and the local control rate of the patients with esophageal cancer."( Meta-analysis of late course accelerated hyperfractionated radiotherapy combined with FP chemotherapy for esophageal carcinoma.
Gao, XS; Li, XY; Liu, CX, 2010
)
0.36
"To investigate the efficacy and toxicity of a short intensive Uracil/Tegafur (UFT) based chemoradiotherapy scheme combined with celecoxib in locally advanced pancreatic cancer."( Phase II trial of Uracil/Tegafur plus leucovorin and celecoxib combined with radiotherapy in locally advanced pancreatic cancer.
Busch, OR; Morak, MJ; Nuyttens, JJ; Padmos, EE; Richel, DJ; Schaake, EE; van der Gaast, A; van Eijck, CH; van Tienhoven, G; Vervenne, WL, 2011
)
0.91
"5 Gy radiotherapy combined with UFT 300 mg/m(2) per day, leucovorin (folinic acid) 30 mg and celecoxib 80 0mg for 28 days concomitant with radiotherapy."( Phase II trial of Uracil/Tegafur plus leucovorin and celecoxib combined with radiotherapy in locally advanced pancreatic cancer.
Busch, OR; Morak, MJ; Nuyttens, JJ; Padmos, EE; Richel, DJ; Schaake, EE; van der Gaast, A; van Eijck, CH; van Tienhoven, G; Vervenne, WL, 2011
)
0.67
"Based on the lack of response, the substantial toxicity of mainly gastro-intestinal origin and the reported mediocre overall and progression free survival, we cannot advise our short intensive chemoradiotherapy schedule combined with celecoxib as the standard treatment."( Phase II trial of Uracil/Tegafur plus leucovorin and celecoxib combined with radiotherapy in locally advanced pancreatic cancer.
Busch, OR; Morak, MJ; Nuyttens, JJ; Padmos, EE; Richel, DJ; Schaake, EE; van der Gaast, A; van Eijck, CH; van Tienhoven, G; Vervenne, WL, 2011
)
0.67
" Administration of TSU-68 in combination with SOX is generally well tolerated."( A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy.
Ahn, JB; Chung, HC; Jeung, HC; Jung, M; Kim, HR; Rha, SY; Roh, JK; Shin, SJ, 2012
)
0.38
"To observe the local control rate, survival time and side effect of three-dimensional conformal radiation therapy combined with Tegafur for postoperative recurrent rectal carcinoma."( [Effecacy of three-dimensional conformal radiation therapy combined with Tegafur for postoperative recurrent rectal carcinoma].
Li, WL; Liu, XH, 2011
)
0.81
"Three-dimensional conformal radiation therapy combined with Tegafur for postoperative recurrent rectal carcinoma have definite effect, with a high local control rate, and patients well tolerance the treatment without serious side effect."( [Effecacy of three-dimensional conformal radiation therapy combined with Tegafur for postoperative recurrent rectal carcinoma].
Li, WL; Liu, XH, 2011
)
0.84
" To the best of our knowledge, cases of EGC combined with metachronous osteosclerotic multiple bone and bone marrow metastases that respond to chemoradiotherapy are very rare."( Early gastric cancer combined with multiple metachronous osteosclerotic bone and bone marrow metastases that responded to chemoradiotherapy.
Chiba, F; Kiyozaki, H; Konishi, F; Saito, M; Shuto, C; Takata, O; Yamada, S; Yoshida, T, 2011
)
0.37
" We investigated the activity and toxicity of S-1 in combination with cisplatin in patients with unresectable non-small cell lung cancer (NSCLC)."( An open-label, multicenter, three-stage, phase II study of s-1 in combination with cisplatin as first-line therapy for patients with advanced non-small cell lung cancer.
Baggstrom, M; Graham, C; Herbst, R; Jones, D; Saito, K; Sandler, A; Zergebel, C, 2011
)
0.37
"To retrospectively evaluate the efficacy and tolerability of mitomycin-C (MMC) in combination with fluoropyrimidines as salvage 3rd -or 4th-line therapy in metastatic colorectal cancer (MCRC) patients."( Mitomycin-C in combination with fluoropyrimidines in the treatment of metastatic colorectal cancer after oxaliplatin and irinotecan failure.
Alkis, N; Benekli, M; Demirci, U; Gumus, M; Isikdogan, A; Kaplan, MA; Koca, D; Ozdemir, NY; Sevinc, A; Uncu, D; Unek, T; Yetisyigit, T; Yilmaz, U,
)
0.13
"MMC in combination with fluoropyrimidines is safe and active in heavily-pretreated MCRC patients."( Mitomycin-C in combination with fluoropyrimidines in the treatment of metastatic colorectal cancer after oxaliplatin and irinotecan failure.
Alkis, N; Benekli, M; Demirci, U; Gumus, M; Isikdogan, A; Kaplan, MA; Koca, D; Ozdemir, NY; Sevinc, A; Uncu, D; Unek, T; Yetisyigit, T; Yilmaz, U,
)
0.13
"In the current study, we have evaluated the clinical and immunological responses in patients with advanced pancreatic carcinoma who received dendritic cell (DC)-based immunotherapy in combination with gemcitabine and/or S-1."( Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma.
Homma, S; Imai, K; Kimura, Y; Koido, S; Okamoto, M; Shimamura, K; Shimodaira, S; Sunamura, M; Takahashi, H; Tomoda, T; Tsukada, J; Yonemitsu, Y, 2012
)
0.38
"Dendritic cell-based immunotherapy (DC vaccine alone or DC vaccine plus lymphokine-activated killer [LAK] cell therapy) in combination with gemcitabine and/or S-1 has been carried out in 49 patients with inoperable pancreatic carcinoma refractory to standard treatment."( Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma.
Homma, S; Imai, K; Kimura, Y; Koido, S; Okamoto, M; Shimamura, K; Shimodaira, S; Sunamura, M; Takahashi, H; Tomoda, T; Tsukada, J; Yonemitsu, Y, 2012
)
0.38
" Survival of patients receiving DC vaccine and chemotherapy plus LAK cell therapy was longer than those receiving DC vaccine in combination with chemotherapy but no LAK cells."( Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma.
Homma, S; Imai, K; Kimura, Y; Koido, S; Okamoto, M; Shimamura, K; Shimodaira, S; Sunamura, M; Takahashi, H; Tomoda, T; Tsukada, J; Yonemitsu, Y, 2012
)
0.38
"Dendritic cell vaccine-based immunotherapy combined with chemotherapy was shown to be safe and possibly effective in patients with advanced pancreatic cancer refractory to standard treatment."( Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma.
Homma, S; Imai, K; Kimura, Y; Koido, S; Okamoto, M; Shimamura, K; Shimodaira, S; Sunamura, M; Takahashi, H; Tomoda, T; Tsukada, J; Yonemitsu, Y, 2012
)
0.38
" We selected neoadjuvant S-1 combined with CDDP therapy for him."( [Type 4 advanced gastric cancer responding to histological complete response after neoadjuvant S-1 combined with CDDP therapy-report of a case].
Asaumi, Y; Doden, K; Fujita, M; Hashizume, Y; Hattori, M; Hayashi, H; Hayashida, Y; Hirano, M; Ito, H; Kaizaki, Y; Kitamura, H; Maeda, K; Miyanaga, T; Miyazaki, M; Ohta, K; Sawada, K; Yagi, D, 2011
)
0.37
"The primary objective of this Phase I study was to assess the safety and tolerability of the vascular endothelial growth factor signalling inhibitor cediranib in combination with cisplatin plus an oral fluoropyrimidine, in Japanese patients with previously untreated advanced gastric cancer."( Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer.
Boku, N; Brown, KH; Hayashi, H; Muro, K; Nakajima, TE; Satoh, T; Shi, X; Shimada, Y; Takahari, D; Taku, K; Yamada, Y, 2012
)
0.38
"Patients received continuous, once-daily oral doses of cediranib 20 mg in combination with either cisplatin (60 mg/m(2) iv day 1) plus S-1 (40-60 mg bid, days 1-21) every 5 weeks for a maximum of eight cycles [Arm A]; or cisplatin (80 mg/m(2) iv, day 1) plus capecitabine (1,000 mg/m(2) bid, days 1-14) every 3 weeks for a maximum of six cycles [Arm B]."( Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer.
Boku, N; Brown, KH; Hayashi, H; Muro, K; Nakajima, TE; Satoh, T; Shi, X; Shimada, Y; Takahari, D; Taku, K; Yamada, Y, 2012
)
0.38
"Cediranib 20 mg/day in combination with cisplatin and S-1 or capecitabine was tolerable, with no new toxicities identified, and showed preliminary evidence of antitumour activity."( Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer.
Boku, N; Brown, KH; Hayashi, H; Muro, K; Nakajima, TE; Satoh, T; Shi, X; Shimada, Y; Takahari, D; Taku, K; Yamada, Y, 2012
)
0.38
"As there are no reports of S-1 in combination with trastuzumab in clinical settings, we evaluated the safety and efficacy of S-1 in combination with trastuzumab for human epidermal-growth factor receptor (HER2)-positive metastatic breast cancer (MBC) and determined the recommended dose (RD)."( Phase I study of S-1 in combination with trastuzumab for HER2-positive metastatic breast cancer.
Ito, T; Kamigaki, S; Morita, S; Nakayama, T; Noguchi, S; Sakamoto, J; Taguchi, T; Takashima, T; Yoshidome, K, 2011
)
0.37
" Two cycles of intraperitoneal chemotherapy with docetaxel combined with S-1, were administrated and gastrectomy with lymph node dissection was performed in cases without macroscopic PC at post-NIPS staging laparoscopy."( Intraperitoneal docetaxel combined with S-1 for advanced gastric cancer with peritoneal dissemination.
Doki, Y; Fujiwara, Y; Kurokawa, Y; Miyata, H; Mori, M; Nakajima, K; Takiguchi, S; Yamasaki, M, 2012
)
0.38
"This study indicated that the NIPS combined with surgery was highly active and well tolerated by advanced gastric cancer patients with PC."( Intraperitoneal docetaxel combined with S-1 for advanced gastric cancer with peritoneal dissemination.
Doki, Y; Fujiwara, Y; Kurokawa, Y; Miyata, H; Mori, M; Nakajima, K; Takiguchi, S; Yamasaki, M, 2012
)
0.38
" The Committee for Medicinal Products for Human Use of the European Medicines Agency concluded that S-1 in combination with cisplatin (75 mg/m²) was noninferior to 5-FU plus cisplatin (100 mg/m²) in patients with advanced gastric cancer and adopted a positive opinion recommending the marketing authorization for this product for the treatment of advanced gastric cancer when given in combination with cisplatin."( The European Medicines Agency review of Tegafur/Gimeracil/Oteracil (Teysuno™) for the treatment of advanced gastric cancer when given in combination with cisplatin: summary of the Scientific Assessment of the Committee for medicinal products for human use
Abadie, E; Calvo Rojas, G; Camarero, J; Garcia-Carbonero, R; Matt, P; Pignatti, F; Ter Hofstede, H; van Zwieten-Boot, B, 2011
)
0.64
" The study was designed to identify the maximum tolerable dose and the dose-limiting toxicities of two schedules of S-1 combined with oxaliplatin and bevacizumab, in advanced solid tumor patients."( Phase I study of two schedules of oral S-1 in combination with fixed doses of oxaliplatin and bevacizumab in patients with advanced solid tumors.
Chung, KY; Hollywood, E; Saito, K; Saltz, LB; Segal, M; Zergebel, C, 2011
)
0.37
"S-1, oxaliplatin and bevacizumab can be administered with acceptable safety and tolerability and without evidence of pharmacokinetic interactions."( Phase I study of two schedules of oral S-1 in combination with fixed doses of oxaliplatin and bevacizumab in patients with advanced solid tumors.
Chung, KY; Hollywood, E; Saito, K; Saltz, LB; Segal, M; Zergebel, C, 2011
)
0.37
" Preoperative RT combined with S-1 was feasible and well tolerated."( Preoperative radiotherapy combined with S-1 for advanced lower rectal cancer: phase I trial.
Ikushima, H; Iwata, T; Kashihara, H; Kurita, N; Miyatani, T; Morimoto, S; Nishioka, M; Sato, H; Shimada, M; Takasu, C; Yoshikawa, K,
)
0.13
" Here, we report on a case of treatment of far advanced gastric cancer with synchronous multiple liver metastases with prompt S-1 in combination with fractional cisplatin sandwiched between twostage surgery."( Pathological complete response of synchronous multiple liver metastases associated with advanced gastric cancer to gastrectomy and prompt S-1 treatment in combination with fractional cisplatin: report of a case.
Hatao, F; Kiyokawa, T; Kokudo, N; Mise, Y; Nomura, S; Nunobe, S; Seto, Y; Shimizu, N; Sugawara, Y; Wada, I,
)
0.13
"To evaluate the efficacy and safety profile of S-1 combined with oxaliplatin (SOX) against unresectable advanced or metastatic gastric cancer."( S-1 combined with oxaliplatin as first line chemotherapy for Chinese advanced gastric cancer patients.
Liu, B; Luo, C; Xu, Q; Ying, J; Zhong, H; Zhu, L,
)
0.13
"The aim of this study was to evaluate the safety and efficacy of vaccination with human leukocyte antigen (HLA)-A24-restricted human vascular endothelial growth factor receptor 1 (VEGFR1)-1084 and VEGFR2-169 combined with chemotherapy in patients with advanced gastric cancer."( Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer.
Doki, Y; Fujiwara, Y; Kurokawa, Y; Masuzawa, T; Miyata, H; Mori, M; Nakajima, K; Nakamura, A; Nakamura, Y; Okada, K; Osawa, R; Takeda, K; Takiguchi, S; Tsunoda, T; Yamasaki, M; Yoshida, K, 2012
)
0.38
" The aim of the study was to determine the maximum tolerated dose (MTD) and recommended dose (RD) of BV combined with irinotecan plus S-1, and to observe the safety and efficacy of this regimen as second-line chemotherapy in patients with advanced colorectal cancer."( Phase I study of bevacizumab combined with irinotecan and S-1 as second-line chemotherapy in patients with advanced colorectal cancer.
Akashi, K; Arita, S; Baba, E; Esaki, T; Kishimoto, J; Kumagai, H; Kusaba, H; Mitsugi, K; Uchino, K, 2013
)
0.39
"To evaluate the efficacy and safety of weekly paclitaxel combined with S-1 or fluorouracil in the first line treatment of advanced gastric carcinoma."( [A phase II prospective randomized controlled trial of weekly paclitaxel combined with S-1 or fluorouracil for advanced gastric carcinoma].
Ba, Y; Deng, T; Guo, ZQ; Hu, CH; Huang, DZ; Meng, JC; Wan, HP; Wang, ML; Xiong, JP; Xu, N; Yan, Z; Yao, Y; Yu, Z; Yu, ZH; Zhang, Y; Zheng, RS; Zhuang, ZX, 2012
)
0.38
" Weekly paclitaxel combined with S-1 is a safe regimen and has a promising efficacy."( [A phase II prospective randomized controlled trial of weekly paclitaxel combined with S-1 or fluorouracil for advanced gastric carcinoma].
Ba, Y; Deng, T; Guo, ZQ; Hu, CH; Huang, DZ; Meng, JC; Wan, HP; Wang, ML; Xiong, JP; Xu, N; Yan, Z; Yao, Y; Yu, Z; Yu, ZH; Zhang, Y; Zheng, RS; Zhuang, ZX, 2012
)
0.38
"Both amrubicin (Am) and S-1 are effective against non-small-cell lung cancer (NSCLC), and preclinical studies have demonstrated that the effect of tegafur/uracil, the original compound of S-1, in combination with Am significantly inhibits tumor growth."( Phase I/II study of amrubicin in combination with S-1 as second-line chemotherapy for non-small-cell lung cancer without EGFR mutation.
Kondo, T; Murakami, S; Oshita, F; Saito, H; Sugiura, M; Yamada, K, 2013
)
0.59
" We report the first case of lung injury due to S-1 in combination with pneumocystis pneumonia (PCP), because the radiological findings and clinical courses were compatible with S-1-induced lung injury combined with PCP."( S-1-induced lung injury combined with pneumocystis pneumonia.
Yano, S, 2013
)
0.39
" The purpose of this phase I study was to evaluate the safety, pharmacokinetics, and preliminary efficacy of sorafenib in combination with S-1 plus CDDP."( A phase I study of sorafenib in combination with S-1 plus cisplatin in patients with advanced gastric cancer.
Fuse, N; Hashizume, K; Ito, Y; Kato, K; Kiyota, N; Kuroki, Y; Minami, H; Ohtsu, A; Yamada, Y, 2014
)
0.4
" Pharmacokinetic analysis showed no significant differences in the exposures of sorafenib when administered alone or in combination with S-1 and CDDP."( A phase I study of sorafenib in combination with S-1 plus cisplatin in patients with advanced gastric cancer.
Fuse, N; Hashizume, K; Ito, Y; Kato, K; Kiyota, N; Kuroki, Y; Minami, H; Ohtsu, A; Yamada, Y, 2014
)
0.4
"To investigate the anti-tumor effect of celecoxib combined with tegafur gimeracil oteracil potassium on subcutaneous xenograft tumor of gastric cancer in nude mice and analyze the possible mechanism."( [Inhibitive effect of celecoxib combined with tegafur gimeracil oteracil potassium on the growth of xenograft tumor of gastric cancer in nude mice].
Chen, X; Luo, Z; Meng, C, 2013
)
0.89
" This phase 2 study evaluated the benefits and tolerability of weekly intravenous and intraperitoneal paclitaxel (PTX) treatment combined with oral S-1 in patients with gastric cancer who had macroscopic peritoneal metastasis."( A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis.
Emoto, S; Ishigami, H; Kitayama, J; Watanabe, T; Yamaguchi, H; Yamashita, H, 2013
)
0.39
" Two patients received only SOX as chemotherapy, while the others received SOX in combination with one of the three molecular-targeting agents, bevacizumab, cetuximab, and panitumumab."( Impact of chemotherapy with S-1 and oxaliplatin (SOX) in combination with molecular-targeting agents on colorectal liver metastases.
Akiba, T; Enomoto, H; Kawahara, H; Toyama, Y; Watanabe, K; Yanaga, K, 2013
)
0.39
" In the other four patients who received SOX in combination with molecular targets, the size of liver metastases appeared unchanged at three months after limited chemotherapy by CT scan."( Impact of chemotherapy with S-1 and oxaliplatin (SOX) in combination with molecular-targeting agents on colorectal liver metastases.
Akiba, T; Enomoto, H; Kawahara, H; Toyama, Y; Watanabe, K; Yanaga, K, 2013
)
0.39
"This study evaluated the efficacy and safety of S-1 combined with docetaxel (SD) following doxorubicin plus cyclophosphamide (AC) as neoadjuvant therapy in patients with HER2-negative, stage II-III breast cancer."( S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial.
Chung, HC; Kim, EK; Kim, JH; Kim, MJ; Kim, SI; Koo, JS; Lee, S; Moon, YW; Park, BW; Park, S; Sohn, J, 2013
)
0.39
"Given all axillary lymph node positive diseases, neoadjuvant S-1 combined with docetaxel following AC showed a favorable anti-tumor activity but gastrointestinal discomfort should be carefully considered for future studies."( S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial.
Chung, HC; Kim, EK; Kim, JH; Kim, MJ; Kim, SI; Koo, JS; Lee, S; Moon, YW; Park, BW; Park, S; Sohn, J, 2013
)
0.39
" To date, no studies have evaluated the efficacy and safety of trastuzumab combined with SP in patients with human epidermal growth factor receptor type 2 (HER2)-positive AGC."( Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1).
Doki, Y; Furukawa, H; Gamoh, M; Imamura, H; Komatsu, Y; Kurokawa, Y; Miwa, H; Nishina, S; Okuda, H; Sakai, D; Shimokawa, T; Sugimoto, N; Tsuda, M; Tsujinaka, T, 2014
)
0.4
"Trastuzumab in combination with SP showed promising antitumour activity and manageable toxic effects in patients with HER2-positive AGC."( Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1).
Doki, Y; Furukawa, H; Gamoh, M; Imamura, H; Komatsu, Y; Kurokawa, Y; Miwa, H; Nishina, S; Okuda, H; Sakai, D; Shimokawa, T; Sugimoto, N; Tsuda, M; Tsujinaka, T, 2014
)
0.4
" The goal of this trial was to evaluate the efficacy of TSU-68 in combination with SOX."( A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer.
Choi, YJ; Chun, HG; Chung, HC; Chung, IJ; Han, SW; Kim, JG; Kim, SY; Kim, TW; Kim, YH; Lee, J; Shin, DB; Shin, SJ; Song, HS, 2014
)
0.4
"The optimal radiotherapy technique and combination with systemic therapy in locally advanced gastric cancer patients are far from being resolved despite the fact that radiochemotherapy is becoming more attractive in contemporary clinical practice."( Effect of intensity modulated radiotherapy combined with s-1-based chemotherapy in locally advanced gastric cancer patients.
Gu, BX; Hu, JB; Hu, WX; Sun, XN; Wang, Q, 2014
)
0.4
"The high rate of R0 resections and low rate of locoregional recurrence suggest that IMRT combined with S-1-based chemotherapy is an effective treatment for locally advanced gastric cancer patients."( Effect of intensity modulated radiotherapy combined with s-1-based chemotherapy in locally advanced gastric cancer patients.
Gu, BX; Hu, JB; Hu, WX; Sun, XN; Wang, Q, 2014
)
0.4
" The goal of this study was to evaluate the efficacy and safety of combination therapy of cetuximab and S-1 combined with oxaliplatin (SOX) in Chinese patients with advanced gastric cancer."( Clinical evaluation of cetuximab combined with an S-1 and oxaliplatin regimen for Chinese patients with advanced gastric cancer.
Chen, XB; Hua, YW; Kong, Y; Liu, HX; Ma, EM; Yang, W; Zhang, B; Zhang, YL; Zhang, ZD, 2014
)
0.4
"For patients in the experimental group (cetuximab in combination with SOX (Ce-SOX), 30 patients), once-weekly cetuximab (400 mg/m2 at the first infusion then 250 mg/m2 every week) was administered."( Clinical evaluation of cetuximab combined with an S-1 and oxaliplatin regimen for Chinese patients with advanced gastric cancer.
Chen, XB; Hua, YW; Kong, Y; Liu, HX; Ma, EM; Yang, W; Zhang, B; Zhang, YL; Zhang, ZD, 2014
)
0.4
"These findings suggest that the cetuximab combined with SOX regimen is feasible and shows promising efficacy with tolerable adverse effects in Chinese patients with advanced gastric cancer."( Clinical evaluation of cetuximab combined with an S-1 and oxaliplatin regimen for Chinese patients with advanced gastric cancer.
Chen, XB; Hua, YW; Kong, Y; Liu, HX; Ma, EM; Yang, W; Zhang, B; Zhang, YL; Zhang, ZD, 2014
)
0.4
"The purpose of this phase I study of the dose escalation of oxaliplatin in combination with oral S-1 and pelvic radiation preoperatively for poor-risk lower rectal cancer was to determine the dose-limiting toxicity (DLT) and recommended dose of oxaliplatin."( A phase I trial of preoperative S-1 in combination with oxaliplatin and pelvic radiation for lower rectal cancer with T4 and lateral pelvic lymph node metastasis.
Fujita, S; Hamaguchi, T; Ito, Y; Kinugasa, Y; Moriya, Y; Noura, S; Ohue, M; Saito, N; Sakai, D; Shimada, Y, 2015
)
0.42
"This phase I trial of preoperative S-1 in combination with oxaliplatin and radiation for lower rectal cancer with T4 and lateral pelvic lymph node metastasis revealed that the recommended dose of oxaliplatin was 60 mg/m(2) weekly."( A phase I trial of preoperative S-1 in combination with oxaliplatin and pelvic radiation for lower rectal cancer with T4 and lateral pelvic lymph node metastasis.
Fujita, S; Hamaguchi, T; Ito, Y; Kinugasa, Y; Moriya, Y; Noura, S; Ohue, M; Saito, N; Sakai, D; Shimada, Y, 2015
)
0.42
"In this study, we compared the efficacy and safety of the oral fluoropyrimidine S-1 as monotherapy or in combination with leucovorin as the second-line treatment for patients with metastatic pancreatic cancer whose disease had progressed on gemcitabine treatment."( S-1 as monotherapy or in combination with leucovorin as second-line treatment in gemcitabine-refractory advanced pancreatic cancer: a randomized, open-label, multicenter, phase II study.
Ba, Y; Bai, Y; Ge, F; Jia, R; Li, F; Lin, L; Wang, Y; Xu, H; Xu, J; Xu, N; Zhang, Y, 2014
)
0.4
" Patients randomly received S-1 or S-1 in combination with leucovorin (SL arm) in 21-day cycles."( S-1 as monotherapy or in combination with leucovorin as second-line treatment in gemcitabine-refractory advanced pancreatic cancer: a randomized, open-label, multicenter, phase II study.
Ba, Y; Bai, Y; Ge, F; Jia, R; Li, F; Lin, L; Wang, Y; Xu, H; Xu, J; Xu, N; Zhang, Y, 2014
)
0.4
"The aim of this study is to explore the clinical effect of tegafur gimeracil oteracil combined with pirarubicin hydrochloride (THP) and diamminedichloroplatinum (DDP) for second-line treatment of advanced cardiac carcinoma, and find the most effective method to improve its survival rate and decrease the adverse reactions."( The Clinical Evaluation of Tegafur Gimeracil Oteracil Combined with THP and DDP for Second-Line Treatment of Advanced Cardiac Carcinoma.
Lv, JQ; Wang, HF, 2015
)
0.96
"5-Fluorouracil-based chemotherapy is considered to be a radiosensitizer; however, conventional short-course radiotherapy combined with chemotherapy is generally thought to not be feasible because of the prevalence of side effects."( Feasibility of modified short-course radiotherapy combined with a chemoradiosensitizer for T3 rectal cancer.
Beppu, N; Doi, H; Kakuno, A; Kamikonya, N; Matsubara, N; Tomita, N; Yamanaka, N; Yanagi, H, 2015
)
0.42
"The aim of this study was to evaluate the feasibility of modified short-course radiotherapy combined with a chemoradiosensitizer for T3 rectal cancer."( Feasibility of modified short-course radiotherapy combined with a chemoradiosensitizer for T3 rectal cancer.
Beppu, N; Doi, H; Kakuno, A; Kamikonya, N; Matsubara, N; Tomita, N; Yamanaka, N; Yanagi, H, 2015
)
0.42
"Modified short-course radiotherapy combined with chemoradiosensitizer is a feasible approach for treating T3 rectal cancer."( Feasibility of modified short-course radiotherapy combined with a chemoradiosensitizer for T3 rectal cancer.
Beppu, N; Doi, H; Kakuno, A; Kamikonya, N; Matsubara, N; Tomita, N; Yamanaka, N; Yanagi, H, 2015
)
0.42
"We aimed to assess the efficacy and safety of S-1 combined with cisplatin (SC) over cisplatin alone (C) for the treatment of advanced gastric cancer in China."( S-1 combined with cisplatin versus cisplatin alone for the treatment of advanced gastric cancer: a pilot randomized-controlled trial.
Gao, C; Li, X; Liu, D; Sun, L; Tong, J; Wu, D; Yang, D; Zhang, Q; Zheng, H, 2015
)
0.42
"The use of trastuzumab, a monoclonal antibody targeting the HER2 protein, in combination with 5-fluorouracil/platinum-based chemotherapy improves survival in patients with HER2-positive advanced gastric cancer."( Phase II study of trastuzumab in combination with S-1 and cisplatin in the first-line treatment of human epidermal growth factor receptor HER2-positive advanced gastric cancer.
Choo, SP; Chua, C; Iwasa, S; Lim, HY; Ng, M; Ong, WS; Rha, SY; Tai, DW; Tan, IB; Tham, CK; Yamada, Y; Yong, WP, 2015
)
0.42
" We aimed to assess the safety, tolerance, pharmacokinetics and clinical activity of S-1 combined with sorafenib in patients with mRCC."( Phase I/II study of S-1 in combination with sorafenib for metastatic renal cell carcinoma.
Akaza, H; Eto, M; Fujisawa, M; Hashine, K; Naito, S; Ozono, S; Sakai, H; Shinohara, N; Tomita, Y, 2015
)
0.42
" S-1 was administered orally at 60, 80, 100 or 120 mg/day on days 1-28 of a 42-day cycle in combination with sorafenib (400 or 800 mg/day), given daily with dose adjustment."( Phase I/II study of S-1 in combination with sorafenib for metastatic renal cell carcinoma.
Akaza, H; Eto, M; Fujisawa, M; Hashine, K; Naito, S; Ozono, S; Sakai, H; Shinohara, N; Tomita, Y, 2015
)
0.42
"To analyze the therapeutic actions of tegafur gimeracil oteracil combined with oxaliplatin for treating patients with advanced colorectal cancer, and its effects on the K-ras gene mutation and the CK20 mRNA."( Tegafur gimeracil oter combined with oxaliplatin for advanced colorectal cancer.
Ren, J; Wei, H; Yang, ZH; Yi, LJ; Zheng, JH, 2015
)
2.13
" The control group, which consisted of 20 cases, were treated with capecitabine combined with oxaliplatin."( Tegafur gimeracil oter combined with oxaliplatin for advanced colorectal cancer.
Ren, J; Wei, H; Yang, ZH; Yi, LJ; Zheng, JH, 2015
)
1.86
"Tegafur/gimeracil/oteracil combined with oxaliplatin therapy had better treatment outcomes than capecitabine combined oxaliplatin for advanced colorectal cancer."( Tegafur gimeracil oter combined with oxaliplatin for advanced colorectal cancer.
Ren, J; Wei, H; Yang, ZH; Yi, LJ; Zheng, JH, 2015
)
3.3
"To evaluate the safety and efficacy of gemcitabine combined with S-1 in the treatment of advanced pancreatic cancer."( [Safety and efficacy of gemcitabine combined with S-1 in the treatment of advanced pancreatic cancer].
He, P; Jiang, Y; Yang, K; Zheng, L; Zhong, H, 2015
)
0.42
"Gemcitabine combined with S-1 is effective and safe in the treatment of advanced pancreatic cancer, with less side effects, and can be tolerated by the patients."( [Safety and efficacy of gemcitabine combined with S-1 in the treatment of advanced pancreatic cancer].
He, P; Jiang, Y; Yang, K; Zheng, L; Zhong, H, 2015
)
0.42
"This study aimed to investigate the safety and efficacy of S-l combined with cisplatin plus concurrent chemoradiotherapy (SCCC) versus cisplatin plus concurrent chemoradiotherapy (CCC) for Chinese patients with advanced gastric cancer (AGC)."( S-l combined with cisplatin plus concurrent chemoradiotherapy versus cisplatin plus concurrent chemoradiotherapy for Chinese patients with advanced gastric cancer: a multi-centre randomized controlled trial.
Chen, X; Li, W; Liu, S; Liu, Y; Ma, R; Sun, L, 2016
)
0.43
" In the present study, the efficacy and safety of a modified (1-week shorter administration period) UFT/LV schedule combined with bevacizumab for a similar population are reported."( Uracil-Tegafur and Oral Leucovorin Combined With Bevacizumab in Elderly Patients (Aged ≥ 75 Years) With Metastatic Colorectal Cancer: A Multicenter, Phase II Trial (Joint Study of Bevacizumab, Oral Leucovorin, and Uracil-Tegafur in Elderly Patients [J-BLU
Amagai, K; Denda, T; Higashijima, J; Hiroshima, Y; Hyodo, I; Indo, S; Ishida, H; Maeba, T; Masuishi, T; Mizuta, M; Moriwaki, T; Nakajima, G; Negoro, Y; Nishina, T; Ozeki, M; Sakai, Y; Sato, M; Shimada, M; Takahashi, I; Yamamoto, Y, 2016
)
0.89
"UFT/LV (3 weeks of therapy and 1 week without) combined with biweekly bevacizumab is a tolerable and effective treatment option for elderly patients (aged ≥ 75 years) with metastatic colorectal cancer."( Uracil-Tegafur and Oral Leucovorin Combined With Bevacizumab in Elderly Patients (Aged ≥ 75 Years) With Metastatic Colorectal Cancer: A Multicenter, Phase II Trial (Joint Study of Bevacizumab, Oral Leucovorin, and Uracil-Tegafur in Elderly Patients [J-BLU
Amagai, K; Denda, T; Higashijima, J; Hiroshima, Y; Hyodo, I; Indo, S; Ishida, H; Maeba, T; Masuishi, T; Mizuta, M; Moriwaki, T; Nakajima, G; Negoro, Y; Nishina, T; Ozeki, M; Sakai, Y; Sato, M; Shimada, M; Takahashi, I; Yamamoto, Y, 2016
)
0.89
"To observe the efficacy and safety of chemotherapy regimens oxaliplatin combined with capecitabine (CAPOX) or oxaliplatin combined with tegafur, gimeracil and oteracil potassium capsules (S-1)(SOX), and to investigate the value of expression of thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) proteins in tumor tissue for predicting the efficacy of CAPOX and SOX regimens in advanced gastric cancer patients."( [Comparison of the efficacy and safety of capecitabine or tegafur, gimeracil and oteracil potassium capsules combined with oxaliplatin chemotherapy regimens in the treatment of advanced gastric cancer].
Hui, H; Sun, S; Wan, Y; Wang, X; Wu, J, 2016
)
0.88
" The expression levels of TP and DPD in tumor tissue can be used as a predictive factor for the efficacy of capecitabine or tegafur, gimeracil and oteracil potassium capsules combined with oxaliplatin regimens."( [Comparison of the efficacy and safety of capecitabine or tegafur, gimeracil and oteracil potassium capsules combined with oxaliplatin chemotherapy regimens in the treatment of advanced gastric cancer].
Hui, H; Sun, S; Wan, Y; Wang, X; Wu, J, 2016
)
0.89
" The CT-guided percutaneous radiofrequency ablation (RFA) combined with transcatheter arterial chemoembolization (TACE) procedure was performed on the liver metastasis using degradable starch microspheres (DSM)."( [Liver Metastasis in a Gastric Cancer Patient--A Case of Successful Radiofrequency Ablation Combined with Degradable Starch Microspheres Transcatheter Arterial Chemoembolization].
Dono, K; Hatano, H; Hirabuki, N; Hirota, M; Imamura, H; Nakata, S; Noda, T; Oh, RJ; Ohara, N; Ohira, R; Yakushiji, H; Yasumoto, T, 2015
)
0.42
" Pancreaticoduodenectomy combined with hepatic artery resection was performed, and an end-to-end anastomosis was made between the common and proper hepatic artery to reconstruct the hepatic artery."( [A Case of Pancreatic Head Cancer Treated with Pancreaticoduodenectomy Combined with Hepatic Artery Resection Following Neoadjuvant Chemotherapy].
Furukawa, K; Kagawa, S; Kato, A; Kuboki, S; Maeda, S; Miyazaki, M; Ohtsuka, M; Sakai, N; Shimizu, H; Suzuki, D; Takano, S; Takayashiki, T; Yoshitomi, H, 2015
)
0.42
" When WF is combined with S-1, the prothrombin time-international normalized ratio (PT-INR) and dose adjustment of WF should be closely monitored."( [Evaluation of Drug Interaction between S-1 and Warfarin].
Fuse, N; Ikegawa, K; Nomura, H; Saito, S; Suzuki, S; Yamamoto, K, 2016
)
0.43
"We evaluated the efficacy and safety of 5-weekly S-1 and cisplatin combined with trastuzumab, a monoclonal antibody against human epidermal growth factor receptor type 2 (HER2) for HER2-positive advanced gastric cancer (AGC)."( A phase II prospective study of the trastuzumab combined with 5-weekly S-1 and CDDP therapy for HER2-positive advanced gastric cancer.
Adachi, K; Hirano, A; Hirata, Y; Joh, T; Kataoka, H; Kawai, T; Kitagawa, M; Mizuno, Y; Mizushima, T; Mochizuki, H; Mori, Y; Nakamura, M; Natsume, M; Nishie, H; Sano, H; Seno, K; Shimura, T; Sobue, S; Tsuchida, K, 2016
)
0.43
"Five-weekly S-1 and cisplatin combined with trastuzumab showed effective with favorable safety profile in patients with HER2-positive AGC."( A phase II prospective study of the trastuzumab combined with 5-weekly S-1 and CDDP therapy for HER2-positive advanced gastric cancer.
Adachi, K; Hirano, A; Hirata, Y; Joh, T; Kataoka, H; Kawai, T; Kitagawa, M; Mizuno, Y; Mizushima, T; Mochizuki, H; Mori, Y; Nakamura, M; Natsume, M; Nishie, H; Sano, H; Seno, K; Shimura, T; Sobue, S; Tsuchida, K, 2016
)
0.43
"To observe the short-term efficacy and safety of S-1 combined with cisplatin (DDP) chemotherapy for advanced gastric cancer (AGC)."( S-1 combined with cisplatin chemotherapy for advanced gastric cancer.
Lijun, X; Weidong, C, 2016
)
0.43
" Of these patients, 31 (experimental group) underwent S-1 combined with DDP chemotherapy and 35 received oxaliplatin combined with tegafur and calcium folinate chemotherapy regimen (control group)."( S-1 combined with cisplatin chemotherapy for advanced gastric cancer.
Lijun, X; Weidong, C, 2016
)
0.64
" This study evaluated the efficacy of intensity modulated radiotherapy in combination with gemcitabine and S-1 as neoadjuvant chemoradiotherapy (NACRT) for borderline-resectable pancreatic cancer with arterial involvement (BR-A)."( A phase II trial of neoadjuvant chemoradiotherapy with intensity-modulated radiotherapy combined with gemcitabine and S-1 for borderline-resectable pancreatic cancer with arterial involvement.
Hijikata, Y; Hosokawa, Y; Kasuya, K; Katsumata, K; Nagakawa, Y; Nakajima, T; Nakayama, H; Sahara, Y; Takishita, C; Tokuuye, K; Tsuchida, A, 2017
)
0.46
" However, its efficacy and safety when combined with trastuzumab therapy for human epidermal growth factor receptor 2 (HER2)-positive advanced GC/EGJC remains unclear."( Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer: a phase II trial and biomarker study (WJOG7212G).
Boku, N; Hironaka, S; Hyodo, I; Ito, M; Kimura, Y; Miura, Y; Miyata, Y; Mori, M; Moriwaki, T; Musha, N; Negoro, Y; Nishikawa, K; Nosho, K; Okuda, H; Sakamoto, T; Shinozaki, H; Shinozaki, K; Shirakawa, T; Sugimoto, N; Sukawa, Y; Takano, T; Taku, K; Tokunaga, S; Tsuda, T; Uchino, K; Yonesaka, K; Yoshimura, K; Yoshiyama, H, 2018
)
0.48
"Five-weekly SP therapy combined with trastuzumab therapy showed a good antitumor response and acceptable toxicity in HER2-positive advanced GC/EGJC."( Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer: a phase II trial and biomarker study (WJOG7212G).
Boku, N; Hironaka, S; Hyodo, I; Ito, M; Kimura, Y; Miura, Y; Miyata, Y; Mori, M; Moriwaki, T; Musha, N; Negoro, Y; Nishikawa, K; Nosho, K; Okuda, H; Sakamoto, T; Shinozaki, H; Shinozaki, K; Shirakawa, T; Sugimoto, N; Sukawa, Y; Takano, T; Taku, K; Tokunaga, S; Tsuda, T; Uchino, K; Yonesaka, K; Yoshimura, K; Yoshiyama, H, 2018
)
0.48
"We evaluated the safety, tolerability, pharmacokinetics, and tumor response of ramucirumab in combination with one of three platinum/fluoropyrimidine regimens in Japanese patients with chemotherapy-naïve metastatic gastric/gastroesophageal junction cancer."( Safety, pharmacokinetic, and clinical activity profiles of ramucirumab in combination with three platinum/fluoropyrimidine doublets in Japanese patients with chemotherapy-naïve metastatic gastric/gastroesophageal junction cancer.
Gritli, I; Inoue, K; Kadowaki, S; Muro, K; Nishina, T; Ozeki, A; Piao, Y; Sakai, D; Shitara, K; Yoshikawa, R, 2018
)
0.48
"Ramucirumab 8 mg/kg on days 1 and 8 every 3 weeks in combination with XP, SP, or SOX was generally well tolerated and demonstrated preliminary anti-tumor activity in chemotherapy-naïve Japanese metastatic gastric/gastroesophageal junction cancer patients."( Safety, pharmacokinetic, and clinical activity profiles of ramucirumab in combination with three platinum/fluoropyrimidine doublets in Japanese patients with chemotherapy-naïve metastatic gastric/gastroesophageal junction cancer.
Gritli, I; Inoue, K; Kadowaki, S; Muro, K; Nishina, T; Ozeki, A; Piao, Y; Sakai, D; Shitara, K; Yoshikawa, R, 2018
)
0.48
"Trastuzumab when combined with fluoropyrimidine and cisplatin was proven to improve survival in patients with human epidermal growth factor receptor 2 (HER2)-positive gastric cancer (GC) in the ToGA study."( A multi-institution phase II study of docetaxel and S-1 in combination with trastuzumab for HER2-positive advanced gastric cancer (DASH study).
Fujiwara, T; Hamano, R; Kagawa, S; Kambara, T; Kikuchi, S; Kishimoto, H; Kuroda, S; Kuwada, K; Muraoka, A; Nakayama, H; Nishizaki, M; Noma, K; Shigeyasu, K; Shirakawa, Y; Tanaka, N; Tanakaya, K, 2018
)
0.48
"Trastuzumab in combination with docetaxel and S-1 showed effective antitumor activity and manageable toxicities as first-line treatment for patients with HER2-positive GC."( A multi-institution phase II study of docetaxel and S-1 in combination with trastuzumab for HER2-positive advanced gastric cancer (DASH study).
Fujiwara, T; Hamano, R; Kagawa, S; Kambara, T; Kikuchi, S; Kishimoto, H; Kuroda, S; Kuwada, K; Muraoka, A; Nakayama, H; Nishizaki, M; Noma, K; Shigeyasu, K; Shirakawa, Y; Tanaka, N; Tanakaya, K, 2018
)
0.48
"To investigate the predictive value of secreted protein acidic and rich in cysteine (SPARC) expression in patients with PDAC treated with adjuvant gemcitabine in combination with S-1 (adjuvant GS) or adjuvant gemcitabine alone (adjuvant G alone)."( The high stromal SPARC expression is independently associated with poor survival of patients with resected pancreatic ductal adenocarcinoma treated with adjuvant gemcitabine in combination with S-1 or adjuvant gemcitabine alone.
Kondo, N; Murakami, Y; Nakagawa, N; Okano, K; Shintakuya, R; Sueda, T; Takahashi, S; Uemura, K, 2018
)
0.48
" The patient received gamma knife stereotactic radiosurgery (GKSRS) combined with S-1 treatment."( Successful gamma knife radiosurgery combined with S-1 in an elderly man with local recurrent pancreatic cancer: A case report.
Dong, X; Du, F; Tang, S; Wei, H; Wei, J, 2017
)
0.46
" GKSRS combined with S-1 seems to be a good option in improving efficacy and prolonging life in elderly patients with locally recurrent pancreatic cancer."( Successful gamma knife radiosurgery combined with S-1 in an elderly man with local recurrent pancreatic cancer: A case report.
Dong, X; Du, F; Tang, S; Wei, H; Wei, J, 2017
)
0.46
" However, radiotherapy combined with 5-FU/cisplatin often delivers severe toxicity to patients."( Effects of S-1 combined with radiotherapy in the treatment of advanced esophageal cancer: A systematic review and meta-analysis protocol.
Liu, F; Song, Y; Wang, W; Xing, D, 2018
)
0.48
"Our study will draw an objective conclusion of the effects of S-1 combined with radiotherapy in the treatment of unresectable esophageal cancer and provide level I evidence for clinical decision makings."( Effects of S-1 combined with radiotherapy in the treatment of advanced esophageal cancer: A systematic review and meta-analysis protocol.
Liu, F; Song, Y; Wang, W; Xing, D, 2018
)
0.48
" We examined the safety of WT1-peptide pulsed dendritic cell (WT1-DC) vaccine in combination with chemotherapy in patients with surgically resected pancreatic cancer."( WT1-pulsed Dendritic Cell Vaccine Combined with Chemotherapy for Resected Pancreatic Cancer in a Phase I Study.
Kobayashi, M; Koido, S; Koizumi, T; Koya, T; Nagai, K; Okamoto, M; Sano, K; Shimodaira, S; Sugiyama, H; Yanagisawa, R, 2018
)
0.48
"Eight patients with resectable pancreatic cancer undergoing surgery either combined with S-1 or S-1 plus gemcitabine therapy were enrolled."( WT1-pulsed Dendritic Cell Vaccine Combined with Chemotherapy for Resected Pancreatic Cancer in a Phase I Study.
Kobayashi, M; Koido, S; Koizumi, T; Koya, T; Nagai, K; Okamoto, M; Sano, K; Shimodaira, S; Sugiyama, H; Yanagisawa, R, 2018
)
0.48
" We performed a phase I study of resminostat combined with S-1 as second-line or later therapy in Japanese patients with biliary tract or pancreatic cancer."( Phase I study of resminostat, an HDAC inhibitor, combined with S-1 in patients with pre-treated biliary tract or pancreatic cancer.
Hara, R; Hashimoto, Y; Ikeda, M; Kobayashi, S; Kondo, S; Mitsunaga, S; Morizane, C; Nakamura, O; Ohno, I; Okusaka, T; Sakamoto, Y; Sasaki, M; Takahashi, H; Ueno, H, 2019
)
0.51
"DC-CIK combined with S-1 plus cisplatin provided a favorable PFS and OS in patients with AGC and the combination therapy was safe with tolerable toxicities."( Autologous Dendritic Cell-Cytokine Induced Killer Cell Immunotherapy Combined with S-1 Plus Cisplatin in Patients with Advanced Gastric Cancer: A Prospective Study.
Hobeika, A; Lyerly, HK; Morse, MA; Qiao, G; Ren, J; Song, J; Song, Y; Wang, S; Wang, X; Xia, X; Yi, X; Zhao, L; Zhou, L; Zhou, X, 2019
)
0.51
" Thus, our study aimed to examine the efficacy and safety of Endostar continuous intravenous infusion combined with S-1 and oxaliplatin (SOX) chemotherapy in treating such patients."( Endostar continuous intravenous infusion combined with S-1 and oxaliplatin chemotherapy could be effective in treating liver metastasis from gastric cancer.
Guo, X; Li, Y; Sui, Y; Tan, X; Wang, M; Yang, H, 2018
)
0.48
" The experimental group (n = 30) was treated with Endostar continuous intravenous infusion combined with SOX regimen chemotherapy, and the control group (n = 30) received SOX regimen chemotherapy alone."( Endostar continuous intravenous infusion combined with S-1 and oxaliplatin chemotherapy could be effective in treating liver metastasis from gastric cancer.
Guo, X; Li, Y; Sui, Y; Tan, X; Wang, M; Yang, H, 2018
)
0.48
"Continuous infusion of Endostar combined with SOX chemotherapy could be recommended for the treatment of liver metastasis from gastric cancer due to its high effective rate, and Endostar did not increase the incidence of adverse reactions."( Endostar continuous intravenous infusion combined with S-1 and oxaliplatin chemotherapy could be effective in treating liver metastasis from gastric cancer.
Guo, X; Li, Y; Sui, Y; Tan, X; Wang, M; Yang, H, 2018
)
0.48
" In part 1 (phase II) of ATTRACTION-4, the safety and efficacy of nivolumab combined with S-1 plus oxaliplatin (SOX) or capecitabine plus oxaliplatin (CapeOX) as first-line therapy for unresectable advanced or recurrent human epidermal growth factor receptor 2 (HER2)-negative G/GEJ cancer were evaluated."( Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (A
Azuma, M; Boku, N; Chen, LT; Cho, H; Chung, HC; Fumita, S; Hara, H; Kang, WK; Kang, YK; Kato, K; Komatsu, Y; Lee, KW; Minashi, K; Ryu, MH; Tsuda, M; Yamaguchi, K, 2019
)
0.51
"Nivolumab combined with SOX/CapeOX was well tolerated and demonstrated encouraging efficacy for unresectable advanced or recurrent HER2-negative G/GEJ cancer."( Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (A
Azuma, M; Boku, N; Chen, LT; Cho, H; Chung, HC; Fumita, S; Hara, H; Kang, WK; Kang, YK; Kato, K; Komatsu, Y; Lee, KW; Minashi, K; Ryu, MH; Tsuda, M; Yamaguchi, K, 2019
)
0.51
" We aimed to assess the clinical efficacy and safety of S-1 combined with paclitaxel (PTX) for AGC by performing a systematic review and meta-analysis of the published studies."( S-1 combined with paclitaxel may benefit advanced gastric cancer: Evidence from a systematic review and meta-analysis.
Bian, NN; Min, GT; Wang, YH, 2019
)
0.51
"All published randomized controlled trials (RCTs) of S-1 combined with PTX for AGC were searched."( S-1 combined with paclitaxel may benefit advanced gastric cancer: Evidence from a systematic review and meta-analysis.
Bian, NN; Min, GT; Wang, YH, 2019
)
0.51
" S-1 combined with PTX significantly improved the OS [HR = 0."( S-1 combined with paclitaxel may benefit advanced gastric cancer: Evidence from a systematic review and meta-analysis.
Bian, NN; Min, GT; Wang, YH, 2019
)
0.51
"S-1 combined with PTX may be a good choice for patients with AGC."( S-1 combined with paclitaxel may benefit advanced gastric cancer: Evidence from a systematic review and meta-analysis.
Bian, NN; Min, GT; Wang, YH, 2019
)
0.51
" She underwent chemotherapy comprisingintravenous and intraperitoneal paclitaxel combined with S-1."( [A Case of Robot-Assisted Conversion Surgery for Gastric Cancer with Peritoneal Dissemination That Responded to Intravenous and Intraperitoneal Paclitaxel Combined with S-1 Chemotherapy].
Amano, S; Goto, A; Hanai, T; Hattori, Y; Inaba, K; Kadoya, S; Kato, Y; Kikuchi, K; Nakamura, K; Nakauchi, M; Sugioka, A; Tomatsu, M; Tsuru, Y; Uyama, I, 2019
)
0.51
" A total of 185 patients with inoperable or metastatic pancreatic cancer who were refractory or intolerant to standard primary chemotherapy with gemcitabine plus nab-paclitaxel will be allocated to secondary treatment either with placebo in combination with S-1 (the control group) or TLP0-001 in combination with S-1 (the investigational product group)."( A double-blind randomized comparative clinical trial to evaluate the safety and efficacy of dendritic cell vaccine loaded with WT1 peptides (TLP0-001) in combination with S-1 in patients with advanced pancreatic cancer refractory to standard chemotherapy.
Adachi, T; Akahori, T; Asahara, S; Endo, I; Fujii, T; Furukawa, M; Hakamada, K; Hara, K; Ioka, T; Katanuma, A; Katsuda, M; Kitano, M; Miyazawa, M; Nagano, H; Ohira, M; Ojima, T; Satoi, S; Sudo, K; Ueno, M; Yamada, S; Yamaue, H, 2019
)
0.51
"S-1 plus cisplatin in combination with bevacizumab met the primary endpoint in patients with advanced NSq-NSCLC."( Phase II trial of S-1 plus cisplatin combined with bevacizumab for advanced non-squamous non-small cell lung cancer (TCOG LC-1202).
Aono, H; Fujimoto, S; Gemma, A; Hosomi, Y; Isobe, H; Kubota, K; Minato, K; Miyanaga, A; Okamoto, H; Okuma, Y; Satouchi, M; Takiguchi, Y, 2019
)
0.51
"To evaluate the efficacy and safety of celecoxib combined with chemotherapy in the treatment of metastatic or postoperative recurrent gastric cancer."( A comprehensive evaluation of clinical efficacy and safety of celecoxib in combination with chemotherapy in metastatic or postoperative recurrent gastric cancer patients: A preliminary, three-center, clinical trial study.
Chen, Z; Guan, Q; Guo, Q; Li, Q; Liu, M; Wang, J; Wang, Y; Ye, Y; Zhou, Y, 2019
)
0.51
" In the experimental group (n = 100), patients were treated with celecoxib combined with chemotherapy, and chemotherapy alone was used in the control group."( A comprehensive evaluation of clinical efficacy and safety of celecoxib in combination with chemotherapy in metastatic or postoperative recurrent gastric cancer patients: A preliminary, three-center, clinical trial study.
Chen, Z; Guan, Q; Guo, Q; Li, Q; Liu, M; Wang, J; Wang, Y; Ye, Y; Zhou, Y, 2019
)
0.51
"Celecoxib combined with chemotherapy offers more clinical benefits for COX-2 positive advanced gastric cancer patients."( A comprehensive evaluation of clinical efficacy and safety of celecoxib in combination with chemotherapy in metastatic or postoperative recurrent gastric cancer patients: A preliminary, three-center, clinical trial study.
Chen, Z; Guan, Q; Guo, Q; Li, Q; Liu, M; Wang, J; Wang, Y; Ye, Y; Zhou, Y, 2019
)
0.51
" Recently, superiority of IP administration of paclitaxel (PTX) combined with S-1 and intravenous PTX over conventional systemic chemotherapy was suggested in a phase III study, although the difference in overall survival did not reach statistical significance in the primary analysis."( Phase I Study of Intraperitoneal Administration of Paclitaxel Combined with S-1 Plus Cisplatin for Gastric Cancer with Peritoneal Metastasis.
Ishigami, H; Kanda, M; Kitayama, J; Kobayashi, D; Kodera, Y; Tanaka, C; Yamaguchi, H, 2020
)
0.56
"The present study determined the dose for further clinical trials of IP PTX to be 20 mg/m2, when combined with the 5-weekly SP regimen."( Phase I Study of Intraperitoneal Administration of Paclitaxel Combined with S-1 Plus Cisplatin for Gastric Cancer with Peritoneal Metastasis.
Ishigami, H; Kanda, M; Kitayama, J; Kobayashi, D; Kodera, Y; Tanaka, C; Yamaguchi, H, 2020
)
0.56
" Objectives To evaluate the clinical efficacy and safety of apatinib combined with S-1 in the treatment of advanced ESCC patients after first-line chemotherapy failure."( Clinical efficacy and safety of apatinib combined with S-1 in advanced esophageal squamous cell carcinoma.
Lei, J; Song, X; Wang, Y; Yu, J; Zhang, C; Zhang, N; Zhang, S; Zhao, J, 2020
)
0.56
"The purpose of this trial is to evaluate the efficacy and safety of anlotinib combined with S-1 as the third-line treatment for patients with stage IV NSCLC."( Anlotinib Combined with S-1 in the Third-Line Treatment of Stage IV Non-Small Cell Lung Cancer: Study Protocol for Phase II Clinical Trial.
Du, X; Geng, L; Wen, Y; Xiang, M; Yang, X, 2019
)
0.51
"The expected outcome of this study is that anlotinib combined with S-1 has tolerable toxicity and better ORR than anlotinibmonotherapy."( Anlotinib Combined with S-1 in the Third-Line Treatment of Stage IV Non-Small Cell Lung Cancer: Study Protocol for Phase II Clinical Trial.
Du, X; Geng, L; Wen, Y; Xiang, M; Yang, X, 2019
)
0.51
"The KEYNOTE-659 study evaluated the efficacy and safety of pembrolizumab in combination with chemotherapy as the first-line treatment in Japanese patients with advanced gastric/gastroesophageal junction (G/GEJ) cancer."( Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study.
Amagai, K; Azuma, M; Baba, H; Esaki, T; Han, SR; Hara, H; Hosaka, H; Kawakami, H; Kawazoe, A; Komatsu, Y; Machida, N; Negoro, Y; Nishina, T; Omuro, Y; Oshima, T; Shiratori, S; Shitara, K; Tsuda, M; Yamaguchi, K; Yasui, H; Yoshida, K, 2020
)
0.56
"The purpose of this study was to analyze the safety and feasibility of low-dose apatinib combined with S-1 as a second-line therapy or beyond in Chinese patients with pulmonary and/or hepatic metastases of nasopharyngeal carcinoma (NPC)."( Safety and Feasibility of Low-Dose Apatinib Combined with S-1 as the Second-Line Therapy or Beyond in Chinese Patients with Pulmonary and Hepatic Metastasis of Nasopharyngeal Carcinoma.
Chen, J; Huang, X; Lin, J; Wu, G; Zhang, S; Zhou, L, 2020
)
0.56
" We designed the study of XSLJZD combined with S-1 in the maintenance therapy of Stage III or IV GC and CRC, and hoped that this research program will go further and comprehensively evaluate its efficacy and safety."( Clinical study of XiangShaLiuJunZi decoction combined with S-1 as maintenance therapy for stage III or IV gastric carcinoma and colorectal carcinoma.
Hong, XC; Hu, KH; Liang, QL; Luo, XB; Ou, WT; Yang, HX; Zhang, HJ, 2020
)
0.56
"The aim of this study was to determine the efficacy and safety of XSLJZD combined with S-1 in the maintenance therapy of stage III or IV GC and CRC."( Clinical study of XiangShaLiuJunZi decoction combined with S-1 as maintenance therapy for stage III or IV gastric carcinoma and colorectal carcinoma.
Hong, XC; Hu, KH; Liang, QL; Luo, XB; Ou, WT; Yang, HX; Zhang, HJ, 2020
)
0.56
" Patients with stage III or stage IV GC and CRC will be randomized (1:1) into S-1group, S-1 combined with XSLJZD group for 5 years of maintenance therapy."( Clinical study of XiangShaLiuJunZi decoction combined with S-1 as maintenance therapy for stage III or IV gastric carcinoma and colorectal carcinoma.
Hong, XC; Hu, KH; Liang, QL; Luo, XB; Ou, WT; Yang, HX; Zhang, HJ, 2020
)
0.56
"To explore the efficacy and safety of apatinib (an anti-angiogenic drug) combined with S-1 (a fluorouracil drug) in the third-line chemotherapy for advanced gastric cancer, and to analyze the factors influencing the prognosis."( Efficacy and prognosis analyses of apatinib combined with S-1 in third-line chemotherapy for advanced gastric cancer.
Fu, Y; Wen, W; Wu, Q; Xi, T; Zhao, G,
)
0.13
"Patients with advanced gastric cancer achieve relatively satisfactory short-term therapeutic effects after treatment with apatinib combined with S-1 in the third-line therapy, whose PFS is notably better than those treated with S-1 alone, and they are tolerant to adverse reactions."( Efficacy and prognosis analyses of apatinib combined with S-1 in third-line chemotherapy for advanced gastric cancer.
Fu, Y; Wen, W; Wu, Q; Xi, T; Zhao, G,
)
0.13
"This is a phase 2 study aimed at evaluating the efficacy and safety of TAS-114, a novel deoxyuridine triphosphatase inhibitor, combined with S-1 in patients with advanced gastric cancer (AGC)."( A multicenter phase II study of TAS-114 in combination with S-1 in patients with pretreated advanced gastric cancer (EPOC1604).
Fukutani, M; Hirano, N; Ikeno, T; Kambe, M; Kawazoe, A; Keisho, C; Nakamura, Y; Nomura, S; Saito, Y; Sato, A; Shitara, K; Takahari, D; Tamura, H; Wakabayashi, M, 2021
)
0.62
" We confirmed that Huaier granules combined with Tegafur Gimeracil Oteracil Potassium could promote patient prognosis, with a better disease-free survival rate (51."( Huaier Granule Combined with Tegafur Gimeracil Oteracil Potassium Promotes Stage IIb Gastric Cancer Prognosis and Induces Gastric Cancer Cell Apoptosis by Regulating Livin.
Cai, GQ; Liao, GQ; Liu, S; Liu, WH; Qi, J; Xie, FJ; Yao, CY, 2020
)
1.1
" Herein, we report a pretreated patient with advanced squamous cell lung cancer, who received low-dose of apatinib combined with S-1 as salvage treatment, with good long-term response."( Long-term response with low-dose of apatinib combined with S-1 in pretreated patient with advanced squamous cell lung cancer: A case report.
Chen, J; Wang, J; Zou, Y, 2021
)
0.62
" After progression again, she received low-dose apatinib combined with S-1 as third line treatment."( Long-term response with low-dose of apatinib combined with S-1 in pretreated patient with advanced squamous cell lung cancer: A case report.
Chen, J; Wang, J; Zou, Y, 2021
)
0.62
"This case indicated that low-dose apatinib combined with S-1 might be effective and safe in selected pretreated patients with advanced squamous cell lung cancer."( Long-term response with low-dose of apatinib combined with S-1 in pretreated patient with advanced squamous cell lung cancer: A case report.
Chen, J; Wang, J; Zou, Y, 2021
)
0.62
" We performed this retrospective study to evaluate the efficacy and safety of apatinib combined with S-1/capecitabine as the oral maintenance therapy for these patients."( Oral maintenance therapy using apatinib combined with S-1/capecitabine for esophageal squamous cell carcinoma with residual disease after definitive chemoradiotherapy.
Bai, K; Chen, B; Chi, D; Guo, S; Hu, Y; Li, Q; Ma, H; Zhu, Y, 2021
)
0.62
" Patients were treated with apatinib combined with S-1 /capecitabine after dCRT."( Oral maintenance therapy using apatinib combined with S-1/capecitabine for esophageal squamous cell carcinoma with residual disease after definitive chemoradiotherapy.
Bai, K; Chen, B; Chi, D; Guo, S; Hu, Y; Li, Q; Ma, H; Zhu, Y, 2021
)
0.62
" The aim of the present study is to evaluate the efficacy and safety of apatinib combined with S-1 as the second-line therapy for AGC patients."( Apatinib combined with S-1 as second-line therapy in advanced gastric cancer.
Chen, M; He, H; Qin, R; Qiu, ZY; Tian, GY; Wang, Y; Xi, Y; Zhang, Z, 2021
)
0.62
"We conducted a single-arm phase II trial to investigate the short-term efficacy and safety of apatinib combined with oxaliplatin and S-1 in the treatment of unresectable gastric cancer."( Short-term survival and safety of apatinib combined with oxaliplatin and S-1 in the conversion therapy of unresectable gastric cancer.
Chen, L; Chen, S; Lin, Z; Wang, Y; Wang, Z; Wei, S; Ye, Z; Zeng, Y, 2021
)
0.62
"Apatinib combined with oxaliplatin and S-1 showed good short-term survival and acceptable safety in the conversion therapy of unresectable gastric cancer."( Short-term survival and safety of apatinib combined with oxaliplatin and S-1 in the conversion therapy of unresectable gastric cancer.
Chen, L; Chen, S; Lin, Z; Wang, Y; Wang, Z; Wei, S; Ye, Z; Zeng, Y, 2021
)
0.62
"To evaluate the therapeutic efficacy and safety of S1 monotherapy or combination with nab-paclitaxel for the treatment of elderly patients with metastatic or locally advanced pancreatic adenocarcinoma."( Safety and efficacy of S1 monotherapy or combined with nab-paclitaxel in advanced elderly pancreatic cancer patients: A meta-analysis.
Chen, D; Chen, X; Chen, Y; Cui, S; Du, J; Gu, J; Lin, Z; Luo, H; Ma, C; Wang, C; Yang, L; Yin, M, 2021
)
0.62
"To investigate the clinical efficacy and safety of apatinib combined with tegafur-gimeracil-oteracil potassium (S-1) in the second-line treatment of advanced gastric cancer."( Efficacy of apatinib combined with tegafur gimeracil and oteracil potassium in the second-line treatment of advanced gastric cancer.
Chen, H; Li, P; Liu, L; Xue, L,
)
0.64
" According to the different therapeutic options, patients were categorized into S-1 group (n=63) and Apatinib group (S-1 combined with apatinib, n=63), and drugs were administered orally."( Efficacy of apatinib combined with tegafur gimeracil and oteracil potassium in the second-line treatment of advanced gastric cancer.
Chen, H; Li, P; Liu, L; Xue, L,
)
0.41
"In the second-line treatment of advanced gastric cancer, apatinib combined with S-1 is superior to S-1 alone in term of clinical efficacy, and its adverse reactions can be tolerated."( Efficacy of apatinib combined with tegafur gimeracil and oteracil potassium in the second-line treatment of advanced gastric cancer.
Chen, H; Li, P; Liu, L; Xue, L,
)
0.41
"The purpose of this study was to compare the clinical efficacy and safety of S-1 + oxaliplatin (SOX) chemotherapy regimen combined with trastuzumab and irinotecan + cisplatin (IP) chemotherapy regimen combined with trastuzumab in treating human epidermal growth factor receptor 2 (HER-2)-positive advanced gastric cancer."( Efficacy of trastuzumab combined with SOX or IP chemotherapy regimen in the treatment of advanced gastric cancer.
Fang, X; Li, Q; Wang, L; Xu, D; Zhang, S; Zhang, Z,
)
0.13
"A total of 138 patients with HER-2-positive advanced gastric cancer were divided into SOX group (SOX chemotherapy regimen combined with trastuzumab; n=69) and IP group (IP chemotherapy regimen combined with trastuzumab; n=69)."( Efficacy of trastuzumab combined with SOX or IP chemotherapy regimen in the treatment of advanced gastric cancer.
Fang, X; Li, Q; Wang, L; Xu, D; Zhang, S; Zhang, Z,
)
0.13
"Trastuzumab combined with SOX chemotherapy regimen has an obvious curative effect in the treatment of advanced gastric cancer, which prominently improves the quality of life of patients, lowers the serum tumor marker levels in patients, delays tumor progression, and results in tolerable adverse reactions."( Efficacy of trastuzumab combined with SOX or IP chemotherapy regimen in the treatment of advanced gastric cancer.
Fang, X; Li, Q; Wang, L; Xu, D; Zhang, S; Zhang, Z,
)
0.13
"To explore the safety and effectiveness of paclitaxel and tegafur, gimeracil and oteracil potassium (S-1) combined with apatinib in the conversion therapy for unresectable advanced gastric cancer."( Efficacy of paclitaxel and S-1 combined with apatinib in the conversion therapy for unresectable advanced gastric cancer.
Fang, H; Wu, Z,
)
0.38
"Paclitaxel and S-1 combined with apatinib can achieve a higher R0 resection rate, and improve the survival rate of patients with successful conversion therapy, showing high safety and efficacy."( Efficacy of paclitaxel and S-1 combined with apatinib in the conversion therapy for unresectable advanced gastric cancer.
Fang, H; Wu, Z,
)
0.13
"To explore the application of evidence-based nursing intervention in the treatment of advanced squamous cell carcinoma of the lung by erlotinib combined with tegafur, gimeracil, and oteracil potassium (TS-1) and its influence on quality of life (QOL)."( Application of Evidence-Based Nursing Intervention in the Treatment of Advanced Squamous Cell Carcinoma of the Lung by Erlotinib Combined with Tegafur, Gimeracil, and Oteracil Potassium and Its Influence on Quality of Life.
Fu, F; Huang, X; Liu, S; Wang, H; Wen, J, 2021
)
1.02
"Application of evidence-based nursing intervention in the treatment of advanced squamous cell carcinoma of the lung by erlotinib combined with TS-1 can help patients to relieve pain, improve their psychological state, reduce the incidence of adverse reactions, significantly improve the QOL, and also enhance the satisfaction of clinical nursing."( Application of Evidence-Based Nursing Intervention in the Treatment of Advanced Squamous Cell Carcinoma of the Lung by Erlotinib Combined with Tegafur, Gimeracil, and Oteracil Potassium and Its Influence on Quality of Life.
Fu, F; Huang, X; Liu, S; Wang, H; Wen, J, 2021
)
0.82
"This study aimed to evaluate the effect and safety of anlotinib combined with S-1 in the treatment of recurrent or metastatic esophageal cancer patients who refused or were intolerant to intravenous chemotherapy."( Effect and safety of anlotinib combined with S-1 for recurrent or metastatic esophageal cancer patients who refused or were intolerant to intravenous chemotherapy.
Cai, J; Liu, A; Luo, Y; Zhou, S, 2021
)
0.62
"To investigate the safety and efficacy of camrelizumab in combination with nab-paclitaxel plus S-1 for the treatment of gastric cancer with serosal invasion."( Safety and Efficacy of Camrelizumab in Combination With Nab-Paclitaxel Plus S-1 for the Treatment of Gastric Cancer With Serosal Invasion.
Chen, QY; Huang, CM; Li, P; Lin, JL; Lin, JP; Lin, JX; Lu, J; Wang, JB; Xie, JW; Zheng, CH, 2021
)
0.62
"Camrelizumab combined with nab-paclitaxel plus S-1 could significantly improve the rate of tumor regression grade (TRG 1a/1b) and the rate of pCR in gastric cancer with serosal invasion."( Safety and Efficacy of Camrelizumab in Combination With Nab-Paclitaxel Plus S-1 for the Treatment of Gastric Cancer With Serosal Invasion.
Chen, QY; Huang, CM; Li, P; Lin, JL; Lin, JP; Lin, JX; Lu, J; Wang, JB; Xie, JW; Zheng, CH, 2021
)
0.62
" This study evaluated the safety and efficacy of anlotinib in combination with the GS regimen(hereafter referred to as the A+GS regimen) in the first-line treatment of patients with unresectable or metastatic PC."( A real-world study of anlotinib combined with GS regimen as first-line treatment for advanced pancreatic cancer.
Da, S; Fang, F; Hu, J; Liu, S; Luo, P; Shen, E; Su, Y; Wen, F; Weng, J; Xu, M; Zhan, D; Zhan, G; Zhou, C; Zhou, Q, 2023
)
0.91

Bioavailability

This study was designed to determine the in vitro release of tegafur from a suppository and the in vivo bioavailability of te gafur in rats.

ExcerptReferenceRelevance
"This study was designed to determine the in vitro release of tegafur from a suppository and the in vivo bioavailability of tegafur in rats."( In vitro release of tegafur from a fatty-base suppository and in vivo bioavailability of tegafur.
Araki, Y; Eto, K; Fukuda, T; Gomita, Y; Yoshida, T, 1986
)
0.84
" When lauric acid, as a permeation enhancer, was added to both of the binary vehicles, the in vitro and in vivo skin permeability of three drugs further increased, and the in vivo absorption rate of the drugs from the ethanol/water (60/40) system was larger than that from the ethanol/panasate 800 (40/60) system."( Effect of hydrophilic and lipophilic vehicles on skin permeation of tegafur, alclofenac and ibuprofen with or without permeation enhancers.
Goto, S; Kim, NS; Kitagawa, K; Lee, CK; Uchida, T; Yagi, A, 1993
)
0.52
" The constant's values suggested that the two drugs are poorly absorbed from stomach and main absorption occurred in the intestinal tract."( White beeswax microspheres: a comparative in vitro evaluation of cumulative release of the anticancer agents fluorouracil and ftorafur.
De Caro, V; Di Stefano, V; Giannola, LI, 1993
)
0.29
" Trials of new combinations are warranted to take advantage of the pharmacokinetic properties and oral bioavailability of UFT and leucovorin."( Experience of Oncopaz Cooperative Group with oral fluoropyrimidines in tumors of the stomach, lung, head and neck, and breast.
Belón, J; Blanco, E; Espinosa, E; Feliu, J; Garcia Alfonso, P; Garcia Girón, C; Garrido, P; González Barón, M; Jara, C; Ruiz, A; Vincent, JM; Zamora, P, 1997
)
0.3
" In addition, we sought to determine whether coadministration of UFT and leucovorin alters the bioavailability of these agents."( Oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancer.
Birkhofer, MJ; Meropol, NJ; Noel, D; Sonnichsen, DS, 1997
)
0.3
" In addition, a three-treatment by three-period crossover bioavailability comparison of oral LV 30 mg plus UFT 200 mg versus either LV or UFT alone was scheduled for the 8 days preceding the first cycle of therapy."( Bioavailability and phase II study of oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancer.
Birkhofer, MJ; Ferreira, I; Meropol, NJ; Noel, D; Sonnichsen, DS, 1999
)
0.3
" However, the great interpatient variability observed in UFT and LV pharmacology may have obscured true bioavailability effects in this small patient population."( Bioavailability and phase II study of oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancer.
Birkhofer, MJ; Ferreira, I; Meropol, NJ; Noel, D; Sonnichsen, DS, 1999
)
0.3
" The potential benefit of long bioavailability and oral delivery of UFT compares favorably with continuous infusion regimens without the added morbidity of a catheter and pump."( A phase I study of combined UFT plus leucovorin and radiotherapy for pancreatic cancer.
Bonner, JA; Childs, HA; Newsome, J; Raben, D; Robert, F; Spencer, SA, 2000
)
0.31
" Numerous active 5-FU schedules are in clinical use, but erratic oral bioavailability has historically mandated intravenous administration."( Oral therapy for colorectal cancer: how to choose.
Damjanov, N; Meropol, NJ, 2000
)
0.31
" The unpredictable and low oral bioavailability of 5FU initially discouraged this form of treatment."( The oral fluorinated pyrimidines.
de Bono, JS; Twelves, CJ, 2001
)
0.31
" The effect of food on the oral bioavailability of UFT (2 x 100 mg capsules; dose in terms of FT) and leucovorin (2 x 15 mg tablets) was evaluated in a single-dose, randomized, two-way crossover study."( Effect of food on the oral bioavailability of UFT and leucovorin in cancer patients.
Alberts, D; Brooks, D; Damle, B; Ferreira, I; Kaul, S; Pazdur, R; Ravandi, F; Sonnichsen, D; Stewart, D, 2001
)
0.31
"The purpose is to determine the effect of food on the bioavailability of S-1, an oral formulation of the 5-fluorouracil (5FU) prodrug Ftorafur (FT), 5-chloro-2,4-dihydroxypyridine (CDHP), a dihydropyrimidine dehydrogenase inhibitor, and oxonic acid (an inhibitor of 5FU phosphoribosylation in normal gut mucosa) in a molar ratio of 1:0."( The effect of food on the pharmacokinetics of S-1 after single oral administration to patients with solid tumors.
Beijnen, JH; Fumoleau, P; Giaccone, G; Holwerda, U; Noordhuis, P; Peters, GJ; Schellens, JH; Schornagel, JH; Schrijvers, A; Van Groeningen, CJ; Voorn, D, 2004
)
0.32
" In this single-dose, randomized, two-way crossover study, we investigated the effects of a low-fat Japanese meal on the pharmacokinetics and oral bioavailability of UFT (2 x 100-mg capsules; dose in terms of tegafur) and leucovorin (1 x 25-mg tablet)."( Effects of a low-fat meal on the oral bioavailability of UFT and leucovorin in patients with colorectal cancer.
Furuhata, T; Hosokawa, Y; Ishiyama, G; Iwayama, Y; Kimura, Y; Meguro, M; Mizuguchi, T; Nishidate, T; Okita, K; Sasaki, K; Tsuruma, T, 2009
)
0.54
" To increase the bioavailability of S-1, the administration of S-1 under fasting condition was more effective in the western countries."( Effect of food and a proton pump inhibitor on the pharmacokinetics of S-1 following oral administration of S-1 in patients with advanced solid tumors.
Hilger, RA; Mende, B; Saito, K; Scheulen, ME; Strumberg, D; Zergebel, C, 2012
)
0.38
" It is combined with gimeracil in order to increase its bioavailability and with oteracil to try to reduce its gastrointestinal toxicity."( Tegafur + gimeracil + oteracil. Just another fluorouracil precursor.
, 2013
)
1.83
" Although oral bioavailability was not enantioselective, in-vitro and in-vivo kinetic studies suggested that the enantioselectivity in the hepatic intrinsic clearance of FT directly influences the body clearance in all animal species examined."( Species variation in the enantioselective metabolism of tegafur to 5-fluorouracil among rats, dogs and monkeys.
Ishii, Y; Yamada, H; Yamamiya, I; Yoshida, K; Yoshisue, K, 2014
)
0.65
" Because the oral bioavailability of 5-FU is unpredictable and highly variable, 5-FU is commonly administered intravenously."( Role of ABC transporters in fluoropyrimidine-based chemotherapy response.
Magdy, T; Nies, AT; Schwab, M; Zanger, UM, 2015
)
0.42
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

The dosage of the oral clinical use for human cancer of 5-FU, HCFU, 5'-DFUR and UFT as tegafur (FT) is 200-300mg/d. Recently, we have reported that metronomic S-1 dosing synergistically augmented the therapeutic efficacy of oxaliplatin (l-OHP)-containing PEGylated liposome.

ExcerptRelevanceReference
"In a prospective, multi-centre, randomized study of 109 patients with metastatic gastro-intestinal adenocarcinomas the response rate, survival time and side-effects of two drug combinations, carmustin +5-fluorouracil and carmustin + ftorafur, were compared (same carmustin dosage in both groups)."( [A prospective multi-centre study of the response of metastatic gastrointestinal tumours (author's transl)].
Arnold, H; Drings, P; Geldmacher, J; Hartwich, G; Kredel, L; Mayer, M; Neidhardt, B; Queisser, W; Rösch, W; Schaefer, J; von Oldershausen, HF; Wahrendorf, J, 1979
)
0.26
"5-Fluorouracil (5-FU) was compared to ftorafur, a fraudulent nucleoside analog which acts as a depot form of 5-FU, with respect to influence of dosage level and schedule of administration on toxicity in mice."( Comparison of 5-fluorouracil and ftorafur. I. Quantitative and qualitative differences in toxicity to mice.
Garibjanian, BT; Gaston, MR; Goldin, A; Houchens, DP; Johnson, RK; Kline, I; Syrkin, AB, 1976
)
0.26
" Since she complained of olfactory anesthesia at 2 months of treatment, the dosage of UFT was reduced to 2 capsules daily and the drug was withdrawn after another 2 months of treatment."( [Complete remission of lung metastases of bladder tumor treated by small dosage of UFT: a case report].
Fukuoka, H; Nomura, S; Ogawa, T; Sakanishi, S; Takeda, M, 1991
)
0.28
" It is expected that the dose intensity may clear dose-response relationships which are sometimes obscure in cancer chemotherapy because dose reduction or treatment delay caused by adverse effects."( [Dose intensity in cancer chemotherapy in gastric cancer].
Ishibiki, K; Kumai, K, 1990
)
0.28
"A 58-year-old woman who was inoperable because of S3 (pancreas and colon) and P1 at the initial operation was treated with UFT, ADM and MMC at a dosage of 242."( [An unresectable gastric cancer radically resectable following UFT, ADM, MMC therapy].
Hayashi, S; Kamejima, N; Kasugai, T; Kataoka, M; Kureyama, Y; Masaoka, A; Mitsui, T; Taniwaki, S; Tsuji, H; Watarai, N, 1989
)
0.28
" A resulting dosage reduction of 15Gy was observed in radiotherapy for negative conversion and one of 10mg for bleomycin as a result of incorporation of cisplatin."( [Radiochemotherapy of head and neck cancers: dose reduction through the combination of cisplatin, bleomycin and tegafur].
Kaneko, Y; Mishina, H; Okuyama, S; Saijo, S; Yuasa, R, 1985
)
0.48
" The oral daily dosage of 5'-DFUR was 1,200 mg and that of tegafur was 800 mg, both drugs being administered every day for more than 4 weeks."( [A comparative study of 5'-DFUR and tegafur in recurrent breast cancer].
Abe, O; Ogawa, N; Taguchi, T; Terasawa, T; Tominaga, T; Yoshida, Y, 1985
)
0.79
" In these 5 cases the daily dosage was 800 mg, and the median duration of PR was 51 days."( [Study of chemotherapy in the field of internal medicine--clinical experience with SF-SP].
Fujisawa, T; Imamura, Y; Irie, K; Mizogami, H; Nakamura, T; Nishimura, S; Sawada, Y; Yasutake, K; Yoshida, M; Yoshimura, Y, 1986
)
0.27
" However, increase in tegafur dosage volume did not correlate with 5-FU levels."( [5-FU concentration in the blood and tissue of patients with gastric and colorectal cancer after administration of UFT or tegafur].
Arima, S; Futami, K; Kinashi, M; Shigeta, M; Shimura, H, 1986
)
0.79
" The drug sensitivity of the cultured cancer cells was investigated with a colony forming assay, and a dose-response curve was obtained for the time-dependent anticancer drug."( [Studies on oral-adjuvant chemotherapy of uterine cervical cancer after surgical treatment].
Maeda, T, 1986
)
0.27
" Total Ftorafur (FT) results using the same criteria from the UFT phase II study revealed, from a comparison of dosage and disease type, that UFT did not enhance FT side effects; rather, it markedly increases effectiveness."( [Report on nationwide pooled data and cohort investigation in UFT phase II study].
Kimura, K; Ota, K; Taguchi, T, 1987
)
0.27
" Although average values of the skin reaction after dosing were slightly lower compared to those before dosing in group B, sensitization was effective."( [Study on the preoperative adjuvant therapy of cancer--relation between serum and tumor tissue levels of UFT and OK-432 after administration, and skin reactions to Su-polysaccharide (Su-Ps)].
Ishikawa, M; Kumazawa, H; Rei, S; Saito, H, 1987
)
0.27
" Moreover, intratumoral concentration of 5-FU differed markedly even with the same administration method and dosage level."( [Anti-tumour effect of UFT on human renal cell carcinoma heterotransplanted into nude mice].
Furuta, M; Iizuka, N; Kondo, I; Machida, T; Masuda, F; Mori, Y; Nakada, J; Onishi, T; Suzuki, M, 1988
)
0.27
" The maximum dosage of CDDP administered was gradually increased step by step from 20 mg/day to 40 mg/day every week."( [A clinical trial of cis-platinum (II) in combination with PSK and FT-207 in advanced stomach cancer].
Atarashi, J; Fukuo, Y; Hayashi, Y; Terashi, A; Yano, Y, 1985
)
0.27
" The pharmacologic properties of FT appear to dictate its most useful schedule (continuous oral dosing in multiple doses) and explain why FT alone is not ideal as a 5-FU pro-drug."( Relevance of the pharmacology of oral tegafur to its use as a 5-FU pro-drug.
Byfield, JE; Frankel, SS; Griffiths, JC; Hornbeck, CL; Sharp, TR, 1985
)
0.54
" The daily dosage was 200 mg (3-4 mg/kg body weight)."( Ftorafur therapy in acute pancreatitis.
Gecser, G; Hudvágner, S; Illényi, L; Tekeres, M, 1984
)
0.27
" The optimal dosage was considered to be between 17 mg/kg and 24 mg/kg."( [Joint clinical Phase II study of SF-SP].
Hanatani, Y; Sato, H; Sato, T, 1984
)
0.27
" Long-term daily administration was shown to be more effective than intermittent dosage in the treatment of Lewis lung carcinoma."( [Antitumor effect of FU-O-G, new antitumor agent, following long term administration].
Arakawa, M; Inomata, T; Mizuno, H; Shimizu, F; Umezawa, T, 1984
)
0.27
" At the 1st hr after dosing the 5-FU level in the small intestine was close to, but that in other tissues was much lower than, the 5-FU level in the tumor of both types."( Tissue distribution of 5'-deoxy-5-fluorouridine and derived 5-fluorouracil in tumor-bearing mice and rats.
Fukazawa, H; Hongu, Y; Ichihara, S; Shimizu, H; Suzuki, S, 1980
)
0.26
" The recommended dosage for daily oral administration of FD-1 is 6-12 mg/kg/day."( Review of a new antimetabolic agent, 1,3-bis(tetrahydro-2-furanyl)-5-fluoro-2,4-pyrimidinedione (FD-1).
Taguchi, T, 1980
)
0.26
" The results confirm that it is possible to compare phenotypical normal with nude mice both with regard to dosage levels and therapeutic activity."( Toxicologic and therapeutic examinations with ftorafur in different mouse strains.
Arnold, W; Fichtner, I; Naundorf, H, 1981
)
0.26
" Part II of the trial revealed that neither a higher dosage of ftorafur (2 g/m2/day X 5 days) nor the addition of vincristine to both regimens changed the previously obtained results significantly."( Comparison of ftorafur with 5-fluorouracil in combination chemotherapy of advanced gastrointestinal carcinoma.
Arnold, H; Drings, P; Fritze, D; Geldmacher, J; Hartwich, G; Herrmann, R; Kempf, P; König, H; Meiser, RJ; Nedden, R; Pappas, A; Queisser, W; Schaefer, J; Schnitzler, G; Sievers, H; von Oldershausen, HF; Wahrendorf, J; Westerhausen, M; Witte, S, 1981
)
0.26
" Total dosage of ACNU given safely in one series was considered to be 150-200mg."( [Physiological effects and antitumor efficiency of ACNU in postoperative patients with stomach cancer--an evaluation of the treatment combined with FT-207 or 5-FU dry syrup].
Inuo, T; Kaneko, H; Ohashi, A; Sekizawa, Y; Tsuchiya, S, 1982
)
0.26
" Daily dosage of FT-207 was either 600 or 800 mg and the drug was administered orally."( [FT-207 maintenance therapy of malignant gynecologic cancer].
Jimi, S; Kato, Y; Kawakami, M; Kidera, Y; Matsuyama, T; Morita, T; Nishimura, A; Shigyo, R; Sugimori, H; Tanaka, M; Toyota, Y; Tsukamoto, N; Watanabe, E; Yamashita, H, 1982
)
0.26
" Furthermore, the survival was elevated in proportion to the increase of total dosage of futraful."( [Effect of postoperative long-term chemotherapy of stomach cancer using mitomycin C and futraful--the secondary study (1)].
Abe, O; Akiyama, H; Hattori, T; Hayasaka, A; Inokuchi, K; Inoue, K; Ito, I; Kasai, Y; Kikuchi, K; Kondo, T; Muto, T; Nakajima, T; Sugie, S; Taguchi, T, 1982
)
0.26
" Dose escalation was required in order to control carcinoid symptoms, and the final dosage was 5,950 micrograms/day."( Long-term survival in a patient with malignant carcinoid treated with high-dose octreotide.
Deguchi, H; Deguchi, K; Iwasaki, E; Kobayashi, T; Murashima, S; Shirakawa, S; Tsuda, M; Tsukada, T, 1994
)
0.29
" The cytogenetic effect was ranked 5-FU = HCFU > TF, in both a time-course study and a dose-response study of micronucleus distribution."( Fetal liver micronucleus assay in mice of 5-fluorouracil and related compounds.
Fort, FL; Kikuchi, Y; Nakamura, M, 1993
)
0.29
" The issues under investigation include best chemotherapy dosage and duration, identification of risk factors and the role of preoperative chemotherapy."( ["State of the art" of adjuvant chemo-endocrine therapy for breast cancer in Japan].
Ikeda, T, 1994
)
0.29
"Effects of 5-fluorouracil (5-FU) and UFT on an experimental liver metastasis model were compared at equi-effective dosage levels against subcutaneous tumor of mouse colon 26."( Effect of 5-fluorouracil and UFT on experimental liver metastasis model of colorectal cancer using mouse colon 26 cells.
Kosaki, G; Kurihara, M; Tominaga, T; Yoshida, Y, 1993
)
0.29
"In collaboration with 428 institutions nation-wide, comparative studies on the optimal daily dosage of UFT were carried out for non-curative resection cases of colorectal cancer for two years from January 1984 to December 1985."( [Cooperative Study of Surgical Adjuvant Chemotherapy for Colorectal Cancer (fourth report): five-year results after surgery].
Abe, O; Hattori, T; Inokuchi, K; Kikuchi, K; Komi, N; Kondo, T; Maehara, Y; Sugimachi, K; Taguchi, T; Uchino, J, 1993
)
0.29
"A combined phase I/II study (UFTM) of tegafururacil (UFT) and mitomycin C (MMC) was performed to find the optimal dosage for advanced colorectal cancer."( [Optimal dosage of UFT + MMC combination chemotherapy for advanced colorectal cancer--phase I/II study of combination chemotherapy of MMC with 2-week intervals and intermittent UFT administration--Study Group of UFTM Therapy for Advanced Colorectal Cancer
Ikeda, E; Isomoto, H; Kato, T; Kodaira, S; Okuda, M; Takahashi, T; Teramoto, T; Yamamoto, Y, 1996
)
0.57
" In the CDHP and Oxo treatment groups of rats, the only toxic signs were soft or diarrheal stools on the dosing day."( [Oral single-dose toxicity study of a new antineoplastic agent S-1, and its components, CDHP, and Oxo].
Hayashi, T; Hirota, T; Irimura, K; Ohmae, S; Tanaka, G, 1996
)
0.29
" In addition, 5-FU levels were detectable throughout the 28-day dosing period; however, there was no evidence of significant accumulation of uracil, tegafur, or 5-FU."( Phase I and pharmacokinetic evaluations of UFT plus oral leucovorin.
Pazdur, R, 1997
)
0.5
" Intolerance to single dosing was clearly demonstrated, and only the split dosing was advanced to 500 mg/m2/day."( Phase I and pharmacokinetic study of oral UFT, a combination of the 5-fluorouracil prodrug tegafur and uracil.
Chan, KK; Groshen, S; Jeffers, S; Leichman, CG; Leichman, L; Muggia, FM; Spicer, D; Wu, X, 1996
)
0.51
" The mean residence time of 5-fluorouracil (5-FU) from an S/O/W emulsion was also greater than with other dosage forms."( Prolonged release of tegafur from S/O/W multiple emulsion.
Kang, YG; Kim, CK; Lee, YB; Oh, I; Shin, SC, 1998
)
0.62
" Weekly dosing of paclitaxel produces notable activity, while maintaining relatively low toxicity in heavily pretreated metastatic breast cancer patients."( UFT/oral calcium folinate plus weekly paclitaxel for metastatic breast cancer.
Dethling, J; Kühnle, H; Lück, HJ; Scholz, U, 1999
)
0.3
"This phase I study was undertaken to define the maximum tolerated dose, dose-limiting toxicity, and recommended dosage of UFT (uracil and tegafur) plus oral calcium folinate (Orzel) and vinorelbine (Navelbine) in combination treatment of metastatic breast cancer in patients who have received one prior chemotherapy regimen."( UFT plus oral calcium folinate/vinorelbine for advanced breast cancer.
Déporte-Fety, R; Fumoleau, P; Kerbrat, P; Laguerre, B, 1999
)
0.51
" A comparison of the prescribed dosage and patient records revealed a mean dose rate of 86."( [UFT-E granule compliance in postoperative adjuvant chemotherapy].
Hagiwara, M; Hanai, A; Kanasugi, K; Komoriyama, H; Yamaguchi, S, 1999
)
0.3
" It was suggested that the pharmaceutical technology used in the manufacture was not equivalent even if the products of the same dosage form contain the same kind and content of the active ingredient(s)."( [Evaluation of dissolution behavior for the products containing tegafur and uracil].
Azuma, M; Houchi, H; Ichimaru, K; Ishiki, K; Kujime, T; Minakuchi, K; Shono, F; Umeda, T, 1999
)
0.54
" UFT and other oral 5FU dosing strategies make promising components of combination chemotherapy, deserving further, randomised evaluation."( Epirubicin, cisplatin and oral UFT with leucovorin ('ECU'): a phase I-II study in patients with advanced upper gastrointestinal tract cancer.
Cresswell, H; Dent, JT; Papamichael, D; Seymour, MT; Slevin, ML; Wilson, G, 1999
)
0.3
" Four patients who suffered from PMC-related side effects of grade 1-2 wanted to decrease their dosage of UFT and/or 5-FU."( [Usefulness of pharmacokinetic modulating chemotherapy (PMC) for the postoperative adjuvant therapy of colorectal carcinoma: a preliminary report].
Izumi, S; Nakagawa, J; Nishihara, M; Onoda, Y; Shimizu, N; Shiota, K; Suzuka, I, 1999
)
0.3
" In the second and third courses of the chemotherapy, CBDCA and TXT were administered in the same dosage as in the initial course, but with the oral administration of UFT (600 mg/day)."( [A case of epithelial cancer of the alveoli which responded favorably to the additional administration of UFT for refractory cancer after administration of carboplatin and docetaxel].
Kuwahara, M; Motohiro, A; Takahashi, N; Tsukamoto, S; Ueda, H, 2000
)
0.31
" The ratio of FBAL to 5-FU in Cmax and AUC after dosing of UFT was the lowest among these four test compounds."( [Comparison of pharmacokinetics of 5-FU and alpha-fluoro-beta-alanine, a metabolite of 5-FU, in plasma after administration of UFT, tegafur, 5-FU or doxifluridine to rats].
Hirakawa, Y; Kawaguchi, Y; Kuwata, K; Matsushima, E; Nagayama, S, 2000
)
0.51
"UFT was administered orally at a dosage of 200 mg/day, 2 times a day, to patients over 80 years of age with oral cancer."( [5-FU concentration in the serum and the tumor tissue after administration of UFT 200 mg/day to patients over 80 years of age with oral cancer].
Fukuda, J; Hayatsu, M; Hoshina, H; Iida, A; Kaji, M; Miyamoto, T; Miyaura, Y; Nagashima, K; Ono, K; Takagi, R; Tsurumaki, H, 2000
)
0.31
" This variability makes effective dosing of 5-FU and related drugs difficult."( Oral DPD-inhibitory fluoropyrimidine drugs.
Diasio, RB, 2000
)
0.31
" The removal of one administration of vinorelbine at dose levels 3 and 4 has allowed for increased UFT dosage and AUC0-6 h of fluorouracil, with no dose-limiting toxicity reported for these patients."( UFT/leucovorin plus vinorelbine combination for advanced breast cancer.
Bonneterre, J; Déporte, R; Fargeot, P; Fumoleau, P; Kerbrat, P, 2000
)
0.31
" Based on the feasibility and adverse reactions, the dosage of UFT should be set according to the body surface area at 375-425 mg/m2/day."( [Optimal dosage of UFT in a weekday-on/weekend-off schedule as a postoperative adjuvant chemotherapy for colorectal cancer].
Fukushima, T; Hiki, Y; Kumada, K; Makuuchi, H; Mitomi, T; Nagasaki, H; Nishiyama, K; Ohki, S; Otani, Y; Sadahiro, S; Shimada, H; Takahashi, T; Takemiya, S; Tsukikawa, S; Yamaguchi, S; Yamamura, T, 2000
)
0.31
" These data suggest that UFT/leucovorin should not be dosed simultaneously with food."( Effect of food on the oral bioavailability of UFT and leucovorin in cancer patients.
Alberts, D; Brooks, D; Damle, B; Ferreira, I; Kaul, S; Pazdur, R; Ravandi, F; Sonnichsen, D; Stewart, D, 2001
)
0.31
" The dosage of the oral clinical use for human cancer of 5-FU, HCFU, 5'-DFUR and UFT as tegafur (FT) is 200-300mg/d, 600mg/d, 800-1,200mg/d and 300-600mg/d respectively."( Plasma, intestine and tumor levels of 5-fluorouracil in mice bearing L1210 ascites tumor following oral administration of 5-fluorouracil, UFT (mixed compound of tegafur and uracil), carmofur and 5'-deoxy-5-fluorouridine.
Higashigawa, M; Kagawa, Y; Kakito, H; Kawasaki, H; Kojima, M; Ohkubo, T; Ooi, A; Sakurai, M, 2001
)
0.73
" During preoperative treatment with oral tegafur/uracil plus calcium folinate as an adjunct to radiotherapy in patients with stage II or III rectal cancer, the maximum tolerated dosage of tegafur/uracil was 350 mg/m(2)/day (administered 5 days per week for 5 weeks)."( Oral tegafur/uracil.
Goa, KL; Wellington, K, 2001
)
1.09
"We present the case of a 72-year-old man with gastric tube cancer accompanied by multiple liver metastases, after esophagectomy for esophageal cancer, whose quality of life (QOL) was improved with a small dosage of TS-1."( [A patient with advanced gastric cancer in the gastric tube whose QOL was improved by TS-1].
Ajisaka, H; Fujita, H; Inokuchi, M; Iwata, K; Kaji, M; Konishi, K; Maeda, K; Miwa, A; Yabushita, K; Yamamoto, S; Yoshioka, I, 2002
)
0.31
" The most appropriate dosing option appeared to be 400 mg x m(-2) per day of oral UFT for 14 consecutive days with 900 mg x m(-2) gemcitabine on days 8 and 15."( A phase I study of combination chemotherapy with gemcitabine and oral UFT for advanced non-small cell lung cancer.
Asoh, H; Ichinose, Y; Semba, H; Seto, T; Yamamoto, H; Yoh, K, 2002
)
0.31
" These findings demonstrate that administration of S-1 to patients with impaired renal function may need individualized dosing and pharmacokinetic monitoring."( Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function.
Furukawa, H; Ikeda, M; Imamura, H; Ishida, H; Kawasaki, T; Masutani, S; Satomi, T; Shimizu, J; Tatsuta, M, 2002
)
0.31
" Pharmacodynamic analyses suggest that the utility of pharmacology-based dosing of S-1 should be explored in future trials."( Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancer.
Beard, M; Cohen, SJ; Damle, B; DeCillis, AP; Leichman, CG; Letrent, SP; Meropol, NJ; Proefrock, A; Roedig, B; Yeslow, G, 2002
)
0.31
" Taking into consideration the post-marketing survey finding that adverse reactions to the drug first appear 2-3 weeks after the start of oral TS-1 therapy, we attempted a new dosing regimen for this drug, wherein each session of therapy lasted for 2 weeks, with a one-week interval between two consecutive sessions (herein-after called "the 2-week regimen")."( [A new regimen for TS-1 therapy designed to minimize adverse reactions by introducing a one-week interval after each two-week dosing session].
Hayashi, T; Iijima, S; Kato, T; Kikkawa, N; Kimura, Y; Kurokawa, E; Naoi, Y; Tanigawa, T; Yamamoto, H, 2002
)
0.31
" Beginning on August 9, 1999, TS-1 was administered in a dosage of 50 mg bid, but it was later learned that the patient had ingested only half of that TS-1 dosage (i."( [A case of residual gastric cancer accompanied by esophageal invasion in which residual lesions were eradicated by half-dose administration of TS-1].
Abe, S; Kitago, M; Kojima, M; Kurihara, H; Ogihara, T; Sasanuma, H; Tamura, H; Wada, M, 2002
)
0.31
" The objectives of this study were to determine the clinical toxicities, antitumor effect, survival duration, and a recommended dosage schedule in combination with TS-1 and CDDP."( [A pilot study of TS-1 combined with cisplatin in patients with advanced gastric cancer].
Ina, K; Indo, T; Iwase, H; Iyo, T; Kaida, S; Kusugami, K; Mizuno, T; Nakamura, M; Nakarai, K; Okeya, M; Shimada, M, 2002
)
0.31
" The treatment was interrupted if grade 3/4 toxicity appeared and was resumed at the same dosage on recovery."( Tegafur and uracil plus leucovorin in advanced colorectal cancer: a phase II trial.
Antón-Torres, A; Aparicio, J; Aranda, E; Bretón, JJ; Carrato, A; Díaz-Rubio, E; Fernández-Martos, C; Navarro, M; Rivera, F; Sastre, J, 2001
)
1.75
"A pharmacokinetic model for ftorafur and 5FU was developed and should be useful to further study drug interactions and establish dosing guidelines."( Modelling of ftorafur and 5-fluorouracil pharmacokinetics following oral UFT administration. A population study in 30 patients with advanced breast cancer.
Bonneterre, J; Campone, M; Deporte-Fety, R; Fargeot, P; Fumoleau, P; Kerbrat, P; Urien, S, 2003
)
0.32
" With these findings in mind, we recently devised a new dosing regimen for the drug, by which the drug is administered for 2-week periods separated by 1-week drug-free intervals (the 2-week regimen)."( A new regimen for S-1 therapy aiming at adverse reaction mitigation and prolonged medication by introducing a 1-week drug-free interval after each 2-week dosing session: efficacy and feasibility in clinical practice.
Hayashi, T; Iijima, S; Kato, T; Kikkawa, N; Kimura, Y; Kurokawa, E; Naoi, Y; Tanigawa, T; Yamamoto, H, 2003
)
0.32
" The percentage of patients who received the drug for 6 months in complete compliance with the dosing schedule, as calculated by the Kaplan-Meier method, was 85% in the 2-week-regimen group and 40% in the 4-week-regimen group."( A new regimen for S-1 therapy aiming at adverse reaction mitigation and prolonged medication by introducing a 1-week drug-free interval after each 2-week dosing session: efficacy and feasibility in clinical practice.
Hayashi, T; Iijima, S; Kato, T; Kikkawa, N; Kimura, Y; Kurokawa, E; Naoi, Y; Tanigawa, T; Yamamoto, H, 2003
)
0.32
" TS-1 was administered with the usual dosage and dose regimen."( [A clinical results of TS-1 in advanced and recurrent gastric cancer in our hospital].
Abe, S; Kitago, M; Kobayashi, T; Kojima, M; Kurihara, H; Nakamura, T; Ogihara, T; Tamura, H, 2003
)
0.32
" Administration of more than 2 courses was attempted for each patient, with the same dosage levels at all 3 scheduled steps."( [Phase I study of gemcitabine (GEM) and UFT combination chemotherapy for unresectable/recurrent pancreatic cancer].
Dono, K; Maruhashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Sakon, M; Takahashi, Y; Tujie, M; Umeshita, K, 2004
)
0.32
" After 7 days of treatment, grade 3 anorexia appeared, so the dosage of TS-1 was reduced to 25 mg/day."( [A case of Barrett's esophageal carcinoma successfully treated with TS-1 in an elderly patient].
Hasegawa, S; Hattori, H; Imazu, H; Komori, Y; Masui, T; Matsubara, T; Nagai, K; Nakamura, Y; Ochiai, M; Sakurai, Y; Syoji, M; Tonomura, S; Uyama, I; Yoshida, I, 2004
)
0.32
"The methods consisted of analysis of background factors, assessment of the administration and dosage of TS-1, and associations with adverse reactions."( [Examination of the feasibility of TS-1 for postoperative advance stomach cancer patients].
Hara, A; Iwamoto, S; Izumi, N; Satake, K; Takahashi, Y; Tokuhara, T, 2004
)
0.32
" The dosage regimen was 4 weeks on and 2 weeks off in 10 cases, and different regimens were used in the other 10 cases."( [Examination of the feasibility of TS-1 for postoperative advance stomach cancer patients].
Hara, A; Iwamoto, S; Izumi, N; Satake, K; Takahashi, Y; Tokuhara, T, 2004
)
0.32
"We evaluated the optimal dosage schedule for combined oral chemotherapy using uracil/tegafur (UFT) and leucovorin (LV) in Yoshida sarcoma-bearing rats."( Preliminary study of the optimal dosing schedule for oral UFT/leucovorin chemotherapy.
Ishikawa, K; Kamijo, A; Makuuchi, H; Murayama, C; Nakamura, T; Sadahiro, S; Saguchi, T; Suzuki, T; Yasuda, S,
)
0.36
"Administration of UFT/LV for 5 days of the week seemed to exhibit superior antitumor activity, with no increase in the incidence of adverse effects, as compared with the consecutive daily dosing schedule."( Preliminary study of the optimal dosing schedule for oral UFT/leucovorin chemotherapy.
Ishikawa, K; Kamijo, A; Makuuchi, H; Murayama, C; Nakamura, T; Sadahiro, S; Saguchi, T; Suzuki, T; Yasuda, S,
)
0.13
" The alternate-day dosage of pyrimidine fluoride anticancer drugs could reduce their adverse effects without compromising their effects."( Alternate-day oral therapy with TS-1 for advanced gastric cancer.
Arai, W; Hirashima, Y; Hosoya, Y; Hyodo, M; Nagai, H; Shirasaka, T; Yasuda, Y; Yokoyama, T, 2004
)
0.32
"We observed patients for clinical effects and adverse effects under alternate-day dosage of TS-1, and determined blood 5-fluorouracil (FU) levels."( Alternate-day oral therapy with TS-1 for advanced gastric cancer.
Arai, W; Hirashima, Y; Hosoya, Y; Hyodo, M; Nagai, H; Shirasaka, T; Yasuda, Y; Yokoyama, T, 2004
)
0.32
"In 72 (78%) of 92 patients, the TS-1 regimen was converted to the alternate-day dosage because of adverse effects."( Alternate-day oral therapy with TS-1 for advanced gastric cancer.
Arai, W; Hirashima, Y; Hosoya, Y; Hyodo, M; Nagai, H; Shirasaka, T; Yasuda, Y; Yokoyama, T, 2004
)
0.32
" The alternate-day dosage of pyrimidine fluoride anticancer drugs could reduce their adverse effects without compromising their effects."( Alternate-day oral therapy with TS-1 for advanced gastric cancer.
Arai, W; Hirashima, Y; Hosoya, Y; Hyodo, M; Nagai, H; Shirasaka, T; Yasuda, Y; Yokoyama, T, 2004
)
0.32
" The first group was given tailored CPT-11, adjusting individual optimal dosage using toxicity-based grading as an index in combination with TS-1, and the second group was given standard TS-1 treatment."( [A randomized phase II clinical trial of tailored CPT-11 + TS-1 vs TS-1 in patients with advanced or recurrent gastric carcinoma as the first-line chemotherapy (JFMC31-0301)].
Kitajima, M; Kubota, T; Mai, M; Saji, S; Sakamoto, J; Takahashi, Y; Takeuchi, T; Toge, T, 2004
)
0.32
" After that TS-1 was administered on a 4-week dosing regimen with a 2-week interval between sessions."( [A case of advanced gastric cancer with paraaortic lymph node metastasis reaching long-term survival by TS-1 treatment].
Ishii, Y; Suzuki, K; Takahashi, M; Yoshida, S, 2005
)
0.33
" Because salvage therapy with S-1 alone showed good antitumor efficacy and beneficial tolerability when the standard dosage was maintained, it was considered that this home therapy was effective for advanced/recurrent breast cancer that was resistant to anthracycline and taxane antitumor drugs."( [Effective salvage chemotherapy with S-1 alone in a patient with lung metastasis of breast cancer].
Itoh, K; Minami, H, 2005
)
0.33
" To design an effective chemotherapy regimen for elderly patients, it is important to establish an effective dose and dosing method based on the patient's chronologic age and a thorough evaluation of the patient's systemic conditions, including the PS level."( [Case study--an elderly patient with Stage IV advanced gastric cancer achieved good performance status (PS) without subjective symptoms for more than two years by chemotherapy].
Aita, K; Goto, T; Matsubara, T; Nemoto, H; Sanada, Y; Sasaya, S; Shirahata, A; Yoshizawa, Y, 2006
)
0.33
"In a 14-day dosing schedule, the MTD of S-1 was 30 mg/m2 and preliminary evidence of antitumor activity was seen in a North American population with refractory upper gastrointestinal malignancies."( Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer.
Anbe, H; Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Houghton, M; Kulke, MH; Meyerhardt, JA; Regan, E; Ryan, DP; Urrea, P; Zhang, J; Zhu, AX, 2007
)
0.34
" As a single agent, S-1 showed higher antitumor activity with its low intestinal toxicity compared to continuous venous infusion 5-FU, the most effective dosing method of 5-FU, and/or to clinically available oral fluoropyrimidines such as UFT, doxyfluridine and capecitabine on various murine tumors and human tumor xenografts."( [Antitumor activity and function of S-1, a new oral tegafur-based formulation].
Fukushima, M, 2006
)
0.58
"We developed a combination chemotherapy, comprising weekly dosing of iv cisplatin (days 1 and 8) combined with a fixed dose (70 mg/m2/day) of S-1 (days 1-14) for patients with metastatic gastric cancer."( [S-1 combined with weekly dosing of cisplatin for metastatic gastric cancer].
Hyodo, I, 2006
)
0.33
" Furthermore, weekly paclitaxel was found to have a better toxicity profile and to be as effective as an equivalently dosed conventional schedule of delivery every 3 weeks."( [S-1 combined with weekly paclitaxel in patients with advanced gastric cancer].
Gotoh, M; Kawabe, S; Takiuchi, H, 2006
)
0.33
" Based on the results of our previous phase I/II study in patients with gastric cancer, the dosage was established in consideration of safety for outpatient therapy."( [Irinotecan plus oral S-1 in patients with advanced colorectal cancer--biweekly IRIS regimen].
Asaka, M; Komatsu, Y; Kudo, M; Tateyama, M; Yuki, S, 2006
)
0.33
" We carried out 4-week administration of 80-120 mg/day of TS-1 according to body surface area, followed by a 2-week discontinuation, then repeated administration which adjusting the dosage according to the incidence of side effects, and discussed the antitumor effects and adverse events."( [Clinical results of single therapy with TS-1 for advanced/recurrent gastric cancer].
Hatori, S; Imada, T; Kunisaki, C; Makino, T; Ohshima, T; Rino, Y; Suda, T; Takanashi, Y; Yamada, R; Yamazaki, Y, 2006
)
0.33
" We assumed that the recommended dosage of TXT was 30 mg/m(2) and that of TS-1 was 60 mg/m(2) with radiotherapy of 60 Gy."( [A phase I/II study of docetaxel/TS-1 with radiation for esophageal cancer patients--step 1].
Higashida, M; Hirabayashi, Y; Hirai, T; Hiratsuka, J; Imajyo, Y; Kawabe, Y; Matsumoto, H; Murakami, H; Tsunoda, T; Urakami, A; Yamashita, K, 2006
)
0.33
" Based on the result previously reported by us about pharmacokinetic study and recommended administration dosage of TS-1 for patients with impaired renal function, we administered 50 mg/day of TS-1 for four weeks followed by two weeks rest per one course for this patient."( [A case of an elderly patient with gastric cancer successfully treated with TS-1 considering impaired renal function caused by aging].
Fujimi, S; Fukunaga, M; Furukawa, H; Imamura, H; Kamigaki, S; Kishimoto, T; Kondo, M; Miyazaki, Y; Nakata, Y; Nakayama, T; Ohsato, H; Ohshiro, R; Ohta, K; Takemoto, H; Tatsuta, M; Yamamoto, K, 2006
)
0.33
" We therefore reduced the dosage of TS-1 from 80 mg/body/day to 60 mg/body/day."( [A resected case of advanced gastric cancer after treatment with low-dosage TS-1].
Aoyagi, K; Imaizumi, T; Koufuji, K; Matono, K; Miyagi, M; Ogata, Y; Shirouzu, K; Takeda, J; Yano, S, 2007
)
0.34
" Each course consisted of S-1 at a dosage of 100 mg/body/day, twice daily for 21 days, followed by 14 days of drug withdrawal."( [An advanced aged case of intrapulmonary metastasis of non-small cell lung cancer successfully controlled with S-1 capsule therapy alone for an extended period].
Katayama, T; Watari, M, 2007
)
0.34
"The developed model may be useful to optimize the dosage regimen of TS-1 under various clinical conditions."( Development of a pharmacokinetic model to optimize the dosage regimen of TS-1, a combination preparation of tegafur, gimeracil and oteracil potassium.
Hori, S; Inoue, S; Ohtani, H; Sawada, Y; Tsujimoto, M, 2007
)
0.55
"Chemoradiation based on S-1, a novel oral antitumor agent of fluorinated pyrimidines, is the treatment for T2N0 glottic carcinoma; however, the optimal scheduling and dosing have still not been established."( A phase I study of concurrent chemoradiotherapy with S-1 for T2N0 glottic carcinoma.
Inoue, T; Kiba, T; Murata, H; Nagata, K; Nagata, M; Shimode, Y; Tomoda, K; Tsuji, H; Yamashita, T; Yukawa, H, 2006
)
0.33
" Dosing of S-1 is different between Western and Asian populations due to differences in metabolism by CYP2A6."( Medical treatment for advanced gastroesophageal adenocarcinoma.
Ajani, JA; Cen, P, 2007
)
0.34
" A dosage of 335 mg/m2/day of UFT was given perorally on daily schedule."( Metronomic chemotherapy using weekly low-dosage CPT-11 and UFT as postoperative adjuvant therapy in colorectal cancer at high risk to recurrence.
Akagi, Y; Fukushima, T; Ishibashi, N; Mori, S; Murakami, H; Ogata, Y; Shirouzu, K; Ushijima, M, 2007
)
0.34
"Although it is recommended that the standard S-1 dosage should be based on how large the body surface area is, an on-site setting of the appropriate dosage is often lower than the standard one, depending on the individual's condition and considering possible side effects and so, on."( [Determining S-1 dosage at hospitals prioritizing cancer chemotherapy].
Anami, S; Furukawa, H; Hasegawa, K; Imamura, H; Kitada, N; Miyabe, T; Morimoto, S; Morita, S; Tabuse, K; Watari, M; Yamasaki, H, 2008
)
0.35
" The urinary uracil value reflecting DPD activity of the whole body could be used as an index of recurrence at the time of long-term dosage of S-1."( [Study of a relationship between a change in the urinary uracil value after a S-1 long-term administration and the recurrence of stomach cancer].
Akiyama, I; Fujita, Y; Hasegawa, K; Morimoto, S; Shono, Y; Tabuse, K; Tsuji, T, 2008
)
0.35
" The PBPK and PD models were combined, and various dosing strategies were tested."( A combined pharmacokinetic-pharmacodynamic (PK-PD) model for tumor growth in the rat with UFT administration.
Dhiman, A; Shuler, ML; Sung, JH, 2009
)
0.35
" GEM was administrated at a dosage of 1 g/m(2) intravenously weekly 3 of 4 weeks and UFT at a dosage of 200 mg/day orally continuously."( A randomized phase II trial of adjuvant chemotherapy with uracil/tegafur and gemcitabine versus gemcitabine alone in patients with resected pancreatic cancer.
Furukawa, K; Ito, H; Kato, A; Kimura, F; Miyazaki, M; Nozawa, S; Otsuka, M; Shimizu, H; Togawa, A; Yoshidome, H; Yoshitomi, H, 2008
)
0.58
" Furthermore, 'alternate-day S-1 regimen' may improve the dosing schedule for 5-FU by utilizing its strongly time-dependent mode of action; the former is characterized by the low incidences of myelotoxicity and non-hematologic toxicities (e."( Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas.
Shirasaka, T, 2009
)
0.35
" Creatinine clearance of this patient calculated by Cockcroft-Gault method was 44 mL/min and renal function was impaired, so we reduced the administration dosage to 50 mg/day."( [A case of an older adult patient with recurrent gastric cancer successfully treated by low-dose S-1 for a long time].
Danno, K; Imaoka, S; Iwazawa, T; Kano, T; Kimura, Y; Miyazaki, S; Monden, T; Nakano, Y; Ohnishi, T; Tono, T; Yano, H, 2009
)
0.35
"Etoposide 50 mg/m(2), UFT 250 mg/m(2) and leucovorin 90 mg (fixed dose) were dosed in 3 gifts approximately 8h apart for 14 days followed by 1 week rest every 3 weeks until progressive disease (PD)."( Oral UFT, etoposide and leucovorin in recurrent non-small cell lung cancer: a non-randomized phase II study.
Aerts, JG; Gras, J; Hoogsteden, H; Pouw, E; Pronk, T; Salomé, J; Schmitz, PI; Surmont, V; Tan, KY; van Klaveren, RJ; Vernhout, R, 2009
)
0.35
" It was started by a standard dosage of 4-week administration with 2 weeks rest since 2000(A group)."( [Examination of s-1 therapy for adjuvant chemotherapy in patients with advanced gastric cancer].
Matsui, K; Nakagawa, S; Nashimoto, A; Nomura, T; Takii, Y; Tanaka, O; Tsuchiya, Y; Yabusaki, H, 2009
)
0.35
"The percentage of patients who complied with the dosing instructions completely during a 1-year period was 70."( [Examination of s-1 therapy for adjuvant chemotherapy in patients with advanced gastric cancer].
Matsui, K; Nakagawa, S; Nashimoto, A; Nomura, T; Takii, Y; Tanaka, O; Tsuchiya, Y; Yabusaki, H, 2009
)
0.35
"This phase II study evaluated the toxicity and efficacy of a novel dosing schedule of docetaxel and S-1 as treatment for advanced gastric cancer."( Phase II study of biweekly docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer.
Egashira, A; Emi, Y; Kakeji, Y; Maehara, Y; Morita, M; Oki, E; Sadanaga, N; Takahashi, I, 2009
)
0.35
" Regulating the dosage and intervals of S-1 enabled the patients in both cases to survive with cancer as outpatients for 2 years and 2 months after the initial visit (1 year and 10 months from the start of the administration of S-1) in the former case and 3 years from the initial visit (2 years and 1 month from the start of the administration of S-1) in the latter case."( [Two cases of head and neck squamous cell carcinoma in which S-1 administration resulted in long-term sustained QOL].
Furuya, A; Kobayashi, S; Monden, T; Mori, T; Ono, T; Sanbe, T; Shimane, T; Suzaki, H, 2009
)
0.35
" S-1 dosage was assigned based on body surface area (BSA), which is different from the Japanese dosing system."( Two dosages of oral fluoropyrimidine S-1 of 35 and 40 mg/m2 bid: comparison of the pharmacokinetic profiles in Korean patients with advanced gastric cancer.
Ahn, JB; Chung, HC; Jeung, HC; Noh, SH; Rha, SY; Roh, JK; Shin, SJ, 2010
)
0.36
" It is also considered necessary to adjust the dosage of the anticancer drugs and the dosing period for patients with a PS of 2 when preparing a chemotherapeutic regimen for digestive carcinoma, including stomach carcinoma."( [Combination chemotherapy of S-1 and CPT-11 for advanced recurrent gastric cancer].
Akasaka, O; Anan, H; Ando, T; Iwase, S; Kasama, M; Koh, R; Matsueda, R; Miwa, H; Morita, S, 2009
)
0.35
"9%, respectively, compared with dosing on an empty stomach."( Effects of a low-fat meal on the oral bioavailability of UFT and leucovorin in patients with colorectal cancer.
Furuhata, T; Hosokawa, Y; Ishiyama, G; Iwayama, Y; Kimura, Y; Meguro, M; Mizuguchi, T; Nishidate, T; Okita, K; Sasaki, K; Tsuruma, T, 2009
)
0.35
" He was treated with single agent S-1 in 10 courses on a 4-week dosing regimen with a 2-week interval."( [A case of advanced gastric cancer with paraaortic lymph node recurrence reaching a long-term survival by S-1 chemotherapy].
Iwanaga, T; Iwasaki, Y; Matsumoto, H; Matsumura, H; Nakano, D; Ohashi, M; Takahashi, K; Yamaguchi, T, 2009
)
0.35
" But, we dosed down with S-1 due to severe diarrhea."( [A case of successful control of recurrent duodenal carcinoma receiving paclitaxel].
Akitake, H; Ebisui, C; Fujimoto, T; Hama, N; Kashiwazaki, M; Konishi, M; Maekawa, T; Ookubo, K; Ootsuka, M; Taniguchi, M; Tsujie, M; Yoshioka, S, 2009
)
0.35
" This phase I study was performed to determine the recommended dosage (RD) of metronomic chemotherapy using oral fluoropyrimidine S-1 plus weekly irinotecan (CPT-11) in patients with previously untreated advanced or recurrent colorectal cancer."( Dosage escalation study of S-1 and irinotecan in metronomic chemotherapy against advanced colorectal cancer.
Akagi, Y; Ishibashi, N; Mori, S; Ogata, Y; Sasatomi, T; Shirouzu, K, 2009
)
0.35
"This study was conducted to evaluate the efficacy and safety and to compare dosing schedules of gemcitabine combined with S-1 in chemo-naïve non-small cell lung cancer patients."( Randomized phase II study of two different schedules of gemcitabine and oral S-1 in chemo-naïve patients with advanced non-small cell lung cancer.
Ando, M; Funada, Y; Hata, A; Katakami, N; Kotani, Y; Negoro, S; Satouchi, M; Shimada, T; Urata, Y; Yoshimura, S, 2010
)
0.36
" Whether the therapeutic effectiveness of modified regimens is similar to that of the standard dosage remains unclear."( Alternate-day treatment with S-1 in patients with gastric cancer: a retrospective study of strategies for reducing toxicity.
Arai, W; Haruta, H; Hirashima, Y; Hosoya, Y; Hyodo, M; Kurashina, K; Nagai, H; Saito, S; Sakuma, K; Shirasaka, T; Ui, T; Yasuda, Y; Yokoyama, T; Zuiki, T, 2010
)
0.36
" In 116 patients, S-1 was initially given at the standard dosage but was switched to alternate-day treatment because of toxicity within 28 days on average."( Alternate-day treatment with S-1 in patients with gastric cancer: a retrospective study of strategies for reducing toxicity.
Arai, W; Haruta, H; Hirashima, Y; Hosoya, Y; Hyodo, M; Kurashina, K; Nagai, H; Saito, S; Sakuma, K; Shirasaka, T; Ui, T; Yasuda, Y; Yokoyama, T; Zuiki, T, 2010
)
0.36
" With such renal malfunction, pharmacokinetics of the drug was considerably changed compared with normal control, and the dosage should be reduced."( [Construction of a system for proper TS-1 application].
Azuma, S; Hasegawa, K; Kagawa, K; Katada, Y; Morimoto, S; Tabuse, K, 2010
)
0.36
" It may well prove to be an effective treatment in the elderly provided the dosage and administration are appropriate."( [Advanced gastric cancer in an elderly woman showing histopathologic CR after a course of S-1 and CDDP combination therapy].
Egawa, H; Kadokawa, Y; Kawabe, A; Nakajima, S; Sonoda, K, 2010
)
0.36
" When chemotherapy with S-1 or UFT/LV started from the micrometastasis stage, not the advanced macroscopic metastasis stage, anti-LNM efficacy of S-1 was significantly higher than that of UFT/LV at the dosage in which antitumor activity of the two drugs against primary subcutaneous tumor was comparable."( Characterization of a novel lymph node metastasis model from human colonic cancer and its preclinical use for comparison of anti-metastatic efficacy between oral S-1 and UFT/ LV.
Hirai, T; Ito, Y; Kato, T; Kodera, Y; Nakanishi, H; Nakao, A, 2010
)
0.36
" In view of the side effects such as reduction in appetite and leukocyte, the dosage has been reduced as of the second course of treatment."( [A case of breast cancer with multiple hepatic metastasis successfully treated with S-1/PTX and S-1 chemotherapy].
Fujikuni, N; Hashimoto, M; Iwako, H; Kuranishi, F; Kuroda, Y; Moriyuki, T; Niitsu, H, 2010
)
0.36
" To expand the range of applications and investigate the clinical value of the combination strategy, the therapeutic benefit of metronomic S-1 dosing in combination with oxaliplatin (l-OHP)-containing PEG-coated liposomes was evaluated in a murine colon carcinoma-bearing mice model."( Combination therapy of metronomic S-1 dosing with oxaliplatin-containing polyethylene glycol-coated liposome improves antitumor activity in a murine colorectal tumor model.
Doi, Y; Ichihara, M; Ishida, T; Kiwada, H; Matsumoto, H; Okada, T, 2010
)
0.36
" However, because of decreased relative dose intensity during treatment, further study is warranted to determine optimal dosage and combination."( A pilot study of S-1 plus cisplatin versus 5-fluorouracil plus cisplatin for postoperative chemotherapy in histological stage IIIB-IV (M0) gastric cancer.
Ahn, JY; Chung, HC; Hyung, WJ; Jeung, HC; Lee, SS; Noh, SH; Rha, SY, 2012
)
0.38
" The regimen of pre-op CCRT was a radiation dosage of 45  Gy in 20 fractions and oral tegafur-uracil (UFUR) and leucovorin."( The impact of preoperative chemoradiotherapy on advanced low rectal cancer.
Chang, SC; Chen, WS; Jiang, JK; Kao, PS; Lee, RC; Liang, WY; Lin, JK; Lin, TC; Wang, HS; Wang, LW; Yang, SH, 2010
)
0.58
" In the Phase I part, dose-limiting toxicities occurred in all three patients, given mitoxantrone at the dosage of 10 mg/m(2)/day, and the recommended mitoxantrone dosage was determined to be 8 mg/m(2)/day."( A phase I/II study of combined chemotherapy with mitoxantrone and uracil/tegafur for advanced hepatocellular carcinoma.
Furuse, J; Ikeda, M; Ishii, H; Mitsunaga, S; Morizane, C; Nakachi, K; Okusaka, T; Suzuki, E; Ueno, H, 2011
)
0.6
" Therefore, we reduced the administration dosage to 60 mg/ day."( [An elderly patient with advanced gastric cancer maintaining complete response for over 3 years by oral administration of UFT following short span of S-1].
Baba, H; Beppu, T; Okabe, K; Sano, O; Sugiyama, S; Wada, A; Yamanaka, T, 2010
)
0.36
" Though grade 3 neutropenia appeared after 2 courses of the combined therapy, the patient well tolerated it after controlling the dosing schedule."( [A case of complete response of gemcitabine (GEM) monotherapy-refractive liver metastatic pancreatic cancer treated with GEM+S-1 combined chemotherapy].
Hatata, T; Ikeguchi, M; Kondo, A; Naka, T; Takaya, S; Taniguchi, K, 2011
)
0.37
" We judged that curative resection was impossible and finished the operation after giving an intra-abdominal dosage of cisplatin(CDDP)at 85mg."( [A case of gastric carcinoma with peritoneal metastasis successfully treated by combination chemotherapy of S-1 and cisplatin].
Gon, H; Ishida, T; Iwasaki, T; Kanemitsu, K; Nakajima, T; Okuda, T; Tanaka, K; Toyokawa, A; Yamashita, H, 2011
)
0.37
" The dosage of S-1 was set of three levels (1: 80 mg/m², 2: 65 mg/m², 3: 50 mg/m²)."( Phase I study of S-1 in combination with trastuzumab for HER2-positive metastatic breast cancer.
Ito, T; Kamigaki, S; Morita, S; Nakayama, T; Noguchi, S; Sakamoto, J; Taguchi, T; Takashima, T; Yoshidome, K, 2011
)
0.37
" The median S-1 dosage was about 5 courses, and the median of the S-1 total dosage was 10."( [Evaluation of S-1 for stage IV gastric cancer].
Fujita, I; Furukawa, K; Kanazawa, Y; Kato, S; Shirakawa, T; Uchida, E; Yamada, T; Yokoi, K, 2011
)
0.37
"It is essential that the dosage level of warfarin is appropriately adjusted by frequent PT-INR measurements when warfarin and S-1 are coadministered."( Individual differences in prothrombin time-international normalized ratio variation following coadministration of the anticancer agents S-1 and warfarin: 3 case reports.
Hori, S; Kondo, G; Maeda, T; Miki, A; Satoh, H; Sawada, Y; Yamamuro, F, 2011
)
0.37
"S-1 based chemoradiation is the recommended treatment for rectal cancer; however, the optimal scheduling and dosing are not yet established."( Preoperative radiotherapy combined with S-1 for advanced lower rectal cancer: phase I trial.
Ikushima, H; Iwata, T; Kashihara, H; Kurita, N; Miyatani, T; Morimoto, S; Nishioka, M; Sato, H; Shimada, M; Takasu, C; Yoshikawa, K,
)
0.13
" The present study indicates that further investigation is needed to determine the best dosing and dosing schedule."( [The clinical effect of combination therapy for oral cancer with S-1, superselective intra-arterial chemotherapy, and radiation therapy].
Fukumoto, S; Higuchi, T; Horinouchi, Y; Uehara, S; Yamamoto, C; Yasumori, K; Yoshida, M; Yoshikawa, H, 2011
)
0.37
" Patients in the control group were treated with the chemotherapeutic agent tegafur (1,000 mg/day for 5 days); patients in the experimental group were treated with the same dosage of tegafur combined with 1 mg lentinan diluted in 250 ml normal saline."( Combination therapy with lentinan improves outcomes in patients with esophageal carcinoma.
Bi, Z; Gu, XM; Wang, JL; Zou, JW, 2012
)
0.61
" By the results of this survey, it was found that it is necessary to perform a medical teaching including dosage form to contribute to the adherence improvement of the patients."( [Evaluation of the S-1 granule forms in gastric cancer patients who received treatment with S-1 capsule-questionnaire survey about drug dosage forms].
Anami, S; Fujii, C; Fujino, M; Furukawa, H; Hachino, Y; Imamura, H; Kawabata, R; Kishimoto, T; Sumida, R, 2012
)
0.38
" Recently, we showed that the combination of oral metronomic S-1 dosing with oxaliplatin (l-OHP)-containing PEG-coated "neutral" liposomes exerted excellent antitumor activity."( Combination therapy with metronomic S-1 dosing and oxaliplatin-containing PEG-coated cationic liposomes in a murine colorectal tumor model: synergy or antagonism?
Abu Lila, AS; Doi, Y; Ichihara, M; Ishida, T; Kiwada, H; Okada, T, 2012
)
0.38
" Thus, the reduced efficacy of standard chemotherapy dosage in Chinese cancer patients may be explained by the lack of CYP2A6-mediated S-1 bioconversion to 5-FU."( Characteristic CYP2A6 genetic polymorphisms detected by TA cloning-based sequencing in Chinese digestive system cancer patients with S-1 based chemotherapy.
Fang, WJ; Huang, MZ; Jin, DZ; Mao, CY; Mou, HB; Peng, L; Xu, N; Zhao, P; Zheng, YL, 2012
)
0.38
" We examined the effects, the rate of compliance with all of the dosing instructions, cancer recurrence, and the survival rate with S-1 by the administration method for 31 cases."( [Alternate-day oral therapy with S-1 for adjuvant chemotherapy of gastric cancer].
Kawai, Y; Matsumura, M; Mekata, E; Sato, M; Shimizu, K; Tagi, T; Takebayashi, K; Tani, T; Yamamoto, H, 2012
)
0.38
" After recovery from the adverse event, another 4 courses at a 20% lower dosage for safety were administered."( [A case of S-1-resistant resected advanced gastric cancer with para-aortic lymph node recurrence responding to bi-weekly CPT-11 and CDDP].
Ikeda, T; Minamoto, K; Yuasa, I, 2012
)
0.38
" In the present study we estimated radiation dose-response curves for various grades of tumor regression after preoperative CRT."( Radiation dose-response model for locally advanced rectal cancer after preoperative chemoradiation therapy.
Appelt, AL; Bentzen, SM; Jakobsen, A; Pløen, J; Vogelius, IR, 2013
)
0.39
" The radiation dose-response relationship for a specific grade of histopathologic tumor regression was parameterized in terms of the dose required for 50% response, D50,i, and the normalized dose-response gradient, γ50,i."( Radiation dose-response model for locally advanced rectal cancer after preoperative chemoradiation therapy.
Appelt, AL; Bentzen, SM; Jakobsen, A; Pløen, J; Vogelius, IR, 2013
)
0.39
"A highly significant dose-response relationship was found (P=."( Radiation dose-response model for locally advanced rectal cancer after preoperative chemoradiation therapy.
Appelt, AL; Bentzen, SM; Jakobsen, A; Pløen, J; Vogelius, IR, 2013
)
0.39
"This study demonstrated a significant dose-response relationship for tumor regression after preoperative CRT for locally advanced rectal cancer for tumor dose levels in the range of 50."( Radiation dose-response model for locally advanced rectal cancer after preoperative chemoradiation therapy.
Appelt, AL; Bentzen, SM; Jakobsen, A; Pløen, J; Vogelius, IR, 2013
)
0.39
" If it were possible to predict the development of bone marrow suppression before the white blood cell (WBC) count had actually decreased, treatment could be improved by strict dosage control and/or the prophylactic administration of hematopoietic drugs."( Protective effect of the Japanese traditional medicine juzentaihoto on myelosuppression induced by the anticancer drug TS-1 and identification of a potential biomarker of this effect.
Matsumoto, C; Naito, Y; Ogawa, K; Omatsu, T; Tsuchiya, N; Yamamoto, M; Yoshikawa, T, 2012
)
0.38
" When administering cancer chemotherapy to the elderly aged 70 and older, the patient's renal function, PS and Ccr, should be studied, and a regimen and dosage should be carefully selected."( [Tolerable evaluation for chemotherapy with S-1 plus cisplatin in elderly patients with advanced and recurrent gastric cancer].
Ito, D; Iwai, M; Kimura, M; Nakao, T; Okada, K; Usami, E; Yasuda, T; Yoshimura, T, 2012
)
0.38
"This study was performed to investigate the compliance, safety, dosage modifications (dose reduction and/or schedule change [including permanent S-1 withdrawal]), and clinical parameters that predict S-1 dosage modification in gastric cancer patients receiving adjuvant S-1 chemotherapy."( Safety, compliance, and predictive parameters for dosage modification in adjuvant S-1 chemotherapy for gastric cancer.
Kim, HH; Kim, JH; Kim, SJ; Kim, YJ; Lee, JS; Lee, KW; Park, DJ, 2013
)
0.39
"We recently proposed an S-1 combined with oxaliplatin (SOXL) regimen, a combination treatment consisting of oral metronomic S-1 dosing and intravenous administration of oxaliplatin (l-OHP) containing PEGylated liposomes, which showed potent antitumor activity in vivo."( Abrogation of the accelerated blood clearance phenomenon by SOXL regimen: promise for clinical application.
Abu Lila, AS; Ishida, T; Kiwada, H; Nagao, A, 2013
)
0.39
" Pharmacists should consider reducing the treatment dosage and providing nutritional support in such cases."( Pharmaceutical care for patients undergoing s-1 plus Cisplatin therapy for unresectable recurrent gastric cancer.
Kaneoka, Y; Kimura, M; Sugiyama, T; Teramachi, H; Tsuchiya, T; Usami, E; Yasuda, T; Yoshimura, T, 2013
)
0.39
"Patients received oral sunitinib on a continuous daily dosing (CDD) or 2-weeks-on/2-weeks-off schedule (Schedule 2/2; 25 mg/day or 37."( Phase I study of sunitinib plus S-1 and cisplatin in Japanese patients with advanced or metastatic gastric cancer.
Boku, N; Hashigaki, S; Kimura, N; Lechuga, M; Machida, N; Miyata, Y; Muro, K; Suzuki, M, 2014
)
0.4
" The experimental arm's dosage schedule was paclitaxel 60 mg/m2 (intravenous infusion) on days 1, 8 and 15 and S-1 80-120 mg/d (oral administration) on days 1-14."( A multicentre randomised trial comparing weekly paclitaxel + S-1 with weekly paclitaxel + 5-fluorouracil for patients with advanced gastric cancer.
Ba, Y; Deng, T; Guo, Z; Hu, C; Huang, D; Meng, J; Wan, H; Wang, M; Xiong, J; Xu, N; Yan, Z; Yao, Y; Yu, Z; Zhang, Y; Zheng, R; Zhuang, Z, 2013
)
0.39
" Grade 4 neutropenia was revealed, but the treatment could be continued by G-CSF or by down dosing the anticancer agents."( [An 84-year-old man with highly advanced gastric cancer showing good response after chemotherapy with docetaxel, cisplatin and S-1 combination therapy].
Fukumoto, M; Irei, Y; Maruyama, S; Matsuki, A; Nakagawa, S; Nashimoto, A; Nomura, T; Takii, Y; Tsuchiya, Y; Yabusaki, H, 2013
)
0.39
" The dosage of S-1 was based on the body surface area (BSA) as follows: 40 mg bid (total 80 mg/day) for a BSA of <1."( Phase II trial of gemcitabine and S-1 for patients with advanced pancreatic cancer.
Choi, DR; Han, B; Jang, G; Jeon, JY; Jung, JY; Kim, HJ; Kim, HS; Kim, HY; Kim, IG; Kim, JH; Kwon, JH; Park, CK; Song, H; Zang, DY, 2013
)
0.39
" We summarize evidence from the published literature supporting this association and provide dosing recommendations for fluoropyrimidines based on DPYD genotype (updates at http://www."( Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing.
Caudle, KE; Diasio, RB; Klein, TE; McLeod, HL; Schwab, M; Swen, JJ; Thorn, CF, 2013
)
0.39
"Our study indicates that S-1 monotherapy is safe and well tolerated in chemotherapy-naïve elderly patients with AGC, but exerts limited activity when given using a tailor-made dosing strategy based on renal function."( Phase II study of S-1 monotherapy in patients over 75 years of age with advanced gastric cancer (OGSG0404).
Furukawa, H; Iijima, S; Imamura, H; Imano, M; Kimura, Y; Kishimoto, T; Kurokawa, Y; Maruyama, K; Morimoto, T; Otsuji, T; Takiuchi, H; Yamashita, K, 2014
)
0.4
" However, there is a paucity of data from sufficiently powered pharmacokinetic and pharmacodynamic studies to support dosage recommendations in such patients."( Optimization of cancer chemotherapy on the basis of pharmacokinetics and pharmacodynamics: from patients enrolled in clinical trials to those in the 'real world'.
Fujita, K; Sasaki, Y, 2014
)
0.4
"We recently reported that combination therapy with metronomic S-1 dosing and oxaliplatin (l-OHP)-containing PEGylated liposomes improved antitumor activity in a murine colorectal tumor model."( Sequential treatment of oxaliplatin-containing PEGylated liposome together with S-1 improves intratumor distribution of subsequent doses of oxaliplatin-containing PEGylated liposome.
Abu Lila, AS; Doi, Y; Ishida, T; Kiwada, H; Nagao, A; Nakamura, H, 2014
)
0.4
" S-1 dosage was started at level 1 (55."( A phase I study of concurrent chemoradiotherapy using oral s-1 for head and neck cancer.
Fujimoto, Y; Itoh, Y; Kato, S; Naganawa, S; Nakashima, T, 2014
)
0.4
" She was treated with oral S-1, administered on alternate days at a dosage of 80mg/day (orally, twice per day), as postoperative adjuvant chemotherapy."( [A case of appearance of a prominent rash in response to alternate-day S-1 administration as adjuvant chemotherapy for lower gingival cancer].
Goto, M; Nakayama, Y; Yamashita, Y, 2014
)
0.4
"40 patients with locally advanced gastric cancer received intensity-modulated radiotherapy (IMRT) at a dosage of 45-50."( Effect of intensity modulated radiotherapy combined with s-1-based chemotherapy in locally advanced gastric cancer patients.
Gu, BX; Hu, JB; Hu, WX; Sun, XN; Wang, Q, 2014
)
0.4
"Oral UFT plus leucovorin given by either dosage schedule is a very safe regimen for adjuvant chemotherapy."( Safety analysis of two different regimens of uracil-tegafur plus leucovorin as adjuvant chemotherapy for high-risk stage II and III colon cancer in a phase III trial comparing 6 with 18 months of treatment: JFMC33-0502 trial.
Baba, H; Hamada, C; Kakeji, Y; Katsumata, K; Koda, K; Kodaira, S; Kondo, K; Matsuoka, J; Morita, T; Nishimura, G; Sadahiro, S; Saji, S; Sasaki, K; Sato, S; Tsuchiya, T; Usuki, H; Yamaguchi, Y, 2014
)
0.65
" We determined the recommended dosage for CDDP-TAI plus S-1 combination therapy for advanced HCC."( Transarterial infusion chemotherapy with cisplatin plus S-1 for hepatocellular carcinoma treatment: a phase I trial.
Hosoi, H; Ikeda, M; Kondo, S; Mitsunaga, S; Morizane, C; Okusaka, T; Shimizu, S; Terazawa, T; Ueno, H, 2014
)
0.4
"The recommended dosage for further evaluation of this combination therapy in phase II studies is 65 mg/m(2) CDDP and 80 mg/m(2) S-1."( Transarterial infusion chemotherapy with cisplatin plus S-1 for hepatocellular carcinoma treatment: a phase I trial.
Hosoi, H; Ikeda, M; Kondo, S; Mitsunaga, S; Morizane, C; Okusaka, T; Shimizu, S; Terazawa, T; Ueno, H, 2014
)
0.4
"This study attempted to determine the therapeutic dosage of irinotecan and S-1 (IRIS) as a second-line treatment for colorectal cancer (CRC)."( Phase I/II trial of irinotecan and S-1 combination chemotherapy as a second-line treatment for advanced colorectal cancer.
Akazawa, K; Funakoshi, K; Hasegawa, J; Hatakeyama, K; Maruyama, S; Okada, T; Takii, Y; Tani, T; Yamazaki, T, 2013
)
0.39
" The irinotecan dose was then escalated to determine the maximum-tolerated dose and the recommended dose at a fixed dosage of S-1 (80 or 65 mg·m(-2)·day(-1))."( Phase I/II trial of irinotecan and S-1 combination chemotherapy as a second-line treatment for advanced colorectal cancer.
Akazawa, K; Funakoshi, K; Hasegawa, J; Hatakeyama, K; Maruyama, S; Okada, T; Takii, Y; Tani, T; Yamazaki, T, 2013
)
0.39
"This review aims to provide an evidence-based update of clinical trials that have investigated the clinical efficacy, adverse-event profile, dosage and administration of S-1, given alone or in combination with conventional chemotherapeutics and new target-oriented drugs, in the management of colorectal cancer (CRC)."( Efficacy of S-1 in colorectal cancer.
Baba, H; Miyamoto, Y; Sakamoto, Y; Yoshida, N, 2014
)
0.4
"Plasma concentrations of FT enantiomers were determined in rats, dogs and monkeys following intravenous and oral dosing of the racemate (5 mg/kg)."( Species variation in the enantioselective metabolism of tegafur to 5-fluorouracil among rats, dogs and monkeys.
Ishii, Y; Yamada, H; Yamamiya, I; Yoshida, K; Yoshisue, K, 2014
)
0.65
"The dosing regimen for 1 course was as follows: BV (7."( [Study of S-1 and oxaliplatin(SOX) plus bevacizumab as first-line therapy in patients with unresectable colorectal cancer].
Higashi, Y; Ishikawa, S; Maruo, H; Murakami, T; Nishiyama, R; Shoji, T; Suzuki, K; Taniguchi, M; Yamazaki, M, 2014
)
0.4
"Accurate glomerular filtration rate (GFR) evaluation is significant for drug dosing of carboplatin, anticancer drug excreted mainly from kidney."( Renal function evaluation in patients with cancer who were scheduled to receive carboplatin or S-1.
Ando, Y; Hayashi, M; Kamiya, H; Kobayashi, R; Maruyama, S; Matsuo, S; Nakao, M; Shibata, K; Shimokata, T; Teramachi, H; Tsuchiya, T; Yasuda, Y, 2015
)
0.42
" Subjects were 41 patients with cancer whose GFR values were measured by Cin for drug dosing studies of carboplatin or S-1 in Nagoya University Hospital from 2007 to 2010 and 29 non-cancer patients."( Renal function evaluation in patients with cancer who were scheduled to receive carboplatin or S-1.
Ando, Y; Hayashi, M; Kamiya, H; Kobayashi, R; Maruyama, S; Matsuo, S; Nakao, M; Shibata, K; Shimokata, T; Teramachi, H; Tsuchiya, T; Yasuda, Y, 2015
)
0.42
" The safety and dosage of S-1 combined with postoperative radiotherapy have not yet been evaluated."( Phase I study of postoperative radiotherapy concurrent with S-1 in patients with gastric cancer.
Bi, F; Cao, D; Chen, Y; Gou, HF; Li, Q; Li, ZP; Liu, JY; Peng, XC; Qiu, M; Shen, YL; Wang, X; Xu, F; Yang, Y; Yi, C; Zhao, YQ, 2015
)
0.42
" In both arms, S-1 dosing (oral) will be based on body surface area (80 mg/day for body surface area<1."( Randomized phase II study of S-1 dosing schedule for resected colorectal cancer.
Doki, Y; Hasegawa, J; Hata, T; Ikeda, M; Ikenaga, M; Kato, T; Matsuda, C; Mizushima, T; Mori, M; Murata, K; Nakata, K; Nezu, R; Nishimura, J; Ohue, M; Satoh, T; Sekimoto, M; Shingai, T; Takemasa, I; Uemura, M; Yamamoto, H, 2015
)
0.42
"We conducted a prospective pharmacokinetic study to develop an S-1 dosage formula based on renal function."( Development of an S-1 dosage formula based on renal function by a prospective pharmacokinetic study.
Boku, N; Booka, E; Gomi, D; Hamamoto, Y; Ichiyama, T; Imamura, CK; Kawakubo, H; Kitagawa, Y; Mizukami, T; Soejima, K; Takahashi, T; Takeuchi, H; Tanigawara, Y; Tateishi, K, 2016
)
0.43
" The S-1 dosage formula was derived as follows:[Formula: see text]where AUC is the area under the concentration-time curve, CLcr is creatinine clearance, and BSA is body surface area."( Development of an S-1 dosage formula based on renal function by a prospective pharmacokinetic study.
Boku, N; Booka, E; Gomi, D; Hamamoto, Y; Ichiyama, T; Imamura, CK; Kawakubo, H; Kitagawa, Y; Mizukami, T; Soejima, K; Takahashi, T; Takeuchi, H; Tanigawara, Y; Tateishi, K, 2016
)
0.43
"We have developed a novel formula for determining the S-1 dosage on the basis of renal function."( Development of an S-1 dosage formula based on renal function by a prospective pharmacokinetic study.
Boku, N; Booka, E; Gomi, D; Hamamoto, Y; Ichiyama, T; Imamura, CK; Kawakubo, H; Kitagawa, Y; Mizukami, T; Soejima, K; Takahashi, T; Takeuchi, H; Tanigawara, Y; Tateishi, K, 2016
)
0.43
" The other 36 received CRC at the same cisplatin and radiotherapy dosage as for CRSC."( Concurrent radiotherapy with S-1 plus cisplatin versus concurrent radiotherapy with cisplatin alone for the treatment of locally advanced cervical carcinoma: a pilot randomised controlled trial.
Han, S; Li, Z; Lin, N; Mao, W, 2016
)
0.43
" SNK-411 in doses of 25 and 50 mg/kg (both dosing regimens) significantly increased survival rate and lifespan of animals with tumors."( Effect of 2-Isobutyl-4,6-dimethyl-5-hydroxypyrimidine on the Growth of Lewis Lung Carcinoma and Survival of Mice.
Durnev, AD; Kovakenko, LP; Kuznetsova, OS; Nikitin, SV; Tallerova, AV, 2016
)
0.43
" The prothrombin time international normalized ratio divided by current warfarin dosage (PT-INR/dose) was measured over time to evaluate warfarin titer in each patient."( Impact of capecitabine and S-1 on anticoagulant activity of warfarin in patients with gastrointestinal cancer.
Doki, Y; Haraguchi, N; Hata, T; Kudo, T; Mizushima, T; Mori, M; Nishimura, J; Sakai, D; Satoh, T; Takahashi, H; Yamamoto, H, 2016
)
0.43
" The dose of S-1 was escalated in a stepwise fashion from 40 (level 1) to 60 mg/m (level 2) and then 80 mg/m (level 3), whereas the dosage of irinotecan remained the same (150 mg/m)."( Phase I Clinical Study of Irinotecan Plus S-1 in Patients With Advanced or Recurrent Cervical Cancer Previously Treated With Platinum-Based Chemotherapy.
Kimura, T; Kobayashi, E; Kozasa, K; Mabuchi, S; Owa, T; Tomimatsu, T; Tsutui, T; Yamashita, M; Yoki, T; Yokoi, E, 2016
)
0.43
" Furthermore, patients for whom treatment was discontinued or dosage was reduced demonstrated a large reduction in body mass index."( Investigation into the Establishment of Indicators for Pharmaceutical Intervention in Cancer Pharmacotherapy.
Kimura, M, 2016
)
0.43
" Recently, we have reported that metronomic S-1, orally available tegafur formulation, dosing synergistically augmented the therapeutic efficacy of oxaliplatin (l-OHP)-containing PEGylated liposome without increasing the toxicity in animal model."( Improvement of intratumor microdistribution of PEGylated liposome via tumor priming by metronomic S-1 dosing.
Abu Lila, AS; Doi, Y; Ishida, T; Matsumoto, H; Okada, T; Shimizu, T,
)
0.37
" Clinically, metronomic S-1 dosing has been approved for the standard first- and second-line treatment of metastatic or advanced stage of colorectal (CRC)."( Metronomic S-1 dosing and thymidylate synthase silencing have synergistic antitumor efficacy in a colorectal cancer xenograft model.
Abu Lila, AS; Fukushima, M; Huang, CL; Ishida, T; Moriyoshi, N; Wada, H, 2017
)
0.46
" After reducing the dosage of S-1, her diarrhea became milder, and she was able to continue S-1 chemotherapy."( The Capsule Endoscopy Findings in S-1-induced Enteritis with Severe Diarrhea during Adjuvant Chemotherapy for Gastric Cancer (with Video).
Goto, M; Harada, S; Higuchi, K; Kodama, K; Kojima, Y; Nouda, S; Ota, K; Ozaki, H; Takeuchi, T, 2018
)
0.48
"5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hrs after dosing in each period."( Pharmacokinetic and bioequivalence study between two formulations of S-1 in Korean gastric cancer patients.
Cho, K; Cho, S; Gwon, MR; Kang, WY; Kim, BK; Kim, JG; Lee, HW; Ohk, B; Seong, SJ; Sung, YK; Yoon, YR, 2019
)
0.51
" After 6 weeks, we changed the schedule to the same dosage of S-1 for 1 week followed by 2-week discontinuation."( [Long-Term Complete Response in an Unresectable Advanced Gastric Cancer Patient Treated with Low-Dose S-1].
Ando, F; Kawano, Y; Matsuda, A; Matsumoto, S; Miyashita, M; Sakurazawa, N; Suzuki, H; Yamahatsu, K; Yoshida, H, 2019
)
0.51
"She had received 4 cycles of palliative therapy using oral apatinib (425 mg daily) plus S-1 (40 mg twice daily for 4 weeks, with a 2-week drug-free interval), followed by maintenance low-dose apatinib (250 mg daily) plus S-1 at the same dosage thereafter."( S-1 plus apatinib as first-line palliative treatment for stage IVB gastroesophageal junction adenocarcinoma: A case report and review of the literature.
Liu, D; Yu, GM; Zhang, C; Zhang, M, 2020
)
0.56
" Adjuvant apatinib (425 mg daily for a month, and 250 mg daily for another month) plus S-1 at the same dosage were administered for 2 months."( Neoadjuvant apatinib plus S-1 in locally advanced pulmonary adenocarcinoma: A case report and review of the literature.
Liu, D; Wang, X; Yang, DP; Zhang, C; Zhang, M, 2020
)
0.56
" Thereafter, salvage minimally invasive Ivor-Lewis esophagectomy and 2-field lymph node dissection was performed, followed by oral apatinib plus S-1 at the prior dosage for 6 months."( S-1 plus apatinib followed by salvage esophagectomy for irinotecan-refractory small cell carcinoma of the esophagus: A case report and review of the literature.
Gong, LB; Wu, W; Yu, GM; Zhang, C; Zhang, M, 2020
)
0.56
" Although weekly paclitaxel followed by reduced S-1 dosage was introduced after surgery, the recurrent mass was observed in the para-aortic region after 2 years."( [A Case of Long-Term Survival with Far Advanced Gastric Cancer after Multidisciplinary Treatments, including Conversion Surgery].
Akiyama, T; Fujiwara, Y; Higashida, M; Iwamoto, R; Kinoshita, S; Kitagawa, S; Kubota, H; Mineta, S; Okada, T; Okamoto, Y; Tsuruta, A; Ueno, M; Ueno, T; Watanabe, Y, 2020
)
0.56
"The main advantage of targeted genotyping is the existence of prospectively validated genotype-based dosing guidelines."( Joint Belgian recommendation on screening for DPD-deficiency in patients treated with 5-FU, capecitabine (and tegafur).
Bm Claes, K; Borbath, I; Casneuf, V; Demey, W; Geboes, KP; Haufroid, V; Van den Eynde, M; Verheezen, Y; Verstraete, AG, 2022
)
0.93
"The aim of this study was to evaluate clinical validity of the S-1 dosage formula based on body surface area (BSA) and creatinine clearance (CLcr) to achieve the target area under the concentration-time curve of 5-FU, which we had developed and refined in each prospective pharmacokinetic study."( Evaluation of clinical validity of an S-1 dosage formula based on renal function using data of the SPIRITS and the G-SOX trials.
Boku, N; Booka, E; Imamura, CK; Kawakubo, H; Kitagawa, Y; Takeuchi, H; Takeuchi, M; Tanigawara, Y, 2022
)
0.72
"It is suggested that the refined S-1 dosage formula can recommend optimal dose in terms of safety and efficacy."( Evaluation of clinical validity of an S-1 dosage formula based on renal function using data of the SPIRITS and the G-SOX trials.
Boku, N; Booka, E; Imamura, CK; Kawakubo, H; Kitagawa, Y; Takeuchi, H; Takeuchi, M; Tanigawara, Y, 2022
)
0.72
" A proper dosing strategy to avoid severe myelosuppression-induced discontinuation of chemotherapy is required."( Predictive marker for exposure-driven haematological toxicity of tegafur-uracil and proposed modified-dosage regimen by pharmacometric approach in rats.
Ito, Y; Kobuchi, S; Matsui, M, 2022
)
0.96
" Although dosage determination criteria according to plasma drug concentrations are required, the relationship between pharmacokinetics and drug response after multiple oral 5-FU derivative administrations remain unknown."( A Pharmacokinetic-Pharmacodynamic Model Predicts Uracil-tegafur Effect on Tumor Shrinkage and Myelosuppression in a Colorectal Cancer Rat Model.
Ito, Y; Kobuchi, S; Nakamura, T; Okamura, M; Tsuda, M, 2023
)
1.16
"Plasma 5-FU exposure levels increased with the dosing time, and large variations were observed in tumor 5-FU concentrations (32."( A Pharmacokinetic-Pharmacodynamic Model Predicts Uracil-tegafur Effect on Tumor Shrinkage and Myelosuppression in a Colorectal Cancer Rat Model.
Ito, Y; Kobuchi, S; Nakamura, T; Okamura, M; Tsuda, M, 2023
)
1.16
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
organohalogen compoundA compound containing at least one carbon-halogen bond (where X is a halogen atom).
pyrimidinesAny compound having a pyrimidine as part of its structure.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency1.58490.044717.8581100.0000AID485294
thioredoxin reductaseRattus norvegicus (Norway rat)Potency89.12510.100020.879379.4328AID588453
Microtubule-associated protein tauHomo sapiens (human)Potency7.94330.180013.557439.8107AID1468
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID540317
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency35.48130.01789.637444.6684AID588834
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency7.50590.00798.23321,122.0200AID2546; AID2551
lamin isoform A-delta10Homo sapiens (human)Potency15.18610.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (196)

Assay IDTitleYearJournalArticle
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID137194Antitumor activity against P-388 Leukemia in female BDF1 mice expressed as percent T/C at dose 12.5 mg/kg1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
Studies on the synthesis of chemotherapeutics. 10. Synthesis and antitumor activity of N-acyl- and N-(alkoxycarbonyl)-5-fluorouracil derivatives.
AID136586In vivo antitumor activity against MH 134 cell line in female BDF1 mice after oral administered dose of 50 mg/kg1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Studies on the synthesis of chemotherapeutics. 12. Synthesis and antitumor activity of N-phthalidyl-5-fluorouracil derivatives.
AID137192Antitumor activity against Meth A cells in female BDF1 mice expressed as percent T/C at dose 50 mg/kg1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
Studies on the synthesis of chemotherapeutics. 10. Synthesis and antitumor activity of N-acyl- and N-(alkoxycarbonyl)-5-fluorouracil derivatives.
AID96794In vitro antitumor activity against mouse myeloid leukemia L12101982Journal of medicinal chemistry, May, Volume: 25, Issue:5
Synthesis and biological evaluation of novel pyrimidine nucleoside analogues of 1,4-oxathiane, 1,4-dithiane, and 1,4-dioxane.
AID312609Effect on cell viability of HUVEC cells after 48 hrs2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.
AID137190Antitumor activity against Meth A cells in female BDF1 mice expressed as percent T/C at dose 100 mg/kg1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
Studies on the synthesis of chemotherapeutics. 10. Synthesis and antitumor activity of N-acyl- and N-(alkoxycarbonyl)-5-fluorouracil derivatives.
AID1146933Antitumor activity against mouse Ehrlich carcinoma cells allografted in ddY mouse assessed as tumor inhibition at 0.15 mmol/kg, po qd for 7 days measured on day 10 relative to control1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Studies on antitumor agents, 2. Syntheses and antitumor activities of 1-(tetrahydro-2-furanyl)-5-fluorouracil and 1,3-bis(tetrahydro-2-furanyl)-5-fluorouracil.
AID201738Percent reduction against sarcoma 180J tumor growth in mice when administered intraperitoneally at dose 200 mg/kg1980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
Fluorinated pyrimidine nucleosides. 4. Synthesis and antitumor testing of a series of 2',5'-dideoxy- and 2',3',5'-trideoxynucleosides of 5-fluorouracil.
AID1146868Antibacterial activity against Staphylococcus aureus ATCC 6538P assessed as growth inhibition after 24 hrs by plate dilution method1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Studies of antitumor agents. 1. Resolution of racemic 1-(tetrahydro-2-furanyl)-k-fluorouracil into the R and S isomers and examination of the biological activities of the isomers.
AID201737Percent reduction against sarcoma 180J tumor growth in mice when administered intraperitoneally at dose 100 mg/kg1980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
Fluorinated pyrimidine nucleosides. 4. Synthesis and antitumor testing of a series of 2',5'-dideoxy- and 2',3',5'-trideoxynucleosides of 5-fluorouracil.
AID123964Hypnotic activity expressed as sleeping time was determined in ddN strain mice by the icv administration of 2.0 uMol/mouse of the compound; None indicates that the mouse could not fall into sleep1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
N-substituted oxopyrimidines and nucleosides: structure-activity relationship for hypnotic activity as central nervous system depressant.
AID1146870Antibacterial activity against Micrococcus flavus ATCC 10240 assessed as growth inhibition after 24 hrs by plate dilution method1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Studies of antitumor agents. 1. Resolution of racemic 1-(tetrahydro-2-furanyl)-k-fluorouracil into the R and S isomers and examination of the biological activities of the isomers.
AID312620Anticancer activity against human LS1034 cells after 72 hrs in the presence of HMTA by Hoechst test2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.
AID136594In vivo antitumor activity against P-388 Leukemia cell line in female BDF1 mice after oral administered dose of 50 mg/kg1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Studies on the synthesis of chemotherapeutics. 12. Synthesis and antitumor activity of N-phthalidyl-5-fluorouracil derivatives.
AID312612Antitumor activity against human HT29 xenografted CD1 mouse at 50 mg/kg, po2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.
AID1146943Antitumor activity against rat AH-130 cells allografted in Donryu rat assessed as tumor inhibition at 0.45 mmol/kg, po qd for 7 days measured on day 10 relative to control1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Studies on antitumor agents, 2. Syntheses and antitumor activities of 1-(tetrahydro-2-furanyl)-5-fluorouracil and 1,3-bis(tetrahydro-2-furanyl)-5-fluorouracil.
AID312627Antiangiogenic activity against HUVEC cells assessed as tube formation at 80 uM after 8 hrs2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.
AID21232Partition coefficient is determined for the compound from its equilibrium concentrations in organic phase to that in aqueous buffer of pH 7.41987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
N-substituted oxopyrimidines and nucleosides: structure-activity relationship for hypnotic activity as central nervous system depressant.
AID312619Anticancer activity against mouse CT26 cells after 72 hrs in the presence of HMTA by Hoechst test2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.
AID97731Evaluated in vitro for the Cytotoxic activity in the L1210 cell culture screen at 1 uM Maximum cell kill in a 72-h period1985Journal of medicinal chemistry, Feb, Volume: 28, Issue:2
Synthesis and antitumor activity of a series of ftorafur analogues: the effect of varying electronegativity at the 1'-position.
AID312604Anticancer activity against human LS1034 cells after 72 hrs by Hoechst test2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.
AID312621Anticancer activity against human BXPC3 cells after 72 hrs in the presence of HMTA by Hoechst test2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.
AID293749Cytotoxicity against human A549 cells at 400 uM after 48 hrs by MTT assay2007Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6
Synthesis and cytotoxicity of novel fatty acid-nucleoside conjugates.
AID312625Anticancer activity against human BXPC3 cells after 72 hrs in the presence of succinate by Hoechst test2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.
AID1146949Toxicity in Donryu rat allografted with rat AH-130 cells assessed as body weight change at 0.45 mmol/kg, po administered for 7 days measured on day 10 relative to control1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Studies on antitumor agents, 2. Syntheses and antitumor activities of 1-(tetrahydro-2-furanyl)-5-fluorouracil and 1,3-bis(tetrahydro-2-furanyl)-5-fluorouracil.
AID1146881Toxicity in Donryu rat allografted with rat Yoshida cells assessed as body weight at 90 mg/kg, ip administered daily for 7 days starting 24 hrs after tumor inoculation measured on 10th day post-tumor inoculation (Rvb = 53 gms)1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Studies of antitumor agents. 1. Resolution of racemic 1-(tetrahydro-2-furanyl)-k-fluorouracil into the R and S isomers and examination of the biological activities of the isomers.
AID231414Antitumor activity against sarcoma 180J infected mice was evaluated as ratio of number of survivors to the number of tested animals at dose 100 mg/kg, ip; 15/161980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
Fluorinated pyrimidine nucleosides. 4. Synthesis and antitumor testing of a series of 2',5'-dideoxy- and 2',3',5'-trideoxynucleosides of 5-fluorouracil.
AID1146876Antitumor activity against rat AH-130 cells allografted in Donryu rat assessed as tumor weight at 90 mg/kg, ip administered daily for 7 days starting 24 hrs after tumor inoculation measured on 10th day post-tumor inoculation (Rvb = 4.73 +/- 1.19 gms)1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Studies of antitumor agents. 1. Resolution of racemic 1-(tetrahydro-2-furanyl)-k-fluorouracil into the R and S isomers and examination of the biological activities of the isomers.
AID1741082Antiproliferative activity against human A549 cells measured after 48 hrs by SRB assay2020European journal of medicinal chemistry, Oct-01, Volume: 203Fluoropyrimidin-2,4-dihydroxy-5-isopropylbenzamides as antitumor agents against CRC and NSCLC cancer cells.
AID1146929Toxicity in po dosed ddY mouse after 3 days by up and down method1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Studies on antitumor agents, 2. Syntheses and antitumor activities of 1-(tetrahydro-2-furanyl)-5-fluorouracil and 1,3-bis(tetrahydro-2-furanyl)-5-fluorouracil.
AID136879Antitumor activity against L-1210 in female BDF1 mice expressed as percent T/C at dose 200 mg/kg1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
Studies on the synthesis of chemotherapeutics. 10. Synthesis and antitumor activity of N-acyl- and N-(alkoxycarbonyl)-5-fluorouracil derivatives.
AID1146880Toxicity in Donryu rat allografted with rat AH-130 cells assessed as body weight at 90 mg/kg, ip administered daily for 7 days starting 24 hrs after tumor inoculation measured on 10th day post-tumor inoculation (Rvb = 64.1 gms)1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Studies of antitumor agents. 1. Resolution of racemic 1-(tetrahydro-2-furanyl)-k-fluorouracil into the R and S isomers and examination of the biological activities of the isomers.
AID312611Inhibition of HDAC in po dosed mouse 4T1 tumor implanted in BALB/c mouse assessed as histone acetylation level after 4 hrs2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.
AID1146940Antitumor activity against rat Yoshida cells allografted in Donryu rat assessed as tumor inhibition at 0.45 mmol/kg, po qd for 7 days measured on day 10 relative to control1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Studies on antitumor agents, 2. Syntheses and antitumor activities of 1-(tetrahydro-2-furanyl)-5-fluorouracil and 1,3-bis(tetrahydro-2-furanyl)-5-fluorouracil.
AID1146936Antitumor activity against mouse Sarcoma 180 cells allografted in ICR mouse assessed as tumor inhibition at 0.15 mmol/kg, po qd for 7 days measured on day 10 relative to control1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Studies on antitumor agents, 2. Syntheses and antitumor activities of 1-(tetrahydro-2-furanyl)-5-fluorouracil and 1,3-bis(tetrahydro-2-furanyl)-5-fluorouracil.
AID1146879Antitumor activity against rat Yoshida cells allografted in Donryu rat assessed as inhibition of tumor growth at 90 mg/kg, ip administered daily for 7 days starting 24 hrs after tumor inoculation measured on 10th day post-tumor inoculation1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Studies of antitumor agents. 1. Resolution of racemic 1-(tetrahydro-2-furanyl)-k-fluorouracil into the R and S isomers and examination of the biological activities of the isomers.
AID97732Evaluated in vitro for the Cytotoxic activity in the L1210 cell culture screen at 10 uM Maximum cell kill in a 72-h period1985Journal of medicinal chemistry, Feb, Volume: 28, Issue:2
Synthesis and antitumor activity of a series of ftorafur analogues: the effect of varying electronegativity at the 1'-position.
AID136590In vivo antitumor activity against Meth A cell line in female BDF1 mice after oral administered dose of 50 mg/kg1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Studies on the synthesis of chemotherapeutics. 12. Synthesis and antitumor activity of N-phthalidyl-5-fluorouracil derivatives.
AID137196Percentage change in median survival time of P388 (leukemia) inoculated female mice following 25 mg/kg i.p.1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
Studies on the synthesis of chemotherapeutics. 10. Synthesis and antitumor activity of N-acyl- and N-(alkoxycarbonyl)-5-fluorouracil derivatives.
AID1146934Antitumor activity against mouse Ehrlich carcinoma cells allografted in ddY mouse assessed as tumor inhibition at 0.45 mmol/kg, po qd for 7 days measured on day 10 relative to control1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Studies on antitumor agents, 2. Syntheses and antitumor activities of 1-(tetrahydro-2-furanyl)-5-fluorouracil and 1,3-bis(tetrahydro-2-furanyl)-5-fluorouracil.
AID1136876Growth inhibition of human HeLa cells1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Synthesis and biological activities of ftorafur metabolites. 3'- and 4'-hydroxyftorafur.
AID1754294Antitumor activity against human Bel-7402 cells implanted in BALB/c-nu mouse assessed as tumor growth inhibition at 100 mg/kg, IG administered everyday for 7 days relative to control2021Bioorganic & medicinal chemistry, 07-01, Volume: 41A new sulfated triterpene glycoside from the sea cucumber Colochirus quadrangularis, and evaluation of its antifungal, antitumor and immunomodulatory activities.
AID312613Antitumor activity against human HT29 xenografted CD1 mouse assessed as decrease in CEA level2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID312618Anticancer activity against human HT29 cells after 72 hrs in the presence of HMTA by Hoechst test2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.
AID1146875Antibacterial activity against Pseudomonas diminuta IAM 1513 assessed as growth inhibition after 24 hrs by plate dilution method1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Studies of antitumor agents. 1. Resolution of racemic 1-(tetrahydro-2-furanyl)-k-fluorouracil into the R and S isomers and examination of the biological activities of the isomers.
AID293748Cytotoxicity against human A549 cells at 200 uM after 48 hrs by MTT assay2007Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6
Synthesis and cytotoxicity of novel fatty acid-nucleoside conjugates.
AID603953In-vivo plasma to lung partition coefficients of the compound, logP(lung) in rat2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
AID1741079Antiproliferative activity against human HCT-116 cells measured after 48 hrs by SRB assay2020European journal of medicinal chemistry, Oct-01, Volume: 203Fluoropyrimidin-2,4-dihydroxy-5-isopropylbenzamides as antitumor agents against CRC and NSCLC cancer cells.
AID1136873Inhibition of cell cycle traverse in human HeLa cells assessed as mitotic index at 200 ug/ml after 16 hrs1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Synthesis and biological activities of ftorafur metabolites. 3'- and 4'-hydroxyftorafur.
AID26811Partition coefficient (logP)1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability.
AID123970Hypnotic activity expressed as sleeping time was determined in ddN strain mice by the iv administration of 0.3 mmol/kg of the compound; None indicates that the mouse could not fall into sleep1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
N-substituted oxopyrimidines and nucleosides: structure-activity relationship for hypnotic activity as central nervous system depressant.
AID312599Anticancer activity against human HT29 cells after 72 hrs by Hoechst test2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.
AID1146945Antitumor activity against rat Walker 256 cells allografted in Wistar rat assessed as tumor inhibition at 0.15 mmol/kg, po qd for 7 days measured on day 10 relative to control1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Studies on antitumor agents, 2. Syntheses and antitumor activities of 1-(tetrahydro-2-furanyl)-5-fluorouracil and 1,3-bis(tetrahydro-2-furanyl)-5-fluorouracil.
AID312623Anticancer activity against mouse CT26 cells after 72 hrs in the presence of succinate by Hoechst test2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.
AID312600Anticancer activity against mouse CT26 cells after 72 hrs by Hoechst test2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.
AID231418Antitumor activity against sarcoma 180J infected mice was evaluated as ratio of number of survivors to the number of tested animals at dose 200 mg/kg, ip; 12/161980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
Fluorinated pyrimidine nucleosides. 4. Synthesis and antitumor testing of a series of 2',5'-dideoxy- and 2',3',5'-trideoxynucleosides of 5-fluorouracil.
AID1136867In-vivo antitumor activity against mouse L1210 cells at 80 mg/kg relative to control1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Synthesis and biological activities of ftorafur metabolites. 3'- and 4'-hydroxyftorafur.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID112081Compound was tested for the effect on the survival time of the mice bearing P388 leukemia at dose 60 mg/kg1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
(o- and p-Nitrobenzyloxycarbonyl)-5-fluorouracil derivatives as potential conjugated bioreductive alkylating agents.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID312603Anticancer activity against mouse Pan02 cells after 72 hrs by Hoechst test2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID312626Antiangiogenic activity against HUVEC cells assessed as tube formation at 80 uM after 3 hrs2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.
AID312622Anticancer activity against human HT29 cells after 72 hrs in the presence of succinate by Hoechst test2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.
AID409956Inhibition of mouse brain MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID136588In vivo antitumor activity against Meth A cell line in female BDF1 mice after oral administered dose of 200 mg/kg1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Studies on the synthesis of chemotherapeutics. 12. Synthesis and antitumor activity of N-phthalidyl-5-fluorouracil derivatives.
AID312601Anticancer activity against human BXPC3 cells after 72 hrs by Hoechst test2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.
AID312605Anticancer activity against human U251 cells after 72 hrs by Hoechst test2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.
AID137191Antitumor activity against Meth A cells in female BDF1 mice expressed as percent T/C at dose 200 mg/kg1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
Studies on the synthesis of chemotherapeutics. 10. Synthesis and antitumor activity of N-acyl- and N-(alkoxycarbonyl)-5-fluorouracil derivatives.
AID1146939Antitumor activity against rat Yoshida cells allografted in Donryu rat assessed as tumor inhibition at 0.15 mmol/kg, po qd for 7 days measured on day 10 relative to control1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Studies on antitumor agents, 2. Syntheses and antitumor activities of 1-(tetrahydro-2-furanyl)-5-fluorouracil and 1,3-bis(tetrahydro-2-furanyl)-5-fluorouracil.
AID1146937Antitumor activity against mouse Sarcoma 180 cells allografted in ICR mouse assessed as tumor inhibition at 0.45 mmol/kg, po qd for 7 days measured on day 10 relative to control1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Studies on antitumor agents, 2. Syntheses and antitumor activities of 1-(tetrahydro-2-furanyl)-5-fluorouracil and 1,3-bis(tetrahydro-2-furanyl)-5-fluorouracil.
AID136593In vivo antitumor activity against P-388 Leukemia cell line in female BDF1 mice after oral administered dose of 25 mg/kg1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Studies on the synthesis of chemotherapeutics. 12. Synthesis and antitumor activity of N-phthalidyl-5-fluorouracil derivatives.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID136584In vivo antitumor activity against MH 134 cell line in female BDF1 mice after oral administered dose of 200 mg/kg1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Studies on the synthesis of chemotherapeutics. 12. Synthesis and antitumor activity of N-phthalidyl-5-fluorouracil derivatives.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID154359Average days survival of female CDF1 mice bearing lymphocytic leukemia, when 10 E-6 tumor cells were injected intraperitoneally, dosed for 9 days at 20 mg/kg.1985Journal of medicinal chemistry, Feb, Volume: 28, Issue:2
Synthesis and antitumor activity of a series of ftorafur analogues: the effect of varying electronegativity at the 1'-position.
AID1146869Antibacterial activity against Sarcina lutea ATCC 9341 assessed as growth inhibition after 24 hrs by plate dilution method1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Studies of antitumor agents. 1. Resolution of racemic 1-(tetrahydro-2-furanyl)-k-fluorouracil into the R and S isomers and examination of the biological activities of the isomers.
AID136878Antitumor activity against L-1210 in female BDF1 mice expressed as percent T/C at dose 100 mg/kg1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
Studies on the synthesis of chemotherapeutics. 10. Synthesis and antitumor activity of N-acyl- and N-(alkoxycarbonyl)-5-fluorouracil derivatives.
AID137197Antitumor activity against P-388 Leukemia in female BDF1 mice expressed as percent T/C at dose 50 mg/kg1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
Studies on the synthesis of chemotherapeutics. 10. Synthesis and antitumor activity of N-acyl- and N-(alkoxycarbonyl)-5-fluorouracil derivatives.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID136880Antitumor activity against L-1210 in female BDF1 mice expressed as percent T/C at dose 300 mg/kg1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
Studies on the synthesis of chemotherapeutics. 10. Synthesis and antitumor activity of N-acyl- and N-(alkoxycarbonyl)-5-fluorouracil derivatives.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID293745Cytotoxicity against human Ec9706 cells at 400 uM after 48 hrs by MTT assay2007Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6
Synthesis and cytotoxicity of novel fatty acid-nucleoside conjugates.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID312624Anticancer activity against human LS1034 cells after 72 hrs in the presence of succinate by Hoechst test2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.
AID137195Percentage change in median survival time of P388 (leukemia) inoculated female mice following 200 mg/kg i.p.1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
Studies on the synthesis of chemotherapeutics. 10. Synthesis and antitumor activity of N-acyl- and N-(alkoxycarbonyl)-5-fluorouracil derivatives.
AID1146946Antitumor activity against rat Walker 256 cells allografted in Wistar rat assessed as tumor inhibition at 0.45 mmol/kg, po qd for 7 days measured on day 10 relative to control1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Studies on antitumor agents, 2. Syntheses and antitumor activities of 1-(tetrahydro-2-furanyl)-5-fluorouracil and 1,3-bis(tetrahydro-2-furanyl)-5-fluorouracil.
AID293744Cytotoxicity against human Ec9706 cells at 200 uM after 48 hrs by MTT assay2007Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6
Synthesis and cytotoxicity of novel fatty acid-nucleoside conjugates.
AID136589In vivo antitumor activity against Meth A cell line in female BDF1 mice after oral administered dose of 200 mg/kg; death1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Studies on the synthesis of chemotherapeutics. 12. Synthesis and antitumor activity of N-phthalidyl-5-fluorouracil derivatives.
AID23734Micelle/water partition coefficient (Pmic) of the compound was determined1996Journal of medicinal chemistry, Jun-21, Volume: 39, Issue:13
Thermodynamic aspects of hydrophobicity and the blood-brain barrier permeability studied with a gel filtration chromatography.
AID153603Evaluated for the antitumor activity in the P388 lymphocytic leukemia in female CDF1 mice injected intraperitoneally with 10 E-6 tumor cells dosed for 9 days at 20 mg/kg1985Journal of medicinal chemistry, Feb, Volume: 28, Issue:2
Synthesis and antitumor activity of a series of ftorafur analogues: the effect of varying electronegativity at the 1'-position.
AID1146871Antibacterial activity against Bacillus subtilis ATCC 6633 assessed as growth inhibition after 24 hrs by plate dilution method1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Studies of antitumor agents. 1. Resolution of racemic 1-(tetrahydro-2-furanyl)-k-fluorouracil into the R and S isomers and examination of the biological activities of the isomers.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID136592In vivo antitumor activity against P-388 Leukemia cell line in female BDF1 mice after oral administered dose of 200 mg/kg1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Studies on the synthesis of chemotherapeutics. 12. Synthesis and antitumor activity of N-phthalidyl-5-fluorouracil derivatives.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1146931Toxicity in po dosed ddY mouse after 2 weeks by up and down method1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Studies on antitumor agents, 2. Syntheses and antitumor activities of 1-(tetrahydro-2-furanyl)-5-fluorouracil and 1,3-bis(tetrahydro-2-furanyl)-5-fluorouracil.
AID293743Cytotoxicity against human Ec9706 cells at 100 uM after 48 hrs by MTT assay2007Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6
Synthesis and cytotoxicity of novel fatty acid-nucleoside conjugates.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID312610Antiangiogenic activity against HUVEC cells assessed as tube formation at 80 uM after 24 hrs2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.
AID1146942Antitumor activity against rat AH-130 cells allografted in Donryu rat assessed as tumor inhibition at 0.15 mmol/kg, po qd for 7 days measured on day 10 relative to control1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Studies on antitumor agents, 2. Syntheses and antitumor activities of 1-(tetrahydro-2-furanyl)-5-fluorouracil and 1,3-bis(tetrahydro-2-furanyl)-5-fluorouracil.
AID137187Antitumor activity against MH 134 cells in female BDF1 mice expressed as percent T/C at dose 2000 mg/kg1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
Studies on the synthesis of chemotherapeutics. 10. Synthesis and antitumor activity of N-acyl- and N-(alkoxycarbonyl)-5-fluorouracil derivatives.
AID123974Hypnotic activity in ddN strain mice by the iv administration of 0.5 mmol/kg; No activity.1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
N-substituted oxopyrimidines and nucleosides: structure-activity relationship for hypnotic activity as central nervous system depressant.
AID1146932Toxicity in po dosed ddY mouse after 3 weeks by up and down method1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Studies on antitumor agents, 2. Syntheses and antitumor activities of 1-(tetrahydro-2-furanyl)-5-fluorouracil and 1,3-bis(tetrahydro-2-furanyl)-5-fluorouracil.
AID136585In vivo antitumor activity against MH 134 cell line in female BDF1 mice after oral administered dose of 25 mg/kg1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Studies on the synthesis of chemotherapeutics. 12. Synthesis and antitumor activity of N-phthalidyl-5-fluorouracil derivatives.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID136587In vivo antitumor activity against Meth A cell line in female BDF1 mice after oral administered dose of 150 mg/kg1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Studies on the synthesis of chemotherapeutics. 12. Synthesis and antitumor activity of N-phthalidyl-5-fluorouracil derivatives.
AID137193Percentage change in median survival time of P388 (leukemia) inoculated female mice following 100 mg/kg i.p.1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
Studies on the synthesis of chemotherapeutics. 10. Synthesis and antitumor activity of N-acyl- and N-(alkoxycarbonyl)-5-fluorouracil derivatives.
AID136881Antitumor activity against L-1210 in female BDF1 mice expressed as percent T/C at dose 50 mg/kg1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
Studies on the synthesis of chemotherapeutics. 10. Synthesis and antitumor activity of N-acyl- and N-(alkoxycarbonyl)-5-fluorouracil derivatives.
AID312602Anticancer activity against human SK-ES cells after 72 hrs by Hoechst test2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.
AID1146873Antibacterial activity against Klebsiella pneumoniae ATCC 10031 assessed as growth inhibition after 24 hrs by plate dilution method1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Studies of antitumor agents. 1. Resolution of racemic 1-(tetrahydro-2-furanyl)-k-fluorouracil into the R and S isomers and examination of the biological activities of the isomers.
AID136583In vivo antitumor activity against MH 134 cell line in female BDF1 mice after oral administered dose of 150 mg/kg1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Studies on the synthesis of chemotherapeutics. 12. Synthesis and antitumor activity of N-phthalidyl-5-fluorouracil derivatives.
AID137188Antitumor activity against MH 134 cells in female BDF1 mice expressed as percent T/C at dose 50 mg/kg1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
Studies on the synthesis of chemotherapeutics. 10. Synthesis and antitumor activity of N-acyl- and N-(alkoxycarbonyl)-5-fluorouracil derivatives.
AID136591In vivo antitumor activity against P-388 Leukemia cell line in female BDF1 mice after oral administered dose of 100 mg/kg1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Studies on the synthesis of chemotherapeutics. 12. Synthesis and antitumor activity of N-phthalidyl-5-fluorouracil derivatives.
AID293747Cytotoxicity against human A549 cells at 100 uM after 48 hrs by MTT assay2007Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6
Synthesis and cytotoxicity of novel fatty acid-nucleoside conjugates.
AID312608Anticancer activity against human astrocytes cells after 72 hrs by Hoechst test2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID137184Antitumor activity against MH 134 cells in female BDF1 mice expressed as percent T/C at dose 100 mg/kg1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
Studies on the synthesis of chemotherapeutics. 10. Synthesis and antitumor activity of N-acyl- and N-(alkoxycarbonyl)-5-fluorouracil derivatives.
AID1136874Inhibition of cell cycle traverse in human HeLa cells assessed as mitotic index at 100 ug/ml after 16 hrs1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Synthesis and biological activities of ftorafur metabolites. 3'- and 4'-hydroxyftorafur.
AID97734Evaluated in vitro for the Cytotoxic activity in the L1210 cell culture screen at 100 uM Maximum cell kill in a 72-h period r1985Journal of medicinal chemistry, Feb, Volume: 28, Issue:2
Synthesis and antitumor activity of a series of ftorafur analogues: the effect of varying electronegativity at the 1'-position.
AID121013Compound was tested for the effect on the survival time of the mice bearing P388 leukemia at dose 60 mg/kg; ratio of survival time of treated and control1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
(o- and p-Nitrobenzyloxycarbonyl)-5-fluorouracil derivatives as potential conjugated bioreductive alkylating agents.
AID1146874Antibacterial activity against Proteus vulgaris IFO 3045 assessed as growth inhibition after 24 hrs by plate dilution method1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Studies of antitumor agents. 1. Resolution of racemic 1-(tetrahydro-2-furanyl)-k-fluorouracil into the R and S isomers and examination of the biological activities of the isomers.
AID1146877Antitumor activity against rat AH-130 cells allografted in Donryu rat assessed as inhibition of tumor growth at 90 mg/kg, ip administered daily for 7 days starting 24 hrs after tumor inoculation measured on 10th day post-tumor inoculation1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Studies of antitumor agents. 1. Resolution of racemic 1-(tetrahydro-2-furanyl)-k-fluorouracil into the R and S isomers and examination of the biological activities of the isomers.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID189629The capillary permeability of radioligand was measured in Rat brain1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability.
AID140061Tested for PB (pentobarbital)-induced sleep effect expressed as percent control of sleeping time at a dosage (icv) of 2.0 uM concentration1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
N-substituted oxopyrimidines and nucleosides: structure-activity relationship for hypnotic activity as central nervous system depressant.
AID1146878Antitumor activity against rat Yoshida cells allografted in Donryu rat assessed as tumor weight at 90 mg/kg, ip administered daily for 7 days starting 24 hrs after tumor inoculation measured on 10th day post-tumor inoculation (Rvb = 3.65 +/- 0.60 gms)1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Studies of antitumor agents. 1. Resolution of racemic 1-(tetrahydro-2-furanyl)-k-fluorouracil into the R and S isomers and examination of the biological activities of the isomers.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1146930Toxicity in po dosed ddY mouse after 1 week by up and down method1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Studies on antitumor agents, 2. Syntheses and antitumor activities of 1-(tetrahydro-2-furanyl)-5-fluorouracil and 1,3-bis(tetrahydro-2-furanyl)-5-fluorouracil.
AID1146872Antibacterial activity against Escherichia coli NIHJ assessed as growth inhibition after 24 hrs by plate dilution method1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Studies of antitumor agents. 1. Resolution of racemic 1-(tetrahydro-2-furanyl)-k-fluorouracil into the R and S isomers and examination of the biological activities of the isomers.
AID123968Hypnotic activity expressed as sleeping time was determined in ddN strain mice by the iv administration of 0.1 mmol/kg of the compound; None indicates that the mouse could not fall into sleep1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
N-substituted oxopyrimidines and nucleosides: structure-activity relationship for hypnotic activity as central nervous system depressant.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5,656)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990790 (13.97)18.7374
1990's701 (12.39)18.2507
2000's1764 (31.19)29.6817
2010's2167 (38.31)24.3611
2020's234 (4.14)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 48.09

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index48.09 (24.57)
Research Supply Index8.90 (2.92)
Research Growth Index4.74 (4.65)
Search Engine Demand Index82.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (48.09)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1,433 (24.32%)5.53%
Reviews457 (7.76%)6.00%
Case Studies1,947 (33.04%)4.05%
Observational29 (0.49%)0.25%
Other2,026 (34.39%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (122)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase I Study of Combination With TBI-1401(HF10), a Replication-competent HSV-1 Oncolytic Virus, and Chemotherapy in Patients With Stage III or IV Unresectable Pancreatic Cancer. [NCT03252808]Phase 136 participants (Anticipated)Interventional2017-09-25Active, not recruiting
Phase II Study of S-1 in Combination With Oxaliplatin and Irinotecan in Patients With Advanced, Recurrent or Metastatic Biliary Tract Cancer [NCT02527824]Phase 231 participants (Anticipated)Interventional2015-03-31Active, not recruiting
Randomized Phase II Trial of Anastrozole in Combination With/Without Metronomic Tegafur-uracil as Neo-adjuvant Therapy in Postmenopausal Primary Breast Cancer [NCT01262274]Phase 257 participants (Actual)Interventional2010-12-31Terminated(stopped due to Due to an adverse event revelation.)
A Clinical Trial of S-1 Plus Cisplatin Versus 5-FU Plus Cisplatin in Patients With Unresectable or Advanced Gastric Cancer [NCT01198392]Phase 3270 participants (Anticipated)Interventional2008-09-30Recruiting
Phase II Study of S-1 in Combination With Oxaliplatin and Irinotecan in Patients With Advanced, Recurrent or Metastatic Gastric Cancer [NCT02527785]Phase 244 participants (Actual)Interventional2015-02-28Completed
Study of the Efficacy of Maintenance Therapy by UFT or BCG for Superficial Bladder Cancer Against Recurrence in Urological Oncology Council of Northern Tokyo: EMBARK Study [NCT01082510]Phase 3288 participants (Anticipated)Interventional2010-01-31Recruiting
A Randomized Phase II Trial of Perioperative Chemoimmunotherapy Verses Perioperative Chemoimmunotherapy Plus Preoperative Chemoradiation for Locally Advanced Gastric (G) or Gastroesophageal Junction (GEJ) Adenocarcinoma [NCT05161572]Phase 2152 participants (Anticipated)Interventional2021-09-28Recruiting
An Open-Label, Multi-Center, Phase II Study to Evaluate the Efficacy and Safety of PD-1 Antibody Sintilimab Plus Apatinib and Chemotherapy in Patients With HER-2 Negative MSS Advanced or Metastatic GC or GEJ Cancer [NCT05216237]Phase 231 participants (Anticipated)Interventional2022-02-15Recruiting
A Phase II Randomized,Controlled,Open Label,Multicentre Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Extrapancreatic Neuroendocrine Tumor [NCT03204032]Phase 260 participants (Anticipated)Interventional2016-10-31Recruiting
A Single-center Open, Randomized, Controlled Study to Compare the Apapitatin Combined With SOX and SOX for Palliative Adjuvant Chemotherapy in Patients With Advanced Gallbladder Carcinoma [NCT03702491]Phase 2138 participants (Anticipated)Interventional2018-08-10Recruiting
Clinical Study on the Efficacy and Safety of Disitamab Vedotin Combined With Sintilimab and S-1 in the Conversion Treatment of HER2 Overexpression Unresectable Gastric Cancer [NCT05627414]Phase 230 participants (Anticipated)Interventional2023-01-01Not yet recruiting
An Exploratory Study of Tislelizumab in Combination With Oxaliplatin and Tegafur for the Treatment of Gastric Cancer With Liver Metastases [NCT05325528]Phase 2/Phase 340 participants (Anticipated)Interventional2022-04-10Recruiting
A Prospective, Single-arm, Phase II Study of Camrelizumab Combined With Pyrotinib Maleate, Nab-paclitaxel and Tegafur Chemotherapy in First-line Treatment of HER2-positive Gastric Cancer [NCT05070598]Phase 235 participants (Anticipated)Interventional2021-09-07Recruiting
A Non-randomized Phase II Study of Apatinib Mesylate Tablets Plus Tegafur Gimeracil Oteracil Potassium Capsules in Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck [NCT03096184]Phase 238 participants (Anticipated)Interventional2016-12-23Active, not recruiting
Phase II Randomized Controlled Trial Of Dendritic Cell + Cytokine-Induced Killer Cell Immunotherapy With S-1 Versus S-1 Alone As Maintenance Therapy For Advanced Pancreatic Ductal Adenocarcinoma Patients [NCT05955157]Phase 2/Phase 352 participants (Anticipated)Interventional2023-01-03Recruiting
A Phase II and III, Randomized, Multicenter Clinical Study: Toripalimab Plus Radiotherapy for Elderly Esophageal Cancer Patients Treated With Non-chemotherapy Strategy [NCT05817201]Phase 2/Phase 360 participants (Anticipated)Interventional2022-07-01Recruiting
Efficacy and Safety of Nab-Paclitaxel Plus S-1 in the First-line Treatment of Advanced Pancreatic Cancer: A Pilot Single Arm Phase II Study [NCT03415802]Phase 232 participants (Actual)Interventional2015-05-11Completed
A Phase II Study Evaluating the Use of Concurrent Cetuximab, Irinotecan, Oxaliplatin and UFT in the First Line Treatment of Patients With Metastatic Colorectal Cancer [NCT01225744]Phase 247 participants (Actual)Interventional2009-04-30Completed
Feasibility of Switching Fluoropyrimidine Due to Cardiotoxicity in Patients With Solid Tumors: A Retrospective, International and Non-interventional Study [NCT04260269]200 participants (Anticipated)Observational2018-06-01Enrolling by invitation
Randomized Phase II Study of SOX vs mFOLFOX6 as Neoadjuvant Chemotherapy in Patients With Resectable Rectal Cancer (KSCC1301). [NCT02280070]Phase 2110 participants (Anticipated)Interventional2013-09-30Recruiting
Orzel (UFT+Leucovorin) as First-Line Therapy for Metastatic Breast Cancer [NCT00005608]Phase 20 participants Interventional2000-02-29Terminated(stopped due to Drug was pulled from the market.)
Efficacy and Safety Evaluation of Tegio Consolidation Therapy in the Treatment of Nasopharyngeal Carcinoma With High Risk of Metastasis: a Phase II Study [NCT03904225]Phase 2220 participants (Anticipated)Interventional2018-12-14Recruiting
Compare S-1 for 9 Months to 1 Year as Adjuvant Chemotherapy in Stage II Gastric Cancer (SMAC) [NCT03941561]Phase 31,006 participants (Anticipated)Interventional2019-01-01Recruiting
Toxicity OF Fluoropyrimidines: A Comparative Study of the Cardiotoxicity of capEcitabine and tEysuno [NCT01845337]Phase 259 participants (Actual)Interventional2014-02-05Completed
Phase III Randomized Controlled Study of Postoperative Adjuvant Therapy Using TS-1 or TS-1+PSK for Stage II or III Gastric Cancer Patients [NCT00687843]Phase 3480 participants (Anticipated)Interventional2008-06-30Active, not recruiting
Oral Thalidomide and Tegafur-uracil to Decrease Hepatocellular Carcinoma Recurrent After Hepatectomy in High Risk Patients -A Phase II Study [NCT02447679]Phase 240 participants (Actual)Interventional2010-08-31Completed
Phase II Study of S-1 Plus Leucovorin (1 Week on and 1 Week Off) as First-line Treatment for Patients With Metastatic and Recurrent Gastric Cancer [NCT02090153]Phase 239 participants (Actual)Interventional2011-07-31Completed
Phase II Clinical Study of Cadonilimab Combination With Chemotherapy With or Without the Anti-CD47 Antibody AK117 Neoadjuvant/Adjuvant Therapy for Resectable Gastric or Gastroesophageal Junction Adenocarcinoma [NCT05960955]Phase 290 participants (Anticipated)Interventional2023-11-13Recruiting
Randomized Phase II Study of S-1 (SOX) or Capecitabine (XELOX) in Combination With Oxaliplatin in Patients With Recurrent or Metastatic Gastric Cancer [NCT00985556]Phase 2130 participants (Anticipated)Interventional2009-01-31Recruiting
Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Docetaxel and S-1 in Breast Cancer [NCT00994968]Phase 249 participants (Anticipated)Interventional2009-07-31Recruiting
Open Comparative Study With a Cross-over According to Patients'Preference Receiving Xeloda or UFT With Folinic Acid in Advanced or Metastatic Colo-rectal Cancer [NCT00905047]Phase 389 participants (Actual)Interventional2005-09-30Completed
An Exploratory Clinical Trial of Nab-Paclitaxel and Gemcitabine Compared With Gemcitabine and Tegafur in Adjuvant Chemotherapy After Radical Resection of Pancreatic Cancer [NCT04216758]Phase 2300 participants (Anticipated)Interventional2020-01-01Recruiting
A Phase II Study of ORZEL (UFT + Leucovorin) in Elderly (at Least 75 Years Old) Patients With Colorectal Cancer [NCT00004860]Phase 20 participants Interventional2000-10-09Completed
Randomized Phase III Study of UFT+Leucovorin vs. TS-1 as Adjuvant Treatment for Stage III Colon Cancer , and Investigate Predictive Factors Based on Gene Expression [NCT00660894]Phase 31,535 participants (Actual)Interventional2008-04-30Completed
Phase II Study of Combination Chemotherapy With S-1 Plus Avastin in Unresectable or Recurrent Colorectal Cancer After Failure of Prior Chemotherapy, Including Irinotecan and Oxaliplatin Regimens. [NCT00974389]Phase 240 participants (Anticipated)Interventional2009-07-31Recruiting
A Trial of Metronomic Chemotherapy With Tegafur/Uracil for Patients With Locally Advanced (Stage III~IVB) Head and Neck Squamous Cell Carcinoma (HNSCC) [NCT00855881]Phase 2115 participants (Anticipated)Interventional2008-12-31Recruiting
Phase II Randomized Trial of S-1, Leucovorin, Oxaliplatin and Gemcitabine (SLOG) vs Gemcitabine and Cisplatin (GC) in Locally Advanced or Metastatic Biliary Tract Cancer [NCT03406299]Phase 292 participants (Actual)Interventional2018-04-19Active, not recruiting
Apatinib With Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma Of The Stomach [NCT04863430]Phase 241 participants (Anticipated)Interventional2021-05-11Recruiting
Adjuvant Nab-paclitaxel Plus S-1 Versus Capecitabine Plus Oxaliplatin for Patients With Stage III Gastric Cancer After D2 Gastrectomy : a Randomised,Open-label, Phase III Study [NCT04135781]Phase 3616 participants (Anticipated)Interventional2020-03-01Recruiting
A Phase II Study of Tegafur-Uracil as Maintenance Chemotherapy in Patients With Stage II Microsatellite-Stable or Low-Level Microsatellite-Instability Colon Cancer [NCT02887365]Phase 4300 participants (Anticipated)Interventional2014-09-30Recruiting
Identification of the Prognostic Factors of Stage II Colon Cancer Patients Receiving Adjuvant Chemotherapy With UFT [NCT00898846]1,111 participants (Actual)Observational2006-10-31Completed
Phase 2 Study of Comparison Between XELOX (Capecitabine and Oxaliplatin) and Docetaxel, Oxaliplatin and S1 Regimen as Neoadjuvant Chemotherapy for Patients With Locally Advanced Gastric Cancer [NCT02623153]Phase 2200 participants (Anticipated)Interventional2016-01-31Not yet recruiting
A Randomized, Controlled, Double Blind, Multicenter Study of Nimotuzumab Plus S1 Versus Placebo Plus S1 as Maintenance Treatment in Patients With Advanced or Metastatic Pancreatic Cancer After First-line Treatment [NCT02945267]Phase 460 participants (Anticipated)Interventional2016-09-30Not yet recruiting
"A Randomized, Multicenter, Open-label, Phase III Study to Compare the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab, Fluoropyrimidine-based and Platinum-based Chemotherapy (Hereinafter Referred to as Chemotherapy) Versus Chemotherapy in [NCT05144854]Phase 3626 participants (Actual)Interventional2021-11-05Active, not recruiting
Phase II Study of the Maintenance Treatment of UFT (Uracil and Tegafur) After First-line [NCT02903498]Phase 258 participants (Actual)Interventional2009-08-31Completed
S1 Plus Paclitaxel (IV&IP) Plus Bevacizumab (IP) Versus S1 Plus Oxaliplatin(IV) as First-line Treatment in Gastric or Gastroesophageal Junctional Adenocarcinoma With Malignant Ascites: An Open-label, Multicenter Phase II Study [NCT03990103]Phase 266 participants (Anticipated)Interventional2017-11-01Recruiting
[NCT02836977]400 participants (Anticipated)Interventional2016-03-31Active, not recruiting
Anti-tumor Recurrence With Transarterial Chemoembolization (TACE) Plus Tegafur Versus TACE on Patients With Intrahepatic Cholangiocarcinoma After Curative Resection:A Randomized Controlled Study [NCT02588755]180 participants (Anticipated)Interventional2015-12-31Recruiting
The Comparative Trial of UFT + TAM With CMF + TAM in Adjuvant Therapy for Breast Cancer (CUBC) [NCT00152178]Phase 3680 participants (Anticipated)Interventional1996-07-31Completed
A Randomized Controlled Study of Postoperative Adjuvant Chemotherapy of UFT Compared With Surgery Alone for Serosa-negative Advanced Gastric Cancer (NSAS-GC) [NCT00152243]Phase 3500 participants (Anticipated)Interventional1997-06-30Completed
Individualized Management of Pancreatic Cancer With Targeted Therapeutics (IMPACTT): A Phase II Clinical Trial [NCT00429858]Phase 221 participants (Actual)Interventional2007-01-22Terminated(stopped due to Study accrual rate is very slow, it was mandated by NCI to be terminated.)
A Phase III, Open-labelled, Randomised Study of Neoadjuvant Docetaxel+Oxaliplatin+S-1 (DOS) + Surgery + Adjuvant S-1 Versus Surgery + Adjuvant S-1 in Patients With Resectable Advanced Gastric Cancer [NCT01515748]Phase 3530 participants (Actual)Interventional2011-12-30Completed
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01) [NCT06109779]Phase 3750 participants (Anticipated)Interventional2023-12-04Recruiting
A Randomized, Open and Control Clinical Study of Endostar Injection Concomitant With SOX Protocols in Treating Advanced Gastric Cancer [NCT02008422]Phase 3120 participants (Anticipated)Interventional2013-08-31Active, not recruiting
Phase II Study of Neoadjuvant Chemotherapy Wtih S1+Oxaliplatin (SOX) Regimen Followed by Chemoradiation Concurrent With S-1 in Patients With Potentially Resectable Gastric Carcinoma [NCT02024217]Phase 240 participants (Anticipated)Interventional2012-03-31Recruiting
Gimatecan (ST1481) as Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer: an Open-label, Randomized, Controlled Phase II Study [NCT04571489]Phase 260 participants (Anticipated)Interventional2020-12-01Not yet recruiting
A Phase II Double-blind and Randomized Trial Comparing Concurrent Chemoradiotherapy Plus PG2 Injection Versus Concurrent Chemoradiotherapy Plus Placebo in Advanced Pharyngeal or Laryngeal Squamous Cell Carcinoma [NCT01720563]Phase 217 participants (Actual)Interventional2012-12-31Terminated(stopped due to Change study drug dosage form)
A Phase Ib, Open-Label, Multicenter Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Patients With Locally Advanced or Metas [NCT05867121]Phase 1120 participants (Anticipated)Interventional2023-10-02Recruiting
A Phase II Trial of a TS-1/Cisplatin Based Definitive Chemoradiotherapy for Resectable Esophageal Cancer [NCT00659113]Phase 232 participants (Anticipated)Interventional2008-03-31Recruiting
A Phase ll Trial of Induction Docetaxel and S-1 Followed by Concomitant Radiotherapy With Low-dose Daily Cisplatin in Locally Advanced Head and Neck Cancer [NCT00625937]Phase 246 participants (Anticipated)Interventional2006-11-30Recruiting
A Phase II Study of Adjuvant Chemotherapy of S-1 With Oxaliplatin in Gastric Cancer at Stage IIIB/ IV (AJCC 6th) After D2 Resection [NCT02191566]Phase 28 participants (Actual)Interventional2015-05-31Terminated(stopped due to The patient's study enrollment was too low.)
Concurrent Chemoradiotherapy Followed by Tegafur, Gimeracil and Oteracil Potassium Consolidation Chemotherapy in Patients With Locally Advanced Cervical Cancer: a Single Institute, Prospective, Single-arm Trial [NCT04310774]Phase 1/Phase 2200 participants (Anticipated)Interventional2020-04-15Not yet recruiting
Randomized Phase III Trial of Adjuvant Chemotherapy With UFT vs. Observation in Curatively Resected Stage II Colon Cancer [NCT00392899]Phase 32,025 participants (Actual)Interventional2006-10-31Completed
Phase II Clinical Study of Preoperative S-1/CDDP Combination Chemotherapy in Patients With Advanced Gastric Cancer [NCT00088816]Phase 250 participants (Anticipated)Interventional2003-04-30Active, not recruiting
A Prospective, Single-arm, Exploratory Clinical Research on the Efficacy and Safety of Tripletrumab Combined With Oxaliplatin and Teggio (SOX) in First-line Treatment of Unresectable Locally Advanced or Metastatic Gastric and Gastroesophageal Junction Ade [NCT04202484]Phase 220 participants (Anticipated)Interventional2020-02-01Not yet recruiting
Effect and Safety of Adjuvant Huaier Granule Versus Standard Chemotherapy Regimens in Resectable Stage II-III Gastric Cancer Patients: a Prospective, Multi-center, and Observational Study [NCT05498766]828 participants (Anticipated)Observational2023-10-12Recruiting
Randomized Phase III Clinical Study Comparing Postoperative UFT+LV, UFT+LV/UFT and UFT+LV+PSK/UFT+PSK Therapies for Stage III Colorectal Cancer [NCT00209742]Phase 3340 participants (Anticipated)Interventional2005-04-30Active, not recruiting
An Open-label, Single-arm, Multicenter, Phase II Study to Assess the Efficacy and Safety of Aiyi® (Tegafur Gimeracil Oteracil Potassium Capsule) as 2nd Line Treatment in Patients With Advanced Metastatic Breast Cancer [NCT01492543]Phase 230 participants (Anticipated)Interventional2011-12-31Recruiting
PhaseⅡSingle-center, Open-label, Exploratory Clinical Study of Apatinib in Combination With S1 for the Patients With Advanced Non-squamous Head and Neck Cancer [NCT02943252]Phase 230 participants (Anticipated)Interventional2016-10-31Recruiting
A Non-randomized Phase II Study of Apatinib and Tegafur Gimeracil Oteracil Induction Chemotherapy in Locally Advanced Squamous Cell Carcinoma of Head and Neck [NCT03267121]Phase 238 participants (Actual)Interventional2017-10-01Completed
A Randomized Open Label Multicenter Phase 3 Trial Comparing S1 Generic With Capecitabine in Patients With Metastatic Breast Cancer. [NCT01655992]Phase 3386 participants (Anticipated)Interventional2012-01-31Terminated(stopped due to The sponsor decided to stop the study.)
A Clinical Trial Comparing Oral Uracil/Ftorafur (UFT) Plus Leucovorin (LV) With 5-Fluorouracil (5-FU) Plus LV in the Treatment of Patients With Stages II And III Carcinoma of the Colon [NCT00378716]Phase 31,608 participants (Actual)Interventional1997-02-28Completed
Autologous Cytokine-induced Killer Cells Combined Chemotherapy in Advanced Pancreatic Cancer: A Prospective, Randomized, Open, Single Center Phase II Study [NCT03002831]Phase 213 participants (Actual)Interventional2016-11-30Terminated(stopped due to Study halted prematurely and will not resume)
A Prospective, Open-label, Single-Arm, Phase II Study on Biomarkers for Predicting the Efficacy of Neoadjuvant Sintilimab in Combination With Tegafur and Oxaliplatin (SOX) for cStage III Gastric or Gastroesophageal Junction Adenocarcinoma. [NCT05594381]Phase 290 participants (Anticipated)Interventional2022-10-31Not yet recruiting
A Multi-center, Phase II Study to Evaluate Safety and Efficacy of Adjuvant Chemotherapy With Tegafur Gimeracil Oteracil Potassium Capsule Plus Oxaliplatin and Camrelizumab for Stage III Gastric Cancer (FOCUS-02) [NCT04515615]Phase 252 participants (Anticipated)Interventional2020-09-09Active, not recruiting
Nivolumab as add-on to Gemcitabine/S-1 in Metastatic Pancreatic Cancer: a Phase II Trial [NCT04377048]Phase 238 participants (Anticipated)Interventional2020-07-01Not yet recruiting
A Phase II Study of Tegafur/Uracil(UFUR) Plus Thalidomide for the Treatment of Advanced or Metastatic Hepatocellular Carcinoma (HCC) [NCT00519688]Phase 244 participants (Actual)Interventional2006-07-31Completed
Trial UFT/RT Randomized Multicenter Phase III Randomized Trial Testing Ftorafur (UFT) Associated With Neoadjuvant Radiotherapy Versus Radiotherapy Alone in Rectal Adenocarcinoma [NCT00207831]Phase 3219 participants (Actual)Interventional2004-07-31Terminated(stopped due to Terminated after interim analysis)
Controlled Randomized Trial to Evaluate Efficacy of Adjuvant Chemotherapy Between S-1 and UFT for Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Phase III Study [NCT00336947]Phase 3500 participants (Anticipated)Interventional2006-04-30Active, not recruiting
A Phase II Study of Sorafenib Plus Tegafur/Uracil for the Treatment of Advanced or Metastatic Hepatocellular Carcinoma [NCT00464919]Phase 250 participants (Anticipated)Interventional2007-04-30Completed
Randomized Phase II Study of TS-1 Therapy and TS-1+PSK Therapy Against Unresectable Advanced Gastric Carcinoma and Recurrent Gastric Carcinoma [NCT00503321]Phase 2/Phase 313 participants (Actual)Interventional2006-10-31Terminated(stopped due to Patients' enrollment was not sufficient.)
Perioperative Tegafur Gimeracil Oteracil Potassium Capsule Plus Oxaliplatin Versus Capecitabine Plus Oxaliplatin in Patients With Localized Advanced Gastric Cancer [NCT01516944]Phase 2/Phase 3749 participants (Actual)Interventional2012-02-29Completed
A Phase II Trial of Sorafenib Plus Tegafur-uracil (UFT) vs. Sorafenib as First Line Systemic Treatment for Patients With Advanced Stage HCC, Unresectable & Not Eligible for Local Ablation &/or TACE [NCT01539018]Phase 277 participants (Actual)Interventional2012-01-31Terminated(stopped due to After interim results data showed no evidence of a difference between both groups)
Phase I Study Of Weekly Paclitaxel In Combination With ORZEL (UFT + Leucovorin) For Advanced Non-Hematological Malignancies [NCT00009828]Phase 10 participants (Actual)Interventional1999-12-31Withdrawn
Phase I Study Of Oral Etoposide In Combination With ORZEL (UFT + Leucovorin) For Advanced Non-Hematological Malignancies [NCT00009815]Phase 10 participants (Actual)Interventional1999-12-31Withdrawn
[NCT00037089]Phase 20 participants InterventionalActive, not recruiting
Randomized Multicenter Controlled Phase III Study of Postoperative Adjuvant Therapy for Stage II/IIIA Gastric Cancer Using TS-1 Alone or TS-1+PSK Combined Therapy [NCT00216034]Phase 3255 participants (Actual)Interventional2005-03-31Completed
Phase II Clinical Study of Preoperative S-1/CPT-11 Combination Chemotherapy in Patients With Locally Advanced Gastric Cancer [NCT00134095]Phase 270 participants (Anticipated)Interventional2004-09-30Active, not recruiting
A Randomized Controlled Study of Postoperative Adjuvant Therapy of UFT Compared With CMF in High-risk Women With Axillary Node-negative Breast Cancer (NSAS-BC) [NCT00152191]Phase 31,300 participants (Anticipated)Interventional1996-10-31Completed
A Randomized Controlled Study of Postoperative Adjuvant Chemotherapy of UFT Compared With Surgery Alone in Patients With Dukes C Colorectal Cancer (NSAS-CC) [NCT00152230]Phase 3900 participants (Anticipated)Interventional1996-10-31Completed
Phase III Clinical Study of Preoperative S-1/CDDP Combination Chemotherapy in Patients With Potentially Resectable Stage III Advanced Gastric Cancer [NCT00182611]Phase 3100 participants (Anticipated)Interventional2004-04-30Completed
An Phase I Dose-Escalation Study of Biweekly Abraxane in Combination With Oxaliplatin and Oral S-1/LV (SOLAR Regimen) as First-line Chemotherapy in Patients With Advanced Gastric, Pancreatic and Biliary Cancers [NCT03162510]Phase 118 participants (Actual)Interventional2018-06-26Completed
Effects of S-1 and Capecitabine in Combination With Oxaliplatin on the Coronary Artery Blood Flow in Patients Metastatic Gastrointestinal Tract Adenocarcinoma: a Randomized Phase II Study [NCT02216149]Phase 220 participants (Actual)Interventional2015-01-31Terminated(stopped due to Slow accrual)
Camrelizumab Plus Apatinib Combined With GEMOX (Gemcitabine and Oxaliplatin ) in the Perioperative Treatment of Locally Advanced Biliary Tract Malignancies: A Prospective, Multicenter, Phase Ⅱ Study [NCT05451290]Phase 230 participants (Anticipated)Interventional2022-09-01Not yet recruiting
Gastrectomy Plus Chemotherapy Versus Chemotherapy Alone for Advanced Gastric Cancer With a Single Non-curable Factor [NCT03001726]228 participants (Anticipated)Observational2017-01-31Enrolling by invitation
[NCT02749526]Phase 270 participants (Anticipated)Interventional2016-04-30Terminated(stopped due to low accrual rate)
Prospective Study With HIPEC-AS in Patients With Locally Advanced, Limited or Extensive Peritoneal Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction [NCT05095467]Phase 2157 participants (Anticipated)Interventional2021-10-31Not yet recruiting
A Prospective, Single-arm, Single-center, Phase II Clinical Trial to Evaluate the Efficacy of Quintuple Method for the Treatment of Multiple Refractory Colorectal Liver Metastases [NCT05774964]Phase 2100 participants (Anticipated)Interventional2023-03-15Not yet recruiting
An Exploratory Non-randomized Controlled Trial for Effect and Safety of Envafolimab Combined With Recombinant Human Endostartin Injection/S-1 in Second-line Treatment of Advanced Non-small Cell Lung Cancer [NCT05529355]Phase 245 participants (Anticipated)Interventional2022-09-18Not yet recruiting
A Multicenter, Double-blind, Randomized Study in Patients With Gastric Cancer Undergoing Postoperative Adjuvant Chemotherapy [NCT03006705]Phase 3800 participants (Actual)Interventional2017-01-31Completed
[NCT00384800]Phase 241 participants (Anticipated)Interventional2006-09-30Recruiting
A Phase III Trial Comparing UFT+PSK to UFT+LV in Stage IIB, III Colorectal Cancer [NCT00385970]Phase 3380 participants (Anticipated)Interventional2006-03-31Active, not recruiting
Phase I Study of Gemcitabine (Gemzar) and UFT/Leucovorin [NCT00003925]Phase 136 participants (Anticipated)Interventional1998-05-31Completed
Phase III Randomized Trial of Immediate Adjuvant Chemotherapy or Delayed Salvage Chemotherapy in Nasopharyngeal Carcinoma Patients With Post-radiation Detectable Plasma EBV DNA [NCT02363400]Phase 3147 participants (Anticipated)Interventional2014-11-30Enrolling by invitation
A Phase II Randomized,Controlled,Open Label,Multicentre Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Pancreatic Neuroendocrine Tumor [NCT03204019]Phase 260 participants (Anticipated)Interventional2016-10-31Recruiting
Lerotinib Versus Investigator's Choice Single-agent Chemotherapy in Patients With Locally Advanced/Metastatic Esophageal Squamous Cell Carcinoma and EGFR Overexpression That Progressed After Second-line Therapy:Phase 3 Study [NCT04415853]Phase 3416 participants (Anticipated)Interventional2021-01-21Recruiting
A Study of Adoptive Invariant Nature Killer T Cell Therapy for Relapsed/Advanced Hepatocellular Carcinoma (HCC) [NCT03175679]Phase 118 participants (Anticipated)Interventional2017-05-01Recruiting
A Study of Specific HCC Antigens CD8+ T Cells Therapy for Treating Patients With Relapsed/Advanced Hepatocellular Carcinoma (HCC) [NCT03175705]Phase 118 participants (Anticipated)Interventional2017-05-01Recruiting
Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Her-2 Negative Unresectable Locally Advanced Gastric Cancer: a National Multicenter Randomized Controlled Study [NCT05914610]Phase 3100 participants (Anticipated)Interventional2023-09-01Not yet recruiting
A Multicenter, Randomized, Controlled Phase III Study of Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy as Adjuvant Regimen for D2/R0 Resected pN3 Gastric (G) or Gastroesophageal Junction (GEJ) Adenocarcinoma [NCT04997837]Phase 3433 participants (Anticipated)Interventional2021-07-21Recruiting
A Randomized, Controlled, Multicenter Study to Compare Preoperative Radiochemotherapy With Preoperative Chemotherapy in Patients With Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma (PREACT Study) [NCT03013010]Phase 3682 participants (Anticipated)Interventional2016-12-31Recruiting
Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer: a Single-arm, Prospective, Multicenter Trial (TAOS-3B-Trial) [NCT05223088]Phase 240 participants (Anticipated)Interventional2021-10-31Recruiting
ONO-4538 Phase II/III Study A Multicenter, Randomized Study in Patients With Unresectable Advanced or Recurrent Gastric Cancer [NCT02746796]Phase 2/Phase 3680 participants (Anticipated)Interventional2016-03-31Completed
The Clinical Research of Mesylate Apatinib Combined With Docetaxel and S-1 as the First-line Treatment of Metastatic Gastric Cancer [NCT03154983]Phase 248 participants (Anticipated)Interventional2017-05-20Recruiting
PHASE I TRIAL OF POST-OPERATIVE COMBINED ORAL UFT PLUS LEUCOVORIN AND RADIATION THERAPY FOR RECTAL CANCER [NCT00002801]Phase 130 participants (Anticipated)Interventional1996-04-30Completed
A Phase II Study of S-1, Irinotecan, and Oxaliplatin in Locally-Advanced Pancreatic Cancer (SIROX Study) - Followed by Curative Surgery and Adjuvant Chemotherapy [NCT03316326]Phase 235 participants (Anticipated)Interventional2017-11-01Not yet recruiting
A Randomized Study of the Effect of First-line Intraperitoneal Paclitaxel in Combination With SOX Versus SOX Alone in Gastric Cancer Patients With Malignant Ascites [NCT03475615]Phase 3215 participants (Anticipated)Interventional2018-03-16Recruiting
A Prospective Randomized Controlled Trial to Compare Oxaliplatin Combined With S-1 (SOX) Versus Oxaliplatin With Capecitabine (XELOX) as Adjuvant Chemotherapy for Stage III Colorectal Cancer Patients [NCT03448549]Phase 31,191 participants (Anticipated)Interventional2018-01-01Recruiting
An Open-Label, Multicenter, Randomized, Phase 3 Study of S-1 and Cisplatin Compared With 5-FU and Cisplatin in Patients With Metastatic Diffuse Gastric Cancer Previously Untreated With Chemotherapy [NCT01285557]Phase 3361 participants (Actual)Interventional2011-04-14Terminated(stopped due to Due to significant changes in investigational and clinical practice landscape of frontline advanced gastric cancer, which challenged viability of trial and increased use of modified chemotherapeutic triplets led to slow participant accrual in study.)
A Phase II Study of Maintenance Tegafur-uracil in Patients With Squamous Cell Carcinoma of Oral Cavity With Extracapsular Spreading of Lymph Nodes [NCT03121313]Phase 268 participants (Anticipated)Interventional2015-02-26Recruiting
Comparison of With and Without Sequential Single Drug Therapy of S-1 After Adjuvant Chemotherapy With Docetaxel Plus S-1 in Stage III Gastric Cancer [NCT05813015]Phase 370 participants (Anticipated)Interventional2023-01-28Recruiting
A Phase II, Open-Label Study of Capecitabine Versus S-1 as Adjuvant Therapy in Patients With Biliary Tract Carcinoma After Surgical Resection [NCT04856761]160 participants (Anticipated)Observational2020-11-01Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01285557 (8) [back to overview]Duration of Response (DR)
NCT01285557 (8) [back to overview]Number of Participants With TEAEs With Severity Greater Than or Equal to (>=) Grade 3
NCT01285557 (8) [back to overview]Overall Response Rate (ORR): Percentage of Participants With Overall Response
NCT01285557 (8) [back to overview]Overall Survival (OS)
NCT01285557 (8) [back to overview]Progression-free Survival (PFS)
NCT01285557 (8) [back to overview]Time to Treatment Failure (TTF)
NCT01285557 (8) [back to overview]Time to Tumor Response (TTR)
NCT01285557 (8) [back to overview]Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAE)
NCT01515748 (10) [back to overview]Overall Survival (OS)
NCT01515748 (10) [back to overview]Percentage of Participants With 3-Year Progression-Free Survival (PFS), as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST)1.1
NCT01515748 (10) [back to overview]Percentage of Participants With R0 Resection
NCT01515748 (10) [back to overview]Number of Participants With Post-Operative Pathological Stage Response
NCT01515748 (10) [back to overview]Number of Participants With Shift of Laboratory Parameters (Aspartate Aminotransferase, Alanine Aminotransferase,Blood Bilirubin,Alkaline Phosphatase and Glucose Levels) From Baseline Grade to Worst NCI-CTCAE Grade >=3
NCT01515748 (10) [back to overview]Number of Participants With Shift of Laboratory Parameters (Calcium, Creatinine and Albumin Levels) From Baseline Grade to Worst NCI-CTCAE Grade >=3
NCT01515748 (10) [back to overview]Number of Participants With Shift of Laboratory Parameters (Creatinine Clearance [Chronic Kidney Disease]) From Baseline Grade to Worst NCI-CTCAE Grade >=3
NCT01515748 (10) [back to overview]Number of Participants With Shift of Laboratory Parameters (Hematology) From Baseline Grade to Worst National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Grade >=3
NCT01515748 (10) [back to overview]Number of Participants With Shift of Laboratory Parameters (Sodium and Potassium Levels) From Baseline Grade to Worst NCI-CTCAE Grade >=3
NCT01515748 (10) [back to overview]Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

Duration of Response (DR)

Duration of response was defined as the time (in months) from date of first confirmed response (CR or PR) to date of first progressive disease (PD) or death. Per the RECIST criteria, definitions were as follows: CR was defined as the disappearance of all target or non-target lesions. Any pathological lymph nodes for target lesions or all lymph nodes for non-target lesions were non-pathological morphologically that was reduced in size in short axis to <10 mm. Analysis was performed by using Kaplan-Meier method. (NCT01285557)
Timeframe: From date of first study medication until cut-off date: 07 March 2014 (approximately 34.7 months)

Interventionmonths (Median)
S-1+Cisplatin5.1
5FU+Cisplatin4.2

[back to top]

Number of Participants With TEAEs With Severity Greater Than or Equal to (>=) Grade 3

An AE was any untoward medical condition that occurred in a participants while participating in a clinical study and does not necessarily had to have a causal relationship with the use of the study medication. TEAEs were defined as AEs that developed or worsened or became serious during on-treatment period (from first dose of study medication up to 30 days of last study medication [maximum duration: 35.7 months]). (NCT01285557)
Timeframe: From first dose of study medication up to 30 days of last study medication (maximum duration: 35.7 months)

InterventionParticipants (Count of Participants)
S-1+Cisplatin157
5FU+Cisplatin78

[back to top]

Overall Response Rate (ORR): Percentage of Participants With Overall Response

ORR was defined as the percentage of participants with objective evidence of complete response (CR) or partial response (PR) based on the Investigator review of the images and application of Response Evaluation Criteria in Solid Tumors (RECIST) criteria. CR was defined as the disappearance of all target or non-target lesions. Any pathological lymph nodes for target lesions or all lymph nodes for non-target lesions were non-pathological morphologically that was reduced in size in short axis to less than (<) 10 millimeter (mm). PR was defined as target lesions with at least 30% decrease in the sum of diameters, taking baseline sum diameters as reference. (NCT01285557)
Timeframe: From date of first study medication until cut-off date: 07 March 2014 (approximately 34.7 months)

Interventionpercentage of participants (Number)
S-1+Cisplatin34.7
5FU+Cisplatin19.8

[back to top]

Overall Survival (OS)

OS was defined as the time from randomization to the date of death for the ITT population. Participants who did not die were censored at the date last known to be alive. Analysis was performed by using Kaplan-Meier method. (NCT01285557)
Timeframe: From the date of randomization until disease progression or death, cut-off date: 15 August 2014 (approximately 40 months)

Interventionmonths (Median)
S-1+Cisplatin7.5
5FU+Cisplatin6.6

[back to top]

Progression-free Survival (PFS)

PFS was defined as the time from date of randomization until date of radiological disease progression or death due to any cause. Disease Progression was defined according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, where any of the 3 criteria have been met: 1) at least 20% increase in the sum of diameters of the target lesions, taking as reference the smallest sum on study, including the baseline sum, 2) Progression in no-target lesion(s), 3) appearance of new lesion(s) Participants who were alive with no PD were censored at the date of the last tumor assessment. Participants who received new anticancer therapy before disease progression were censored at the date of the last evaluable tumor assessment before new anticancer therapy was initiated. Analysis was performed by using Kaplan-Meier method. (NCT01285557)
Timeframe: From date of randomization until disease progression or death, cut-off date: 07 March 2014 (approximately 34.7 months)

Interventionmonths (Median)
S-1+Cisplatin4.4
5FU+Cisplatin3.9

[back to top]

Time to Treatment Failure (TTF)

TTF was defined as the time from date of randomization until date of PD (clinical or radiologic), or permanent discontinuation of study treatment (S-1 or 5-FU), or death due to any cause. Participates who were still on study treatment at the time of the analysis were censored at the last date the participants was known to be on treatment. (NCT01285557)
Timeframe: From date of randomization until disease progression, cut-off date: 07 March 2014 (approximately 34.7 months)

Interventionmonths (Median)
S-1+Cisplatin4.2
5FU+Cisplatin3.8

[back to top]

Time to Tumor Response (TTR)

TTR was defined as the time (in months) from the date of randomization to the date of first observation of response (PR or CR) (whichever status was recorded first). TTR was assessed based on investigator assessment utilizing RECIST 1.1. CR was defined as the disappearance of all target or non-target lesions. Any pathological lymph nodes for target lesions or all lymph nodes for non-target lesions were non-pathological morphologically that was reduced in size in short axis to <10 mm. PR was defined as target lesions with at least 30% decrease in the sum of diameters, taking baseline sum diameters as reference. Analysis was performed by using Kaplan-Meier method. (NCT01285557)
Timeframe: From date of first study medication until cut-off date: 07 March 2014 (approximately 34.7 months)

Interventionmonths (Median)
S-1+Cisplatin1.8
5FU+Cisplatin1.9

[back to top]

Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAE)

AE was defined as any untoward medical condition that occurs in a participants while participating in a clinical study and does not necessarily had to have a causal relationship with the use of the study medication. A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. TEAEs were defined as AEs that developed or worsened or became serious during on-treatment period (from first dose of study medication up to 30 days of last study medication [maximum duration: 35.7 months]). (NCT01285557)
Timeframe: From first dose of study medication up to 30 days of last study medication (maximum duration: 35.7 months)

,
InterventionParticipants (Count of Participants)
TEAETESAE
5FU+Cisplatin11131
S-1+Cisplatin21463

[back to top]

Overall Survival (OS)

OS was defined as the time from randomization to death due to any cause. Analyzed using Kaplan-Meier method. (NCT01515748)
Timeframe: From randomization to date of death due to any cause (maximum duration: up to 10 years)

Interventionmonths (Median)
Surgery + Adjuvant Chemotherapy (SC)NA
Neoadjuvant Chemotherapy +Surgery +Adjuvant Chemotherapy (CSC)NA

[back to top]

Percentage of Participants With 3-Year Progression-Free Survival (PFS), as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST)1.1

PFS was defined as the time from randomization to objective tumor progression, or recurrence or death. Progressive disease (PD) was defined as follows: 1) In Neoadjuvant Chemotherapy +Surgery +Adjuvant Chemotherapy (CSC) Arm, PD was determined according to the RECIST 1.1 Criteria during the neo-adjuvant chemotherapy period; 2) Irrespective of curative resection, if an intraoperative distant metastasis was observed or a distant metastasis was reported from pathology, it was considered PD; 3) If residual cancer cells were visually identified at the resection margin during surgery but could not be completely resected (R2), it was considered PD; 4) If residual cancer cells were finally confirmed at the resection margin during postoperative histology (R1), it was considered PD; 5) In case of finding a recurrence/distant metastasis or a new lesion during follow-up after R0 complete resection, it was defined as the first tumor assessment date when it was observed. (NCT01515748)
Timeframe: 3 years

Interventionpercentage of participants (Number)
Surgery + Adjuvant Chemotherapy (SC)60.24
Neoadjuvant Chemotherapy +Surgery +Adjuvant Chemotherapy (CSC)66.82

[back to top]

Percentage of Participants With R0 Resection

Tumor condition was explained according to the Residual Tumor (R) Classification: R0; No residual cancer (negative cross-section), R1; Microscopically observed residual cancer (positive cross-section), R2; Macroscopically observed residual cancer. (NCT01515748)
Timeframe: Up to 10 years

Interventionpercentage of participants (Number)
Surgery + Adjuvant Chemotherapy (SC)83.74
Neoadjuvant Chemotherapy +Surgery +Adjuvant Chemotherapy (CSC)95.50

[back to top]

Number of Participants With Post-Operative Pathological Stage Response

"TNM pathological stage was determined according to standardized histopathology and the American Joint Committee on Cancer (AJCC) staging system 7th Edition (Stages 0,IA,IB,IIA,IIB,IIIA,IIIB,IIIC and IV). Stage 0=carcinoma in situ with no metastatic potential; Stage IA=T1N0M0; Stage IB=T2N0M0,T1N1M0; Stage IIA=T3N0M0,T2N1M0,T1N2M0;Stage IIB=T4aN0M0,T3N1M0,T2N2M0,T1N3M0;Stage IIIA=T4aN1M0,T3N2M0,T2N3M0;Stage IIIB=T4bN0-1M0,T4aN2M0,T3N3M0;Stage IIIC=T4bN2-3M0, T4aN3M0 and Stage IV= distant metastases (M1) at diagnosis; where T denotes tumor size where T1: tumor invades lamina propria, muscularis mucosae, or submucosa; T2: invades muscularis propria; T3: invasion of subserosa; T4: T4a: penetrate serosa (visceral peritoneum) T4b: invade adjacent tissue and N denotes nodes affected where N1:1-2 positive lymph nodes; N2:3-6 positive lymph nodes; N3: 7 or more positive lymph nodes and M denotes metastases where M0: no distant metastases. Higher stages indicates worse outcome." (NCT01515748)
Timeframe: Up to 10 years

,
InterventionParticipants (Count of Participants)
Stage 0Stage IAStage IBStage IIAStage IIBStage IIIAStage IIIBStage IIICStage IV
Neoadjuvant Chemotherapy +Surgery +Adjuvant Chemotherapy (CSC)23322347361824145
Surgery + Adjuvant Chemotherapy (SC)0918302535494634

[back to top]

Number of Participants With Shift of Laboratory Parameters (Aspartate Aminotransferase, Alanine Aminotransferase,Blood Bilirubin,Alkaline Phosphatase and Glucose Levels) From Baseline Grade to Worst NCI-CTCAE Grade >=3

NCI-CTCAE version 4.03 was used to determine Gr, where Gr refers to severity of AE: Gr 1:mild; asymptomatic/mild symptoms; Gr 2:moderate; minimal; Gr 3:severe/medically significant; Gr 4:life-threatening consequences, Gr 5:death related to AE. Abnormal values for Aspartate and alanine aminotransferase increased were based on Gr1: >ULN-3.0*ULN; Gr2: >3.0-5.0*ULN; Gr3: >5.0-20.0*ULN; Gr4: >20.0*ULN. Blood bilirubin increased: Gr1: >ULN-1.5*ULN; Gr2 >1.5-3.0*ULN; Gr3: >3.0-10.0*ULN; Gr4: >10.0*ULN. Alkaline phosphatase increased: Gr1: >ULN-2.5*ULN; Gr2: >2.5-5.0*ULN; Gr3: >5.0-20.0*ULN; Gr4: >20.0*ULN. Glucose (Hypoglycemia): Gr 1: ULN-160 mg/dL; Gr2: Fasting glucose value >160-250 mg/dL; Gr3: >250-500 mg/dL; Gr4: >500 mg/dL; Gr5: Death. (NCT01515748)
Timeframe: From Baseline up to 30 days after last dose of study drug (maximum duration: up to 10 years)

,
InterventionParticipants (Count of Participants)
Aspartate aminotransferase Gr0 at Baseline toGr>=3Aspartate aminotransferase Gr1 at Baseline toGr>=3Aspartate aminotransferase Gr2 at Baseline toGr>=3Aspartate aminotransferase Gr3 at Baseline toGr>=3Aspartate aminotransferase Gr4 at Baseline toGr>=3Aspartate aminotransferase Gr5 at Baseline toGr>=3Alanine aminotransferase Gr0 at Baseline to Gr >=3Alanine aminotransferase Gr1 at Baseline to Gr >=3Alanine aminotransferase Gr2 at Baseline to Gr >=3Alanine aminotransferase Gr3 at Baseline to Gr >=3Alanine aminotransferase Gr4 at Baseline to Gr >=3Alanine aminotransferase Gr5 at Baseline to Gr >=3Bilirubin increased Gr 0 at Baseline to Gr >=3Bilirubin increased Gr 1 at Baseline to Gr >=3Bilirubin increased Gr 2 at Baseline to Gr >=3Bilirubin increased Gr 3 at Baseline to Gr >=3Bilirubin increased Gr 4 at Baseline to Gr >=3Bilirubin increased Gr 5 at Baseline to Gr >=3Alkaline phosphatase Gr 0 at Baseline to Gr >=3Alkaline phosphatase Gr 1 at Baseline to Gr >=3Alkaline phosphatase Gr 2 at Baseline to Gr >=3Alkaline phosphatase Gr 3 at Baseline to Gr >=3Alkaline phosphatase Gr 4 at Baseline to Gr >=3Alkaline phosphatase Gr 5 at Baseline to Gr >=3Hypoglycemia Gr 0 at Baseline to Gr >=3Hypoglycemia Gr 1 at Baseline to Gr >=3Hypoglycemia Gr 2 at Baseline to Gr >=3Hypoglycemia Gr 3 at Baseline to Gr >=3Hypoglycemia Gr 4 at Baseline to Gr >=3Hypoglycemia Gr 5 at Baseline to Gr >=3Hyperglycemia Gr 0 at Baseline to Gr >=3Hyperglycemia Gr 1 at Baseline to Gr >=3Hyperglycemia Gr 2 at Baseline to Gr >=3Hyperglycemia Gr 3 at Baseline to Gr >=3Hyperglycemia Gr 4 at Baseline to Gr >=3Hyperglycemia Gr 5 at Baseline to Gr >=3
Neoadjuvant Chemotherapy +Surgery +Adjuvant Chemotherapy (CSC)100000100000400000000000000000121310200
Surgery + Adjuvant Chemotherapy (SC)1000000000002110003000004110004132300

[back to top]

Number of Participants With Shift of Laboratory Parameters (Calcium, Creatinine and Albumin Levels) From Baseline Grade to Worst NCI-CTCAE Grade >=3

NCI-CTCAE version 4.03 was used to determine Gr,where Gr refers to severity of AE:Gr 1:mild; asymptomatic/mild symptoms; Gr 2:moderate;minimal; Gr 3:severe/medically significant; Gr 4:life-threatening consequences, Gr 5:death related to AE. Abnormal values for Calcium(Hypocalcemia) were based on Gr1: Corrected serum calcium of ULN -11.5 mg/dL; Gr2: Corrected serum calcium of >11.5-12.5 mg/dL; Gr3: Corrected serum calcium of >12.5-13.5 mg/dL; Gr4: Corrected serum calcium of >13.5 mg/dL;Gr5:Death. Creatinine increased: Gr 1: >1-1.5*baseline; >ULN-1.5*ULN; Gr2: >1.5-3.0*baseline; >1.5-3.0*ULN; Gr3: >3.0 baseline; >3.0-6.0*ULN; Gr4: >6.0 x ULN. Albumin(Hypoalbuminemia): Gr 1: NCT01515748)
Timeframe: From Baseline up to 30 days after last dose of study drug (maximum duration: up to 10 years)

,
InterventionParticipants (Count of Participants)
Hypocalcemia Gr 0 at Baseline to Gr >=3Hypocalcemia Gr 1 at Baseline to Gr >=3Hypocalcemia Gr 2 at Baseline to Gr >=3Hypocalcemia Gr 3 at Baseline to Gr >=3Hypocalcemia Gr 4 at Baseline to Gr >=3Hypocalcemia Gr 5 at Baseline to Gr >=3Hypercalcemia Gr 0 at Baseline to Gr >=3Hypercalcemia Gr 1 at Baseline to Gr >=3Hypercalcemia Gr 2 at Baseline to Gr >=3Hypercalcemia Gr 3 at Baseline to Gr >=3Hypercalcemia Gr 4 at Baseline to Gr >=3Hypercalcemia Gr 5 at Baseline to Gr >=3Creatinine increased Gr 0 at Baseline to Gr >=3Creatinine increased Gr 1 at Baseline to Gr >=3Creatinine increased Gr 2 at Baseline to Gr >=3Creatinine increased Gr 3 at Baseline to Gr >=3Creatinine increased Gr 4 at Baseline to Gr >=3Creatinine increased Gr 5 at Baseline to Gr >=3Hypoalbuminemia Gr 0 at Baseline to Gr >=3Hypoalbuminemia Gr 1 at Baseline to Gr >=3Hypoalbuminemia Gr 2 at Baseline to Gr >=3Hypoalbuminemia Gr 3 at Baseline to Gr >=3Hypoalbuminemia Gr 4 at Baseline to Gr >=3Hypoalbuminemia Gr 5 at Baseline to Gr >=3
Neoadjuvant Chemotherapy +Surgery +Adjuvant Chemotherapy (CSC)000000100000800000200000
Surgery + Adjuvant Chemotherapy (SC)100000100000400000100000

[back to top]

Number of Participants With Shift of Laboratory Parameters (Creatinine Clearance [Chronic Kidney Disease]) From Baseline Grade to Worst NCI-CTCAE Grade >=3

NCI-CTCAE version 4.03 was used to determine Gr, where Gr refers to severity of AE: Gr 1: mild; asymptomatic/mild symptoms; Gr 2: moderate; minimal; Gr 3: severe/medically significant; Gr 4:life-threatening consequences, Gr 5:death related to AE. Abnormal values for Creatinine Clearance(Chronic kidney disease) were based on: Gr 1: estimated glomerular filtration rate (eGFR) or creatinine clearance (CrCl) NCT01515748)
Timeframe: From Baseline up to 30 days after last dose of study drug (maximum duration: up to 10 years)

InterventionParticipants (Count of Participants)
Creatinine Clearance Gr 0 at Baseline to Gr >=3Creatinine Clearance Gr 1 at Baseline to Gr >=3Creatinine Clearance Gr 2 at Baseline to Gr >=3Creatinine Clearance Gr 3 at Baseline to Gr >=3Creatinine Clearance Gr 4 at Baseline to Gr >=3Creatinine Clearance Gr 5 at Baseline to Gr >=3
Neoadjuvant Chemotherapy +Surgery +Adjuvant Chemotherapy (CSC)000000

[back to top]

Number of Participants With Shift of Laboratory Parameters (Hematology) From Baseline Grade to Worst National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Grade >=3

NCI-CTCAE version 4.03 was used to determine Grade(Gr),where Gr refers to severity of AE:Gr 1:mild; asymptomatic/mild symptoms; Gr 2:moderate;minimal; Gr 3:severe/medically significant; Gr 4:life-threatening consequences, Gr 5:death related to AE. Abnormal values for Hemoglobin(Hb)(Anemia) were based on Gr1:0-2g/dL above upper limit of normal(ULN);Gr2: incr. in >2-4g/dL above ULN; Gr3:incr. in >4gm/dL above ULN. White blood cell (WBC) decreased: Gr1:100,000/mm^3, Gr4:clinical manifestations of leucostasis;Gr5:Death. Abnormal Neutrophil count (ANC):- Gr1:NCT01515748)
Timeframe: From Baseline up to 30 days after last dose of study drug (maximum duration: up to 10 years)

,
InterventionParticipants (Count of Participants)
Hb(Anemia) Gr 0 at Baseline to Gr >=3Hb(Anemia) Gr 1 at Baseline to Gr >=3Hb(Anemia) Gr 2 at Baseline to Gr >=3Hb(Anemia) Gr 3 at Baseline to Gr >=3Hb(Anemia) Gr 4 at Baseline to Gr >=3Hb(Anemia) Gr 5 at Baseline to Gr >=3Hb increased Gr 0 at Baseline to Gr >=3Hb increased Gr 1 at Baseline to Gr >=3Hb increased Gr 2 at Baseline to Gr >=3Hb increased Gr 3 at Baseline to Gr >=3Hb increased Gr 4 at Baseline to Gr >=3Hb increased Gr 5 at Baseline to Gr >=3WBC decreased Gr 0 at Baseline to Gr >=3WBC decreased Gr 1 at Baseline to Gr >=3WBC decreased Gr 2 at Baseline to Gr >=3WBC decreased Gr 3 at Baseline to Gr >=3WBC decreased Gr 4 at Baseline to Gr >=3WBC decreased Gr 5 at Baseline to Gr >=3WBC (Leukocytosis) Gr 0 at Baseline to Gr >=3WBC (Leukocytosis) Gr 1 at Baseline to Gr >=3WBC (Leukocytosis) Gr 2 at Baseline to Gr >=3WBC (Leukocytosis) Gr 3 at Baseline to Gr >=3WBC (Leukocytosis) Gr 4 at Baseline to Gr >=3WBC (Leukocytosis) Gr 5 at Baseline to Gr >=3ANC Gr 0 at Baseline to Gr >=3ANC Gr 1 at Baseline to Gr >=3ANC Gr 2 at Baseline to Gr >=3ANC Gr 3 at Baseline to Gr >=3ANC Gr 4 at Baseline to Gr >=3ANC Gr 5 at Baseline to Gr >=3Platelet count decreased Gr0 at Baseline to Gr >=3Platelet count decreased Gr1 at Baseline to Gr >=3Platelet count decreased Gr2 at Baseline to Gr >=3Platelet count decreased Gr3 at Baseline to Gr >=3Platelet count decreased Gr4 at Baseline to Gr >=3Platelet count decreased Gr5 at Baseline to Gr >=3
Neoadjuvant Chemotherapy +Surgery +Adjuvant Chemotherapy (CSC)0410000000008100001000004000000500000
Surgery + Adjuvant Chemotherapy (SC)0010000000001000000000001401000000000

[back to top]

Number of Participants With Shift of Laboratory Parameters (Sodium and Potassium Levels) From Baseline Grade to Worst NCI-CTCAE Grade >=3

NCI-CTCAE version 4.03 was used to determine Gr,where Gr refers to severity of AE: Gr 1: mild; asymptomatic/mild symptoms; Gr 2: moderate; minimal; Gr 3:severe/medically significant; Gr 4:life-threatening consequences, Gr 5:death related to AE. Abnormal values for Sodium (Hyponatremia) were based on Gr1: ULN-150 mmol/L; Gr2: >150-155 mmol/L; Gr3:>155-160 mmol/L;hospitalization; Gr4: >160 mmol/L; life-threatening consequences; Gr5: Death. Potassium (Hypokalemia): Gr 1: ULN-5.5 mmol/L; Gr2: >5.5-6.0 mmol/L; Gr3: >6.0-7.0 mmol/L; hospitalization indicated; Gr4: >7.0 mmol/L; life-threatening consequences; Gr5: Death. (NCT01515748)
Timeframe: From Baseline up to 30 days after last dose of study drug (maximum duration: up to 10 years)

,
InterventionParticipants (Count of Participants)
Hyponatremia Gr 0 at Baseline to Gr >=3Hyponatremia Gr 1 at Baseline to Gr >=3Hyponatremia Gr 2 at Baseline to Gr >=3Hyponatremia Gr 3 at Baseline to Gr >=3Hyponatremia Gr 4 at Baseline to Gr >=3Hyponatremia Gr 5 at Baseline to Gr >=3Hypernatremia Gr 0 at Baseline to Gr >=3Hypernatremia Gr 1 at Baseline to Gr >=3Hypernatremia Gr 2 at Baseline to Gr >=3Hypernatremia Gr 3 at Baseline to Gr >=3Hypernatremia Gr 4 at Baseline to Gr >=3Hypernatremia Gr 5 at Baseline to Gr >=3Hypokalemia Gr 0 at Baseline to Gr >=3Hypokalemia Gr 1 at Baseline to Gr >=3Hypokalemia Gr 2 at Baseline to Gr >=3Hypokalemia Gr 3 at Baseline to Gr >=3Hypokalemia Gr 4 at Baseline to Gr >=3Hypokalemia Gr 5 at Baseline to Gr >=3Hyperkalemia Gr 0 at Baseline to Gr >=3Hyperkalemia Gr 1 at Baseline to Gr >=3Hyperkalemia Gr 2 at Baseline to Gr >=3Hyperkalemia Gr 3 at Baseline to Gr >=3Hyperkalemia Gr 4 at Baseline to Gr >=3Hyperkalemia Gr 5 at Baseline to Gr >=3
Neoadjuvant Chemotherapy +Surgery +Adjuvant Chemotherapy (CSC)700100000000210000400000
Surgery + Adjuvant Chemotherapy (SC)100000000000110000100000

[back to top]

Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

TEAEs were defined as adverse events (AE) that appeared or worsened during the treatment period (up to 30 days after the last dose of the investigational product). SAE was an AE or adverse drug reaction at any dose of the investigational product that corresponded to one of the following: resulting in death or is life threatening; requiring in-patient hospitalization or prolongation of existing hospitalization; resulting in persistent or significant disability of dysfunction; resulting in congenital anomaly or birth defect; important medical event. (NCT01515748)
Timeframe: From randomization up to 30 days after last dose of study drug (maximum duration: up to 10 years)

,
InterventionParticipants (Count of Participants)
Any TEAEAny treatment emergent SAETEAEs leading to permanent discontinuation
Neoadjuvant Chemotherapy +Surgery +Adjuvant Chemotherapy (CSC)23710225
Surgery + Adjuvant Chemotherapy (SC)1905711

[back to top]